



ESCMID Global

European Congress of Clinical Microbiology & Infectious Diseases

Preliminary Programme

Vienna, Austria

11-15 April 2025



<http://www.escmid.org/congress-events/escmid-global>

ESCMID Global 2025 - Programme

Friday, 11 April 2025

SP1 08:30 - 10:30 Hall 0

CLN

Special Session

Antimicrobial Stewardship in Different Scenarios

Chairs Murat Akova (Ankara, Türkiye)
 Andre Fuchs (Augsburg, Germany)
 Maddalena Giannella (Bologna, Italy)
 Angela Huttner (Geneva, Switzerland)
 Benedikt Huttner (Geneva, Switzerland)
 Jose Ramon Pano-Pardo (Zaragoza, Spain)
 Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)
 Holger Rohde (Hamburg, Germany)
 Oana Sandulescu (Bucharest, Romania)
 Jeroen Schouten (Nijmegen, Netherlands)
 Valentijn Schweitzer (Utrecht, Netherlands)
 Thomas Tängdén (Uppsala, Sweden)
 Suzanne Van Asten (Nijmegen, Netherlands)
 Dafna Yahav (Ramat-Gan, Israel)

Co-organised with: ESCMID Education Subcommittee

EW001 08:30 - 10:30 Hall 2

CLN IPC

Educational Session

Surgical site infections: principles and practice in the era of multidrug resistance

Chairs Gabriel Birgand (Nantes, France)
 Efthymia Giannitsioti (Athens, Greece)

W0001 08:30 **Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?** *Camilla Rodrigues (Mumbai, India)*

W0002 08:50 **Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance** *Prasannakumar Palanikumar (Vellore, India)*

W0003 09:10 **Screening for MDR GNR colonisation: is there evidence for prophylaxis?** *Elisabeth Presterl (Vienna, Austria)*

W0004 09:30 **Perioperative prophylaxis in special populations in the era of MDR** *Divyashree Shanthamurthy (Mumbai, India)*

EW002 08:30 - 10:30 Hall 3

ANT

Educational Session

Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts

Chairs Shampa Das (Liverpool, United Kingdom)
 João Paulo Telles (Sao Paulo, Brazil)

W0005 08:30 **Pharmacokinetics 101: navigating the basics for optimal dosing** *Linda Aulin (Leiden, Netherlands)*

W0006 08:50 **The ABCs of population pharmacokinetic models** *Erwin Dreesen (Leuven, Belgium)*

W0007 09:10 **Looking into the crystal ball: exploring the fabulous world of PK-PD simulations** *Vincent Aranzana-Climent (Poitiers, France)*

W0008 09:30 **Decoding population pharmacokinetic papers: interpreting, comparing and discussing results** *Iris K. Minichmayr (Vienna, Austria)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW003 08:30 - 10:30 Hall 5

DX

Educational Session

Challenges in Identification and relevance of slow-growing pathogens

Chairs Kerrie Davies (Leeds, United Kingdom)
 Yann Dumont (Nancy, France)

W0009 08:30 **Sampling and culturing anaerobes** *Hugo Cruz (Porto, Portugal)*

W0010 08:50 **I have an anaerobe: what is it and does it matter?** *Kathleen Boiten (Groningen, Netherlands)*

W0011 09:10 **Actinomyces in clinical samples: when is it worth the trouble?** *Eija Inkeri Könönen (Turku, Finland)*

W0012 09:30 **Nocardiosis: when to test and how to manage results?** *David Lebeaux (Paris, France)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)

EW004 08:30 - 10:30 Hall 6

CLN DX IPC

Educational Session

A hard nut to crack in HIV

Chairs Yoav Keynan (Winnipeg, Canada)
 Justyna Kowalska (Warsaw, Poland)

W0013 08:30 **Viral reservoir: what a physician should know** *Ivailo Alexiev (Sofia, Bulgaria)*

W0014 08:50 **Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians** *Jose Arribas (Madrid, Spain)*

W0015 09:10 **Chronic vascular and pulmonary disease and HIV: what can we do about it?** *Susanne Dam Poulsen (Copenhagen, Denmark)*

W0016 09:30 **Opportunistic infections: most common and most deadly** *Milena Stevanovikj (Sopje, North Macedonia, Republic of)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group

EW005 08:30 - 10:30 Hall 8

DX

Educational Session

Diagnostic parasitology in the XXIst century: is microscopy "+" still useful?

Chairs Miriam José Álvarez-Martínez (Barcelona, Spain)
 Caroline Rönnberg (Stockholm, Sweden)

W0017 08:30 **Artificial Intelligence for the diagnosis of parasitic infections** *Bobbi Pritt (Rochester, United States)*

W0018 08:50 **Histopathology of parasitic infections** *Richard Bradbury (Townsville, Australia)*

W0019 09:10 **Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections** *Sitara Sr Ajampur (Vellore, India)*

W0020 09:30 **Paleoparasitology: what diagnostic tools?** *Ayman El-Badry (Cairo, Egypt)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EW006 08:30 - 10:30 Hall 9

PRO PHEI

Educational Session

Vaccine hesitancy: from issues to solutions through developing communication skills

Chairs Monia Chemais (Soignies, Belgium)
 Petar Velikov (Sofia, Bulgaria)

W0021 08:30 **Vaccine hesitancy and its consequences** *Noni Macdonald (Halifax, Canada)*

W0022 08:50 **Why are patients and parents hesitant about vaccination?** *Eve Dube (Quebec City, Canada)*

W0023 09:10 **Using social media to deal with vaccine hesitancy** *Muge Cevik (St Andrews, United Kingdom)*

ESCMID Global 2025 - Programme

W0024 09:30 Strengthening vaccine confidence in patients and parents *Tba*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SP2 11:00 – 12:00 Hall 0
Special Session

PRO

Principles of systematic reviews (with and without meta-analysis)

Chairs
Chiara Iaria (Palermo, Italy)
Miranda Langendam (Amsterdam, Netherlands)
Blin Nagavci (Gjakove, Kosovo)
Mical Paul (Haifa, Israel)
Luigia Scudeller (Pavia, Italy)

Co-organised with: ESCMID Education Subcommittee

ME007 11:00 – 12:00 Hall 2
Meet-the-Expert

AMR DX

How to interpret resistance patterns from antibiograms

M0025 11:00 *Tommaso Giani (Florence, Italy)*

M0026 11:12 *Diaz Lorena (Santiago, Chile)*

ME008 11:00 – 12:00 Hall 3
Meet-the-Expert

CLN

Children are not just small adults: interactive paediatric cases

M0027 11:00 *Julie Toubiana (Paris, France)*

M0028 11:12 *Sanjay Patel (Winchester, United Kingdom)*

ME009 11:00 – 12:00 Hall 5
Meet-the-Expert

IPC

How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections

M0029 11:00 *Kushlani Jayatileke (Battaramulla, Sri Lanka)*

M0030 11:12 *Walter Zingg (Zurich, Switzerland)*

ME010 11:00 – 12:00 Hall 6
Meet-the-Expert

PHEI

Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience

M0031 11:00 *Ecaterina Noroc (Chisinau, Moldova, Republic of)*

M0032 11:12 *Fakhriddin Nizamov (Almaty, Kazakhstan)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)

ME011 11:00 – 12:00 Hall 8
Meet-the-Expert

CLN

Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare

M0033 11:00 *Jaime Esteban (Madrid, Spain)*

M0034 11:12 *Philippe Morand (Paris, France)*

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)

ME012 11:00 – 12:00 Hall 9
Meet-the-Expert

PHEI

How to understand infectious disease risks in changing climates

M0035 11:00 *Kimberly Fornace (Singapore, Singapore)*

M0036 11:12 *Rachel Lowe (Barcelona, Spain)*

SP3 13:30 – 14:30 Hall 0
Special Session

IPC

Top five mistakes in Infection prevention and control

Chairs
Maeve Doyle (Waterford, Ireland)
Barbara Juliane Holzkecht (Copenhagen, Denmark)
David Ong (Zoetermeer, Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)

Co-organised with: ESCMID Education Subcommittee

ME013 13:30 – 14:30 Hall 2
Meet-the-Expert

CLN TRN

Orthopaedic implant infections: new approaches for improved outcomes

M0037 13:30 *Marjan Wouthuyzen-Bakker (Groningen, Netherlands)*

M0038 13:42 *Trisha Peel (Melbourne, Australia)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME014 13:30 – 14:30 Hall 3
Meet-the-Expert

CLN

Timing of antimicrobials in sepsis and septic shock - the sooner the better?

M0039 13:30 *Laura Evans (Seattle, United States)*

M0040 13:42 *Evangelos Giamarellos-Bourboulis (Athens, Greece)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

ME015 13:30 – 14:30 Hall 5
Meet-the-Expert

CLN

PrEP in Europe: Current gaps and solutions

M0041 13:30 *Teymur Noori (Stockholm, Sweden)*

M0042 13:42 *Milosz Parczewski (Szczecin, Poland)*

Co-organised with: European AIDS Clinical Society (EACS)

ME016 13:30 – 14:30 Hall 6
Meet-the-Expert

CLN

Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines

ESCMID Global 2025 - Programme

M0043 13:30 *Daria Podlekareva (Copenhagen, Denmark)*

M0044 13:42 *Raquel Duarte (Porto, Portugal)*

Co-organised with: European Respiratory Society (ERS)

ME017 13:30 - 14:30 Hall 8

Meet-the-Expert

PRO PHEI

How to navigate Risk Communication in Public Health

M0045 13:30 *Christina Rolfheim-Bye (Oslo, Norway)*

M0046 13:42 *Marius Gilbert (Brussels, Belgium)*

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)

ME018 13:30 - 14:30 Hall 9

Meet-the-Expert

VAX

Do we need antiviral stewardship in immunocompromised hosts? role of cell-mediated immunity

M0047 13:30 *Michelle Yong (Melbourne, Australia)*

M0048 13:42 *Genovefa Papanicolaou (New York, United States)*

SP4 14:45 - 15:45 Hall 0

Special Session

PRO

Science Slam - How to Communicate Science with Clarity

Chairs
Mary Horgan (Dublin, Ireland)
Jaroslav Hrabak (Plzen, Czech Republic)
Nina Khanna (Basel, Switzerland)
Preeti Malani (Ann Arbor, United States)
Emily G. McDonald (Montreal, Canada)
Joshua Nosanchuk (Bronx, United States)
Jesús Rodríguez-Baño (Seville, Spain)

Co-organised with: ESCMID Education Subcommittee

ME019 14:45 - 15:45 Hall 2

Meet-the-Expert

CLN DX

Healthcare-associated CNS infections

M0049 14:45 *Diederik Van De Beek (Amsterdam, Netherlands)*

M0050 14:57 *Alexandra Maillies (Paris, France)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME020 14:45 - 15:45 Hall 3

Meet-the-Expert

TRN

Translation of gut microbiome data to clinical practice: a guide for clinicians

M0051 14:45 *Aycan Gundogdu (Kayseri, Türkiye)*

M0052 14:57 *Niranjan Nagarajan (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

ME021 14:45 - 15:45 Hall 5

Meet-the-Expert

PRO

How to make sense out of guidelines and scientific evidence

M0053 14:45 *Luigia Scudeller (Pavia, Italy)*

M0054 14:57 *Blin Nagavci (Gjakove, Kosovo)*

Co-organised with: ESCMID Guidelines Subcommittee

ME022 14:45 - 15:45 Hall 6

Meet-the-Expert

CLN

Multidisciplinary management of bone and joint infections: Is there a recipe for success?

M0055 14:45 *Natividad Benito (Barcelona, Spain)*

M0056 14:57 *Tiziana Ascione (Naples, Italy)*

Co-organised with: ESCMID Study Group for Lyme Borrellosis (ESGBOR)

ME023 14:45 - 15:45 Hall 8

Meet-the-Expert

PHEI

How to manage and prevent travellers' diarrhoea

M0057 14:45 *Tinja Laaveri (Helsinki, Finland)*

M0058 14:57 *David Tribble (Bethesda, United States)*

ME024 14:45 - 15:45 Hall 9

Meet-the-Expert

CLN DX IPC

How to diagnose and treat infectious complications in critically ill patients receiving ECMO support

M0059 14:45 *Jordi Riera (Barcelona, Spain)*

M0060 14:57 *Giacomo Grasselli (Besana In Brianza, Italy)*

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

SP5 16:15 - 18:15 Hall 0

Special Session

CLN

Multidisciplinary approach to early sepsis management

Chairs
Markus Bald (Lüdenscheid, Germany)
Aleksandra Davidovic (Lüdenscheid, Germany)
Charalambos Dokos (Lüdenscheid, Germany)

Co-organised with: ESCMID Education Subcommittee

EW025 16:15 - 18:15 Hall 2

Educational Session

AMR DX

AMR surveillance: current challenges and new perspectives

Chair *Tomislav Mestrovic (Varazdin, Croatia)*

W0061 16:15 **The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden** *Authia Gray (Washington, United States)*

W0062 16:35 **Networks for surveillance of AMR in animal pathogens** *Lucie Collineau (Lyon, France)*

W0063 16:55 **Transition to genomic-based methodology for surveillance and outbreak detection to effectively combat AMR** *Camilla Wiuff Coia (Copenhagen, Denmark)*

W0064 17:15 **Implementing and running hospital-wide genomic surveillance of pathogens** *Alexander Mellmann*

ESCMID Global 2025 - Programme

(Münster, Germany)

Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EW026 16:15 – 18:15 Hall 3

Educational Session

AMR

New insights into antifungal agents and resistance

Chairs Anuradha Chowdhary (New Delhi, India)
Jon Salmanton-Garcia (Cologne, Germany)

W0065 16:15 Emerging resistance in *Candida tropicalis* Sharon Chen (Sydney, Australia)

W0066 16:35 Mechanisms of resistance in *Candida glabrata* David Perlin (Nutley, United States)

W0067 16:55 Surveillance of resistance in *Aspergillus* species Maiken Cavling Arendrup (Copenhagen, Denmark)

W0068 17:15 Environmental surveillance for antifungal resistance Eveline Snelders (Wageningen, Netherlands)

EW027 16:15 – 18:15 Hall 5

Educational Session

ANT CLN TRN

Going Viral! Phage Therapy Clinical rounds

Chairs Gregory German (Maple, Canada)
Ameneh Khatami (Sydney, Australia)

W0069 16:15 Clinical cases and lessons from the STAMP protocol Holly Sinclair (Nsw, Australia)

W0070 16:35 Difficult cases treated with phages Ghady Haidar (Pittsburgh, United States)

W0071 16:55 Challenging osteoarticular cases treated with phages Tristan Ferry (Lyon, France)

W0072 17:15 Treating urinary tract infections with phages: dream or reality? Saima Aslam (San Diego, United States)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

EW028 16:15 – 18:15 Hall 6

Educational Session

CLN VAX

Addressing infection challenges in immunocompromised patients: a case-based exploration

Chairs Maddalena Giannella (Bologna, Italy)
Asma Nasim (Karachi, Pakistan)

W0073 16:15 Challenges in managing gastrointestinal infections in patients with primary immunodeficiency Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)

W0074 16:35 Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies Gemma Reynolds (Heidelberg, Australia)

W0075 16:55 Mycobacterial infections in patients with HIV infection Graeme Ayton Meintjes (Observatory, South Africa)

W0076 17:15 Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation Dimitrios P. Kontoyiannis (Houston, Tx, United States)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EW029 16:15 – 18:15 Hall 8

Educational Session

TRN

Impact of diabetes on infectious diseases: what should we know?

Chair Suzanne Van Asten (Nijmegen, Netherlands)

W0077 16:15 The impact of diabetes and host-pathogen interaction and gut microbiome Reinout Van Crevel (Nijmegen, Netherlands)

W0078 16:35 Diabetes and invasive fungal infections Jochem Buil (Nijmegen, Netherlands)

W0079 16:55 Viral infections and diabetes: is there a connection? Malin Flodström-Tullberg (Stockholm, Sweden)

W0080 17:15 Pathogenesis of diabetic wound infection Tba

EW030 16:15 – 18:15 Hall 9

Educational Session

DX IPC

Primer on infection prevention and control: the crucial support by clinical microbiology

Chairs Nico Tom Mutters (Bonn, Germany)
Margreet C. Vos (Rotterdam, Netherlands)

W0081 16:15 Microbial fundamentals: building blocks of infection prevention and control Laurence Armand-Lefevre (Paris, France)

W0082 16:35 Optimising environmental sampling in infection control: rational use of the microbiology laboratory John E. Coia (Esbjerg, Denmark)

W0083 16:55 The crucial role of molecular typing in infection control Stefanie Kampmeier (Würzburg, Germany)

W0084 17:15 How can we link diagnostic and antibiotic stewardship? Constantinos Tsioutis (Nicosia, Cyprus)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

Saturday, 12 April 2025

SY036 08:30 – 10:30 Hall 15

2-hour Symposium

ANT

The quality of antibiotics used in the communities of LMICs

Chairs Thi Thuy Nga Do (Ha Noi, Vietnam)
Christina Obiero (Kilifi, Kenya)

S0105 08:30 The quality of antibiotics and their potential impact on patient outcome and AMR Paul Newton (Oxford, United Kingdom)

S0106 09:00 Community antibiotic access and use in Sub-Saharan Africa Samuel Afari-Asiedu (Kintampo, Ghana)

S0107 09:30 Encountered challenges and reflections on conducting multi-country medicine quality studies Noudy Sengxeu (Vientiane Capital, Lao People's democratic republic)

S0108 10:00 Confusion in appearance of common used antibiotics in LMICs Heiman Wertheim (Nijmegen, Netherlands)

SY031 08:30 – 10:30 Hall 6

2-hour Symposium

CLN VAX

To screen or not to screen prior to transplant?

Chairs Laura Alicia Barcan (Buenos Aires, Argentina)
Oscar Len (Barcelona, Spain)

S0085 08:30 HHV-8 Screening Alessandra Mularoni (Palermo, Italy)

S0086 09:00 TB screening and prevention in endemic regions Rubina Naqvi (Karachi, Pakistan)

S0087 09:30 Screening for and prevention of chagas in

ESCMID Global 2025 - Programme

		immunocompromised hosts <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>	
S0088	10:00	Screening of lung donors for Mollicutes <i>Michael G Ison (Derwood (MD), United States)</i>	
<hr/>			
EF003	08:30 - 09:30		Arena 1
		ePoster Flash Session	
On the frontiers of vaccine driven prevention			
		<i>Chair Maria Ganczak (Zielona Gora, Poland)</i>	
E0021		Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine. <i>J. Parsons* (Liverpool, United Kingdom), K. Subramaniam, L. Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P. Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Carroll</i>	
E0022		A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine. <i>P. Garbes* (Newark, United States), C. Chang, H. Wraight, R. Norton, S. Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Giffear, K. Damjanoska, J. Li</i>	
E0023		A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein-based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale & Trial Design. <i>M. Lassen* (Copenhagen, Denmark), S. Christensen, N. Johansen, K. Skaarup, D. Modin, B. Claggett, C. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen</i>	
E0024		Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years. <i>M. Desai* (Cambridge, United States), E. Comstock, L. Lan, A. Kapoor, F. She, C. Reuter, J. Goswami, F. Priddy, R. Das</i>	
E0025		Comparative Immune Responses to Homologous and Heterologous SARS-CoV-2 Vaccination Using DNA and Protein Platforms. <i>S. Prieto Martín Gil* (Madrid, Spain), S. Prieto Martín Gil, M. López Siles, J.A. Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, A. Pérez, M.J. McConnell</i>	
E0026		Quantitative correlates of protection against SARS-CoV-2 variants using individual-level reconstructed antibody kinetics. <i>T. Russell* (London, United Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O. Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr</i>	
E0027		Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study. <i>L. McGeoch* (London, United Kingdom), S. Foulkes, H. Whitaker, K. Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall</i>	
E0028		Immunogenicity and safety of second COVID-19 booster and Influenza vaccination coadministration. <i>Wagenhäuser* (Würzburg, Germany), J. Reusch, J. Mees, A. Gabel, N. Petri, M. Krone</i>	
E0029		The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania. <i>S. Cristea* (Sibiu, Romania), C. Grigore</i>	
<hr/>			
EF004	08:30 - 09:30		Arena 3
		ePoster Flash Session	
Pharmacology from bench to the bedside			
		<i>Chair Alina Karoline Nussbaumer-Pröll (Wien, Österreich, Austria)</i>	
E0030		Enterococcus faecalis impairs Escherichia coli response to antibiotics in a dual-species intracellular	
E0031		Infection model. <i>F. Van Bambeke* (Brussels, Belgium), G. Wang</i>	
E0032		In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing Enterobacteriales clinical isolates. <i>M. Martens* (Hamburg, Germany), F.M. Docobo-Perez, C. Saucó Carballo, J. Rodríguez-Baño, S. Marchand, L. Keomany, I. Portillo-Calderon, M. Gianella, S. Ambretti, B. Secci, S.G. Wicha</i>	
E0033		In vivo activity and PK of the novel siderophore-cephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant Pseudomonas aeruginosa following subcutaneous administration. <i>W. Wicha* (Bruck An Der Leitha, Austria), S. Paukner</i>	
E0033		Synergistic Potency Unveiled: β-Lactam and β-Lactamase Inhibitor Combination against Mycobacterium abscessus with Dual Action of β-Lactamase Inhibition and Multi-Target Receptor Inactivation. <i>E. Shin* (Cleveland, United States), K.M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J. Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo</i>	
E0034		Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with Mycobacterium abscessus infection. <i>W. Wang* (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q. Dai, G. Lamichhane</i>	
E0035		Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models. <i>R. Saporta* (Uppsala, Sweden), N. Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg</i>	
E0036		Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study. <i>P. Le Turnier* (Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C. Deschanvres, F. Andry, A. Coste, P. Danneels, T. Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R. Lamberet, A. Le Bot, M. Mailliet, P. Petitgas, V. Rabier, S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M. Grégoire, A.G. Leroy, M. Wargny, R. Bellouard</i>	
E0037		No time to waste: hospital-wide assessment of IV-vial and line residuals and impact on target attainment. <i>D. Vanneste* (Leuven, Belgium), M. Gijzen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters, S. Desmet, E. Dreesen, I. Spriet</i>	
E0038		Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: implications for dose selection. <i>D. Fuhs* (Parkville, Australia), A. Boonyasiri, T. Naorungroj, L. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T. Visanu, C. Landersdorfer</i>	
<hr/>			
SY034	08:30 - 10:30		Hall 10
		2-hour Symposium	
Endoscopy: infection risks and mitigation			
		<i>Chairs Elisabeth Presterl (Vienna, Austria) Gordon Ramage (Glasgow, United Kingdom)</i>	
S0097	08:30	Should we be concerned about infection from contaminated endoscopes? <i>Claire Aumeran (Clermont-Ferrand, France)</i>	
S0098	09:00	Prevention of multidrug-resistant infections from contaminated duodenoscopes. <i>Margreet C. Vos (Rotterdam, Netherlands)</i>	
S0099	09:30	Understanding the causes of medical device contamination: it is all biofilm! <i>Roberto Rusconi (Milan, Italy)</i>	
S0100	10:00	Does the European medical Device Regulation bring us safer duodenoscopes? <i>Markus Hell (Salzburg, Austria)</i>	
<hr/>			
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)			

ESCMID Global 2025 - Programme

OS002	08:30 – 10:30	Hall 11	<p>2-hour Oral Session</p> <p>Translating metagenomics into clinical practice</p> <p><i>Chairs</i> Benjamin Peter Howden (Parkville (Victoria), Australia) Paula Mölling (Örebro, Sweden)</p>	<p>people living with HIV Raimonda Matulionyte (Vilnius, Lithuania)</p> <p>S0103 09:30 Integration of HIV and TB care to improve patient outcome in resource-limited settings Akaki Abutidze (Tbilisi, Georgia)</p> <p>S0104 10:00 How researchers can influence policy and practice in HIV/TB care Jens D. Lundgren (Copenhagen, Denmark)</p> <p>Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group</p>
00011	Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study H.L. Nielsen* (Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen			
00012	Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash. J. Alexander* (Orlando, United States), A. Charles			
00013	Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care R. Hammond* (London, United Kingdom), A. Kopeck, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer			
00014	Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaifan, A. Dervishi, P. Kawaletz, H. Stäudle			
00015	Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes E. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser			
00016	Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia			
00017	Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU B. Ran* (Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang			
00018	Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence C. Peng* (Shiyan, China), S. Qi, C. Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun			
00019	A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS) M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B.A. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy			
00020	Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study M. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona			
SY035	08:30 – 10:30	Hall 12	<p>2-hour Symposium</p> <p>Barriers to TB/HIV elimination in low- and high-incidence settings</p> <p><i>Chair</i> Daria Podlekareva (Copenhagen, Denmark)</p>	
S0101	08:30	HIV and TB epidemic: the storm hasn't subsided yet Tetiana Koval (Poltava, Ukraine)		
S0102	09:00	Approaches for latent and active TB screening in		
EW041	08:30 – 10:30	Hall 13	<p>Educational Session</p> <p>RSV infections: diagnosis, surveillance and treatment in the advent of vaccines</p> <p><i>Chair</i> Monika Redlberger-Fritz (Vienna, Austria)</p>	
W0126	08:30	Costs of RSV infection, compared to other respiratory viruses Barbara Rath (Besançon, France)		
W0127	08:50	Virology and host interactions of RSV Richard Sugrue (Singapore, Singapore)		
W0128	09:10	RSV surveillance in the EU/EEA in the vaccine era Eeva Broberg (Solna, Sweden)		
W0129	09:30	RSV fusion inhibitors and monoclonals: current status and future developments Peter Openshaw (London, United Kingdom)		
		Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)		
EW042	08:30 – 10:30	Hall 14	<p>Educational Session</p> <p>Traumatic wound infections: diagnosis and treatment options</p> <p><i>Chairs</i> Amparo Fernández-Rodríguez (Madrid, Spain) Veroniek Saegeman (Sint-Niklaas, Belgium)</p>	
W0130	08:30	Multidrug-resistant infections after trauma in warzone Shehan Hettiaratchy (Hampton, United Kingdom)		
W0131	08:50	Fungal infections during natural disasters Anuradha Chowdhary (New Delhi, India)		
W0132	09:10	Bacteriophage therapy for multidrug-resistant wound infections in trauma Tristan Ferry (Lyon, France)		
W0133	09:30	Infection of burn wounds Nur Benzonana (Istanbul, Türkiye)		
		Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clínica), International Society of Antimicrobial Chemotherapy (ISAC)		
SY037	08:30 – 10:30	Hall 16	<p>2-hour Symposium</p> <p>Unveiling the challenges: nosocomial infections in ECMO-supported patients</p> <p><i>Chairs</i> Antonios Katsounas (Bochum, Germany) Jordi Riera (Barcelona, Spain)</p>	
S0109	08:30	Source of infection and pathogens Christian Eckmann (Hannover, Germany)		
S0110	09:00	Prophylaxis and empiric treatment Giacomo Grasselli (Besana In Brianza, Italy)		
S0111	09:30	Diagnostic criteria and definitions Graeme Maclaren (Singapore, Singapore)		
S0112	10:00	Microbial films Marta Hernández-Meneses (Barcelona, Spain)		
		Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)		

ESCMID Global 2025 - Programme

EW039	08:30 - 10:30	Hall 2
	Educational Session	

CLN DX

Are urinary tract infections still the same?

Chair *Agnes Maria Sonnevend (Pécs, Hungary)*

W0118 08:30 Update on paediatric UTI *Michael Buettcher (Luzern, Switzerland)*

W0119 08:50 Diagnosis and treatment of UTI in the era of antimicrobial resistance *Jennifer Kranz (Aachen, Germany)*

W0120 09:10 Can UTI be prevented? *Chris Harding (Newcastle Upon Tyne, United Kingdom)*

W0121 09:30 Fungal and parasitic infections of the urinary tract *Gladys Mbwani (Mwanza, Tanzania, United Republic of)*

EW040	08:30 - 10:30	Hall 3
	Educational Session	

ANT CLN

OPAT: from aged wine to new vintage

Chairs *Birgit Koch (Rotterdam, Netherlands)*
Sonia Luque (Barcelona, Spain)

W0122 08:30 OPAT: principles, practice and checklists *Charlotte Quintens (Leuven, Belgium)*

W0123 08:50 COPAT: complex outpatient parenteral antimicrobial therapy *Ronald Andrew Seaton (Glasgow, United Kingdom)*

W0124 09:10 Antimicrobial stability and other challenges for OPAT practice? *Mark Gilchrist (London, United Kingdom)*

W0125 09:30 New OPAT safety and efficacy data to guide practice *Matthew Rawlins (Murdoch, Australia)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)

EW038	08:30 - 11:30	Hall 4
	Educational Session	

AMR DX

EUCAST Educational Workshop

Chairs *Marlene Amara (Le Chesnay Cedex, France)*
Alasdair P. Macgowan (Bristol, United Kingdom)

W0113 08:30 EUCAST update *Sören G. Gatermann (Bochum, Germany)*

W0114 08:50 Setting clinical breakpoints, assessing evidence *Anouk Edwina Muller (The Hague, Netherlands)*

W0115 09:10 Benzylpenicillin susceptibility testing of *S. pneumoniae* by disk diffusion *Gunnar Kahlmeter (Tävelsås, Sweden)*

W0116 09:30 What to do when there are no breakpoints *Barbara Juliane Holzknacht (Copenhagen, Denmark)*

W0117 09:50 Detection of resistance mechanisms *Christian Giske (Stockholm, Sweden)*

Co-organised with: EUCAST Steering Committee

OS001	08:30 - 10:30	Hall 5
	2-hour Oral Session	

AMR PHE TRN

One Health means resistance everywhere

Chairs *Alessandra Carattoli (Rome, Italy)*
Prasannakumar Palanikumar (Vellore, India)

O0001 Decoding the role of *bla*_{CPB}-carrying plasmids on

wings: A holistic view using the One Health approach *S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres*

O0002 A novel isolation room model leveraging culture-independent HI-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs *V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng*

O0003 Deciphering the pathogenic potentials and epidemiological identities of *Staphylococcus pseudintermedius* colonizing companion dogs in Sao Paulo *I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales*

O0004 Recent progress towards integrated surveillance of antimicrobial resistance in France *L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin*

O0005 Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination *B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-Kiss, L. Laczko, G. Kardos*

O0006 Emergence of mobile colistin resistance in *Klebsiella* at human-animal-environment interface in Bangladesh *S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T. Walsh, R. Farzana*

O0007 Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective *I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja*

O0008 Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples *E. Ouranou* (Heraklion, Greece), A. Psaroulaki, D. Chochlakis, M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos*

O0009 One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison *G. Knight* (London, United Kingdom), R. Booton, J.V. Robotham, K. Aluzaita, D. Belay, J. Guitian, M. Dione, E. Emes*

O0010 Clinically important sequence types and resistance genes in *Enterobacteriaceae* from coastal environments and gulls *V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Riviére, P. Poeta, G. Igrejas*

SY032	08:30 - 10:30	Hall 7
	2-hour Symposium	

TRN

New insights into *Candida* pathogenesis

Chairs *Aleksandra Barac (Belgrade, Serbia)*
Joshua Nosanchuk (Bronx, United States)

S0089 08:30 Insights into the evolution of *Candida* under antifungal pressure *Attila Gacser (Szeged, Hungary)*

S0090 09:00 How do *Candida* extracellular vesicles modify virulence during disease? *Leonardo Nimrichter (Rio De Janeiro, Brazil)*

S0091 09:30 The commensal to pathogen transition: kind to killer *Ilse D. Jacobsen (Jena, Germany)*

S0092 10:00 Fungal-bacterial interactions: who wins? *Rebecca Hall (Canterbury, United Kingdom)*

SY033	08:30 - 10:30	Hall 8
-------	---------------	--------

ESCMID Global 2025 - Programme

2-hour Symposium

TRN

Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations.

Chairs	<i>Christian Stephan Lentz (Tromsø, Norway)</i> <i>Annelies Zinkernagel (Zurich, Switzerland)</i>	
S0093	08:30	Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infections <i>Christoph Ernst (Cologne, Germany)</i>
S0094	09:00	Single-cell imaging and heterogeneity in antimicrobial resistance <i>Stefano Pagliara (Exeter, United Kingdom)</i>
S0095	09:30	Single-cell RNAseq and heterogeneity in bacterial transcription <i>Anna Kuchina (Seattle, United States)</i>
S0096	10:00	Dissecting the function of individual bacteria in their spatial context <i>Knut Drescher (Basel, Switzerland)</i>

SY043 09:30 - 10:30 Hall 1

1-hour Symposium

IPC

Year in infection control

Chairs	<i>Nico Tom Mutters (Bonn, Germany)</i> <i>Ermira Tartari (Msida, Malta)</i>	
S0134	09:30	<i>Andrew James Stewardson (Melbourne, Victoria, Australia)</i>
S0135	10:00	<i>Kalisvar Marimuthu (Singapore, Singapore)</i>

EF005 09:30 - 10:30 Arena 2

ePoster Flash Session

CLN DX

It's all in the blood

Chair	<i>Colin R. Mackenzie (Neuss, Germany)</i>	
E0039		Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivity <i>L. Hardy* (Antwerp, Belgium), A.S. Heroes, E. Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E. Corsmit, B. De Smet</i>
E0040		Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital network <i>C. Hall* (Hamilton, Canada), C. Fuller, S. Ramondino, C. Main</i>
E0041		Utility of sigmoidal growth curve when no organisms are seen on Gram stain in positive blood cultures <i>D. Crilly* (London, United Kingdom), A. Bapat, J. Youngs, G. Maloney, E. Drakes</i>
E0042		Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of results <i>C. Magri* (Rome, Italy), C. Magri, G. Menchinelli, D. Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti</i>
E0043		Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient Management <i>S. Buyukberber* (Ankara, Türkiye), S. Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H. Dal, T. Kayan</i>
E0044		Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of Türkiye <i>Ö. Türkmen Recen* (Izmir, Türkiye), M. Kiplapinar, H. Özdemir, S. Kurutepe, H. Gazi</i>
E0045		Performance of direct pathogen and β-lactamase detection workflow using MALDI-TOF MS from positive blood culture specimens <i>K. Kosai* (Nagasaki, Japan), Y. Kawamoto, K. Yanagihara</i>
E0046		Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infections <i>L. Van Balen* (Maastricht, Netherlands), R. Koeck</i>
E0047		Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial

susceptibility testing in patients with bloodstream infection in Europe*C. Pina-Vaz* (Oporto, Portugal), F. Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro, J.A. Paiva*

EF006 09:30 - 10:30 Arena 4

ePoster Flash Session

AMR ANT CLN

Emerging developments in antifungal pharmacology

Chair	<i>Roger Brüggemann (Nijmegen, Netherlands)</i>	
E0048		NATURE-US: the natural history of antifungal failure in invasive candidiasis <i>L. Ostrosky-Zeichner* (Houston, United States), P.G. Pappas, M.H. Miceli, A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E. McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P. Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo</i>
E0049		The antidepressant vortioxetine enhances resistance toward multiple azoles <i>S. Rizzo* (Rome, Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B. Posteraro, M. Sanguinetti, F. Bugli, R. Torelli</i>
E0050		Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration <i>A. Desai* (Northbrook, United States), L. Kovanda</i>
E0051		Identification of efflux inhibitors for <i>Candida albicans</i> through a drug repurposing strategy <i>D. Marques* (Lisbon, Portugal), S. Santos Costa, L. Rodrigues</i>
E0052		Clinical outcomes of micafungin 100 mg vs. 150 mg daily for the treatment of <i>Candida auris</i> fungemia <i>J. Hou* (Chicago, IL, United States), Y. Wang, R. Burgos, L. Danziger, E. Drwiega</i>
E0053		Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysis <i>G.R. Thompson* (Davis, California, United States), A. Soriano, M. Bassetti, P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely</i>
E0054		Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by <i>Candida auris</i>: a multicentre, open-label study (CARES) <i>M.H. Miceli* (Ann Arbor, United States), T.F. Patterson, D. Juneja, G.R. Thompson III, P. Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breed, N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M. Middle, M. Hoernig</i>
E0055		High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis <i>S. Wurster* (Houston, United States), N.D. Albert, N.P. Wiederhold, R.E. Lewis, D.P. Kontoyiannis</i>
E0056		Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits <i>R. Petraitiene* (New York, United States), E. Naing, A. Garcia, V. Zigmantaite, R. Grigaleviciute, A. Pocekevicius, M. Zimmerman, A.H. Groll, T.J. Walsh, V. Petraitis</i>

FO050 11:00 - 12:00 Arena 1

Open Forum

PHEI

HIV: a global ethical Conundrum

Chair	<i>Seif Al-Abri (Muscat, Oman)</i>	
F0147	11:00	HIV, from key population to general population: a Pandora's Box <i>Syed Faisal Mahmood (Karachi, Pakistan)</i>
F0148	11:10	Ethical considerations in preventing mother-to-child HIV transmission <i>Glory Alexander (Bangalore, India)</i>
F0149	11:20	HIV drug trials in Africa: ethical concerns <i>Shah Reena (Nairobi, Kenya)</i>

ESCMID Global 2025 - Programme

F0150 11:30 **HIV-related stigma and discrimination in the healthcare setting** *Teymur Noori (Stockholm, Sweden)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

EF014 11:00 – 12:00 **Arena 2**

ePoster Flash Session

IPC PHEI

Infection control and prevention around the World

Chair *Divyashree Shanthamurthy (Mumbai, India)*

E0092 **WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets** *P. Bischoff* (Geneva, Switzerland), S. Tomczyk, G. Satta, E. Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, B. Allegranzi*

E0093 **Healthcare-associated infections in african intensive care units: A multicentre prospective cohort study** *B. Gaye* (Dakar, Senegal), N. Madani, J. Ben Khilil, A. Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. Elombila, W. Najja, M. Kahloul, R. Herch, R. Toumi, E. Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. Badis, L. Messaoud, A. Bouzid, S. Feki, H. Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. Faye, L. Ouanes Besbes, Z. Hammouda, M.S. Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. Ghadhoune, S. Soui, H. Hmouda, R. Ben Dabebiss, A. Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj, H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, R. Abouqal, Y. Coulibaly*

E0094 **Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022** *E. Liddy* (Dublin, Ireland), A. Vellinga, D. Amin*

E0095 **Epidemiology of Central Line-Associated Bloodstream Infections (CLABSIs) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network** *I. Kopsidas* (Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou*

E0096 **Characterisation of plasmids disseminating antibiotic resistance in *Klebsiella pneumoniae* isolates from Pretoria, South Africa** *T. Govender* (Pretoria, South Africa), A. Moultrie, M. Moodley, J. Featherston, M. Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. Said, M. Ehlers, M. Kock*

E0097 **Transmission dynamics of carbapenemase-producing bacteria between hospital and household settings in Benin** *K. Sintondji* (Abomey-Calavi, Benin), V. Dougnon, B. Legba, B.G. Hougbenou, K. Fahiye, H. Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou*

E0098 **Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care units** *M. Salomão* (Sao Paulo Sp, Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, G. Mahon, M. Westercamp, M. Chiarastelli Salomao*

E0099 **Genomic Insights into the Rapid Rise of *Pseudomonas aeruginosa* ST463: A High-Risk Clone's Adaptive Strategy in China** *X. Dong* (Hangzhou, China)*

E0100 **Nanopore long-read only genome assembly for public health surveillance of Enterobacteriales bloodstream infections and plasmid epidemiology in England: A pilot study** *D. Nagy* (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pannetta, G. Rodger, K. Hopkins, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown*

EF015 11:00 – 12:00 **Arena 3**

ePoster Flash Session

ANT CLN DX

Advances in the diagnosis and treatment of skin, bone, and joint infections

Chair *Norma Jung (Köln, Germany)*

E0101 **Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic** *F. Petri* (Milan, Italy), F. Borghonovo, O.K. Mahmoud, R. Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone, A. Gori, E. Berbari*

E0102 **Synovial fluid microRNA biomarkers enable accurate diagnosis of periprosthetic joint infection** *B.J.H. Frank* (Vienna, Austria), T. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A. Diendorfer, M. Hackl, J. Hofstaetter*

E0103 **Diagnostic accuracy of 16S rDNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis** *F. Olearo* (Hamburg, Germany), S. El Zein, E. Portillo M, A. Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker*

E0104 **Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study** *G. Franceschi* (Modena, Italy), M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi, A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni, G. Pavesi, M. Cristina*

E0105 **Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study** *A. Diarra* (Tourcoing, France), V. Delastours, A. Bleibtreu, H. Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B. Valentin, M. Bermejo, P. Gazeau, A. Baldoli, B. Lefevre, A. Asquier, J. Courjon, R. Larcher, L. Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry, I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O. Robineau, E. Senneville*

E0106 **Real-Life Experience with Dalbavancin as Suppressant Antibiotic Treatment in orthopaedic implant-related infections** *R. Escudero-Sánchez* (Madrid, Spain), S. De La Villa Martínez, A. Rico Nieto, M. Sanchez-Somolinos, M. Tacias Pitarch, M. Salaver Lletj, M. Correa Ballester, R. Blanez Hernández, E. Calabuig Muñoz, M. Montero Alonso, L. Guio Carrion, J. Gomez Junyent, M.L. Sorli, F. Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J. Perez-Somarribas Moreno, J.M. Barbero Allende, M.J. Garcia Pais, F.J. Martinez Marco, A. Galeote Rivas, B. De La Torre Escudero, J. Cobo*

E0107 **Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial** *M. Dudareva* (Oxford, United Kingdom), M. Scarborough, M. McNally, M. Kumin, C. Scarborough, W. Vach, J. Ferguson*

E0108 **Clinical and Antibacterial Diversity of *Staphylococcal* Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspective** *F. Zeeshan* (Karachi, Pakistan), A. Naeem, F. Uddin*

E0109 **Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11-year retrospective study** *F. Romani* (Modena, Italy), A. Bedini, A. Spadoni, G. Manzini, G. Franceschi, B. Fontana, M. Sarti, C. Mussini*

ESCMID Global 2025 - Programme

EF016 11:00 – 12:00 Arena 4

ePoster Flash Session

AMR CLN PHEI

Rising threats: antimicrobial resistance in STIs

Chair Marcos Rust (Feldkirch, Austria)

E0110 Important rise of antibiotic resistance of *Mycoplasma genitalium*, a sexually transmitted pathogen, in a French University hospital. *F. Doucet Populaire** (Clamart, France), *W. Ben Nejma, C. Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. Guillet-Caruba, N. Bourgeois-Nicolaos*

E0111 Molecular characterization of antimicrobial resistance and genotyping of *Mycoplasma genitalium* positive samples of the Lisbon area, Portugal. *M. Barros** (Lisbon, Portugal), *F. Pereira, L. Rodrigues*

E0112 Antimicrobial Resistance in *Mycoplasma genitalium*: Surveillance and Management in São Paulo, Brazil. *V. Passarelli** (São Paulo, Brazil), *F. Goldemberg, A. Freitas, C. Picone, C. Lazari, G. Carnevale, M. Thomazella, S. Chamarelli, D. Gennari, C. Pedrozo, G. Hughes, S. Costa*

E0113 Impact of genotypic substitutions on treatment failure for *Mycoplasma genitalium* infection. *N.B. Bana** (Milan, Italy), *A. Nava, D. Fanti, C. Vismara, G. Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. Mulè, L. Denti, M. Puoti, R. Rossotti*

E0114 Macrolide-resistant *Mycoplasma genitalium*: an emerging threat to public health? *J. Ciscar Soriano** (València, Spain), *J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Valentín-Martín, A. Hernández-Cabezas, J.L. Lopez-Hontangas*

E0115 Comparison of carbapenem MIC in wild-type, MDR and XDR *Neisseria gonorrhoeae* isolates. *J. Brousseau** (Paris, France), *A. Braille, M. Mainardis, F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot*

E0116 Unsettling surge in antimicrobial resistance patterns of *Neisseria gonorrhoeae* - A study from national reference centre in India. *D. Sharma** (Delhi, India), *S. Muralidhar, N. Joshi*

E0117 Surveillance of *Neisseria gonorrhoeae* antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024. *M. Giovanni** (Singapore, Singapore), *A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S. Goh, S.T. Koh, Y.E. Tan*

E0118 Molecular surveillance results of *N. gonorrhoeae* in Korea. *K.H. Roh** (Goyang, Korea, Republic of), *C. Liu, Y.H. Suh, H. Lee, K. Lee*

KN044 11:00 – 12:00 Hall 1

Keynote Lecture

AMR PHEI

Asia: an AMR Hot Zone

Chairs *Giulia De Angelis* (Rome, Italy)
Robert Leo Skov (Copenhagen, Denmark)

K0136 11:00 *David L. Paterson* (Singapore, Singapore)

OS010 11:00 – 12:00 Hall 10

1-hour Case Session

CLN

Antimicrobial drugs in action

Chairs *Katy Jeannot* (Besançon, France)
Timothy R. Walsh (Oxford, United Kingdom)

O0072 *In vivo* cefiderocol resistance due to *cirA* modification during treatment. *E. Carretto** (Reggio Emilia, Italy), *P. Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, M. Bardaro, N.C. Facciolongo, S. Mezzadri, T. Walsh*

O0073 Long-term outcomes in dalbavancin-treated patients with vascular graft infection. *A. Specklin** (Reims,

France), *T. Noëi, M. Bonnet, A. Duprey, M. Hentzien*

O0074 Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant *E.coli* on peritonitis in a pediatric liver transplant recipient. *R. Morales Junior** (Cincinnati, United States), *V. Juodinis, C. Donini, J. Sampaio*

O0075 Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by *Cutibacterium acnes* – a case series. *M. Karolyi** (Vienna, Austria), *D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fiscoeder, M. Ortler, C. Wenisch*

O0076 Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant *K. pneumoniae* shunt-related ventriculitis: two case reports. *G. Giuliano** (Siena, Italy), *M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello*

SY047 11:00 – 12:00 Hall 11

1-hour Symposium

IPC

How long should contact isolation precautions be continued?

Chairs *Cansu Cimen* (Oldenburg, Germany)
Kyriaki Tryfinopoulou (Heraklion, Greece)

S0141 11:00 Contact isolation in patients with MDR organisms: Why, when, where? *Gabriel Birgand* (Nantes, France)

S0142 11:30 Is discontinuation of contact precautions associated with an increase in infections? *Daniel Diekema* (Harpswell, United States)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS

ME048 11:00 – 12:00 Hall 12

Meet-the-Expert

DX

Cut a long story short: choosing NGS platforms

M0143 11:00 *Etienne Ruppe* (Paris, France)

M0144 11:12 *Stefan Green* (Chicago, United States)

OS011 11:00 – 12:00 Hall 13

1-hour Oral Session

ANT TRN

Around the lab in 80 ways: a journey through innovative therapeutics

Chairs *Zuzanna Drulis-Kawa* (Wroclaw, Poland)
Helena Zemlickova (Prague, Czech Republic)

O0077 *In vivo* expression of an mRNA encoded multi-mechanistic mAb combination against *Staphylococcus aureus* and protection in a disease model. *C. Tkaczyk** (Gaithersburg, United States), *N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio, S. Bret*

O0078 Hijacking intrinsic resistance in *Mycobacterium abscessus*. *G. Phelps** (Memphis, United States), *S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee*

O0079 Tripartite bacteriophage-based strategy to combat human clinical pathogens. *P. Kalatzis** (Copenhagen, Denmark), *R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M. Clokie, T. Sicheritz-Pontén*

ESCMID Global 2025 - Programme

00080	Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy <i>Y. Tekintas* (Cigli, Türkiye), P.B. Savage, M. Ucuncu</i>
00081	Identification of compounds capable of removing established bacterial biofilms <i>T. Inzana* (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar</i>

ME049	11:00 – 12:00	Hall 14
	Meet-the-Expert	

PRO

How to perform clinical trials in mycoses?

M0145	11:00	<i>Monica Slavin (Melbourne, Australia)</i>
M0146	11:12	<i>Nkechi Azie (Barrington, United States)</i>

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

OS012	11:00 – 12:00	Hall 15
	1-hour Oral Session	

PHEI

Climate Impact and One Health Approaches Against Infectious Diseases

Chair *Chadia Wannous (Paris, France)*

00082	Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective <i>C. Royo-Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. Vilanova Gonzalez, M. Clusas Antolin, L. Trapero</i>
00083	Effects of climate change on Aedes aegypti abundance and dengue transmission <i>L. Geng* (Singapore, Singapore)</i>
00084	Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia <i>M. Fereidouni* (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshkar-Jahromi</i>
00085	Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning <i>E. Athan* (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. O'Brien, E. Layton, A. Fdao, S. Salmon, R. Kinnear</i>
00086	Turning disease surveillance into reality: Using metagenomic sequencing with piggery wastewater <i>M. Muralidhar* (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni</i>

OS013	11:00 – 12:00	Hall 16
	1-hour Oral Session	

CLN DX

Viral challenges in organ transplantation

Chair *Cristiana Oprea (Bucharest, Romania)*

00087	Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients <i>I. Rodríguez-Goncer* (Madrid, Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López-Medrano, J.M. Aguado, I. Rodríguez-Góncer</i>
00088	Real-world Use of Letemovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients <i>A. Mughrabi* (Rochester, Minnesota, United States), B. Bisono-García, S. Chesdachai, N. Ranganath, R. Razonable</i>
00089	Real-world administration of maribavir beyond the eight weeks established in the clinical trial <i>D. Martínez-Simón* (Barcelona, Spain), C. Ribera-Puig,</i>

M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P. Cléries-Rovira, A. Padullés, N. Sabé Fernández, M. Tuset, O. Len

00090	Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients <i>M. Solís* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer</i>
-------	---

00091	Dengue in solid organ transplant recipients <i>S.I. Galian* (Buenos Aires, Argentina), N. Pujato, N.S. Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin, G. Werber</i>
-------	---

SY045	11:00 – 12:00	Hall 2
	1-hour Symposium	

CLN

What happens following TB infection?

Chairs *Catherine Ong (Singapore, Singapore)*
Sean Wasserman (London, United Kingdom)

S0137	11:00	Post-TB disease: burden and treatment strategies <i>Deborah Chong (London, United Kingdom)</i>
S0138	11:30	TB sequelae and fungal infection <i>Helmut Salzer (Linz, Austria)</i>

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet

YIA	11:00 – 12:00	Hall 3
	Awards	

PRO

Young Investigator Award Session

A001	11:00	Deciphering the pathogenic traits and epidemiological identities of <i>Staphylococcus pseudintermedius</i>: an emerging and underestimated zoonotic pathogen <i>Ikechukwu Benjamin Moses (Abakaliki, Brazil)</i>
A002	11:12	Drugs for Vector-borne Infections: Facts and Fibrillations <i>Xin Hui Chan (Oxford, United Kingdom)</i>
A003	11:24	Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet? <i>Matthaios Papadimitriou Olivgeris (Sion, Switzerland)</i>
A004	11:36	Finding a place for observational studies in infectious diseases research <i>Anthony Bai (Kingston, Canada)</i>
A005	11:48	Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis <i>Simon Feys (Leuven, Belgium)</i>

SY046	11:00 – 12:00	Hall 5
	1-hour Symposium	

TRN VAX

New frontiers in bacterial pathogenesis

Chairs *Silvio Daniel Brugger (Zurich, Switzerland)*
Abdou Hachani (Melbourne (vic), Australia)

S0139	11:00	Bacterial infections and cellular immunity <i>Charlotte Odendall (London, United Kingdom)</i>
S0140	11:20	Immuno-metabolism in bacterial diseases <i>Tania Wong (New York, United States)</i>

OS007	11:00 – 12:00	Hall 6
	1-hour Oral Session	

ANT CLN VAX

New developments in prophylaxis and treatment of COVID-19

Chairs *Gülşen Özkaya Sahin (Lund, Sweden)*
Snjezana Zidovec Lepej (Zagreb, Croatia)

ESCMID Global 2025 - Programme

00057	Ensitrelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEPF. Hayden* (Virginia, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara
00058	Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J.C. Cappelleri
00059	COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach. T.F. Aiello* (Barcelona, Spain), C. Teijón-Lumbreras, C. Garcia-Vidal, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó-Gallo, A. Gallardo-Pizarro, A. Martínez-Urrea, R. Méndez, E. Calbo, M. Ballester-Tellez, G. Cuesta-Chasco, M. Marcos, A. Soriano
00060	Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola
00061	Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRY trial C. Massonnaud* (Paris, France), M. Hites, N. Peiffer-Smadja, T.H.L. Han, G. Carcelain, F. Menétré, F. Ader

OS008	11:00 - 12:00	Hall 7
	1-hour Oral Session	

Advancing Malaria Research: From Molecular Insights to Clinical Challenges

Chairs	Kamruddin Ahmed (Kota Kinabalu, Malaysia) Giri Shan Rajahram (Kota Kinabalu, Malaysia)
00062	Influence of second blood meals on <i>Plasmodium vivax</i> development and infectivity in mosquitoes S. Bantuchai* (Bangkok, Thailand), W. Nguitragoon, J. Sattabongkot, C. Kumpitak
00064	Severe imported <i>Plasmodium falciparum</i> malaria with hyperparasitaemia: evaluation of predictors for critical disease T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharter, F. Kurth
00065	The current status of <i>Plasmodium falciparum</i> chloroquine resistance transporter gene (K76T) and <i>Plasmodium falciparum</i> multi-drug resistance gene 1 (N86Y) in Cameroon M. Fru* (Buea, Cameroon)
00066	SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed. E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes

OS009	11:00 - 12:00	Hall 8
	1-hour Case Session	

Osteoarticular uninvited guests

Chairs	Tiziana Ascione (Naples, Italy) Jaime Esteban (Madrid, Spain)
00067	Antibiotic-refractory oligoarthritis in an adolescent caused by <i>Borrelia bavariensis</i> in Croatia N. Kračar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglič, R. Beck, G. Tešović
00068	Progression of vertebral echinococcosis despite radiotherapy treatment M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegria, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D.

00069	Two cases of septic osteoarthritis of <i>Cutibacterium acnes</i> detected by 16S rRNA gene sequencing in immunocompetent adolescents H. Okuno* (Osaka, Japan), K. Shiota, K. Arno
00070	A UK case of Melioidosis with osteomyelitis two years after geographical exposure C. Darlow* (Liverpool, United Kingdom), L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis
00071	When Infection Masquerades as Malignancy: A Case of Disseminated <i>Mycobacterium fortuitum</i> complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN-γ Immunodeficiency Syndrome N. Hiranburana* (Bangkok, Thailand), S. Khahakaew, K. Meesilpavikkai, M. Satja, G. Suwanpimolkul

LBO01	11:00 - 12:00	Hall 9
	1-hour Oral Session	

Advances in vaccine effectiveness for viral respiratory infections

L0001	Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants A. Figueroa* (Cambridge, United States), D. Edwards, K. Johnson, D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt
L0002	JN.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using id.DRIVE H.R. Volkman* (New York, United States), L. De Munter, J.L. Nguyen, T.M.P. Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite, S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E. Marto, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M. Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S. Otero-Romero, A. Riva, A. Torres, F. Martinon Torres, L. Jodar, J.M. McLaughlin, K. Bollaerts
L0003	Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults ≥ 65 years of age in the United States A. Miles* (New York, United States), J.T. Vietri, S. Rosenstock, H. Li, J. Vojčić, L.R. Grant, A. Randall, B.D. Gessner, P. Balmer, A. Cane, P. Peyrani
L0004	Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure D. Jenkin* (Oxford, United Kingdom), E. Sheehan, R. Huq, T. Lambe, S. Gilbert, A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil, N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi, S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O. Mazur, H.T. Belhadef, B. Stoilova, D. Pulido-Gomez, H. Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L. Mclellan, O. Hamilton, V. Simpson, J. Court, N. Murphy, M. Farrar, P. Saunderson
L0005	Vaccination in pregnancy with RSVpreF elicits IgG, IgA and total secretory antibody responses in milk of lactating individuals J. Atwell* (New York, United States), R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan, S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B. Gessner

SY051	13:30 - 14:30	Hall 1
	1-hour Symposium	

Year in infectious diseases

Chairs	Nur Benzonana (Istanbul, Türkiye) Evelina Tacconelli (Verona, Italy)	
S0151	13:30	Yoav Keynan (Winnipeg, Canada)
S0152	14:00	Elisa Cordero Matia (Seville, Spain)

ESCMID Global 2025 - Programme

SY053 **13:30 – 14:30** **Hall 16**
1-hour Symposium

PRO

Developing guidelines with AI tools: are they ready for prime time?

Chairs *Miranda Langendam (Amsterdam, Netherlands)*
Blin Nagavci (Gjakove, Kosovo)

S0155 **13:30** **The PROs and CONS of using AI tools for developing guidelines***Holger Schünemann (Hamilton, Canada)*

S0156 **14:00** **AI in action: validated tools for speeding up your systematic reviews and how to use them***Sara Fernandez (Oslo, Norway)*

Co-organised with: ESCMID Guidelines Subcommittee

SY052 **13:30 – 14:30** **Hall 2**
1-hour Symposium

IPC PHEI

Exploring children's role in infection spread

Chairs *Angelika Berger*
Sanjay Patel (Winchester, United Kingdom)

S0153 **13:30** **Are children really super-spreaders of respiratory viruses?***Emmanuel André (Leuven, Belgium)*

S0154 **14:00** **Should schools be closed at the start of the next pandemic?***Vittoria Colizza (Paris, France)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

EF021 **13:30 – 14:30** **Arena 1**
ePoster Flash Session

AMR CLN DX

Infections in hemato-oncological hosts: from bacterial to viral

Chair *Genovefa Papanicolaou (New York, United States)*

E0139 **Vancomycin-resistant *Enterococcus faecium* bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control study***J. Fung* (Vancouver, Canada), K. Aldhaferi, C. Nishi, J. Lau, A. Mah, A. Wright, R. Stubbins, M. Charles, S. Belga*

E0140 **Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacilli.***J. Grafia* (Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, M. Espasa, D. Marco, S. Fernández, J. Marco-Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Viladot, A. Tuca, P. Puerta-Alcalde*

E0141 **Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy***C. Charalampidis* (Athens, Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. Lazana, C. Chatzidimitriou, A. Zormpa, E. Mastrostamati, I. Grigoropoulos, D. Kavatha, S. Tsiodras, P. Tsirigotis, K. Thomas*

E0143 **The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy***B. Teh* (Melbourne, Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, P. Kinsella, N. Laundry, J. Wolfe, L. Cooley, M.K. Yong, M.A. Slavin*

E0144 **Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity***P. Bono* (Milan, Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, C. Blassoni, G. Giacometti, A. Valzano, M.R. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri*

E0145 **Safety and tolerability of SYN-004 in allogeneic**

hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)*E. Dubberke* (Saint Louis, United States), M. Schroeder, H. Sappington, G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E. Jeremy, M. Keller, A. Bristol, C. Le, S. Connolly, M. Moenk, V. Wacher, M. Kaleko, J. Kuti, M. Olsen*

E0146

Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipients*S. De Aragón De La Cruz* (Basel, Switzerland), C.S. Walti, N. Khanna, K. Leuzinger, J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J. Vosbeck*

E0147

Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patients.*J. Boan Perez* (28010, Spain), J. Boán, J.M. Sánchez-Pina, C. Aizpurúa, I. Rodríguez-Goncer, F. López-Medrano, R. San-Juan, M. Fernández-Ruiz, E. Aparicio, M. Lizasoain, J.M. Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado*

EF022

13:30 – 14:30

Arena 2

ePoster Flash Session

DX

Syndromic testing is still coming of age

Chair *Tommaso Giani (Florence, Italy)*

E0148

Bacterial infections of the central nervous system: addressing the diagnostic gap in non-community-acquired meningitis*G. Menchinelli* (Rome, Italy), M. Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis, B. Posteraro, M. Sanguinetti*

E0149

Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platform*M. Rey* (Barcelona, Spain), L. Pau, C. Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona*

E0150

Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian Hospital*S. Subedi* (Brisbane, Australia), P. Harris, D. Paterson*

E0151

Performance evaluation of the NxTAG® GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospital.*S. Gibaud* (Nantes, France), L. Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P. Lepape, S. Corvec*

E0152

Correct discrimination of Monkeypox virus clades by fast syndromic testing*S. Reister* (Hilden, Germany), L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S. Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-Cámara, J. Michel, A. Puyskens, F. Van Deursen, D. Lueerssen*

E0153

Managing a *Mycoplasma pneumoniae* Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric Emergencies*L. Brusca* (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-Borrás, G. Santillana-Cernuda, M. Ballesterro-Tellez, A. Boronat, J. Perez*

E0154

Performance of BIOFIRE® FILMARRAY® Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – Interim analysis*R. Riccardi* (Bologna, Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P. Viale, M. Giannella*

E0155

Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremia*S. Chantharasut* (Bangkok, Thailand), M. Chayakulkeeree, W. Kamolvit, A. Jitmuang, I. Thaipisuttikul*

E0156

BacteREVEAL: Analytical performance and contribution of BioFire® BCID2 and Vitek® REVEAL™ in intensive care patients with Gram-negative bloodstream infections*C. Roger* (Nîmes, France), L. Oudiane, M. Benyahia, F. Salipante, A.*

ESCMID Global 2025 - Programme

Dubois, L. Muller, J.P. Lavigne, A. Pantel

EF023 13:30 - 14:30 Arena 3

ePoster Flash Session

DX

Effective microbiology for the management of sepsis

Chair Maurizio Sanguinetti (Rome, Italy)

- E0157** **Molecular epidemiology of Klebsiella bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS study** D. Nagy* (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown
- E0158** **Investigating seasonality of antibiotic resistance associated with *E. coli* and *Klebsiella pneumoniae* bloodstream infections** S. Lipworth* (Oxford, United Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, K. Turner
- E0159** **Sensitivity of a host-protein test for microbiologically confirmed bacterial infections** N. Navon* (Tirat Carmel, Israel), E. Reiner, O. Shaham, A. Neuberger, S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. Aufderheide
- E0160** **Comparative genomics of *Klebsiella pneumoniae* from gut colonisation and bloodstream infections reveal novel genetic associations** M. Hetland* (Stavanger, Norway), K.L. Wyres, H.B. Cooper, A. Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr
- E0161** **Conventional microbiology vs. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort study** G. Sanlıdag İsbilen* (Izmir, Türkiye), G. Şanlıdağ İşbilen, B. Akkul, C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, B. Arda, O.R. Sipahi
- E0162** **Contribution of *Escherichia coli* microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control study** N. Maldonado* (Seville, Spain), I. López-Hernández, L.E. López-Cortes, P.M. Martínez Pérez-Crespo, A. García-Montaner, M. Alcade-Rico, A. Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Pulido-Navazo, C. Labayru Echeverría, A.I. Aller-García, L. Boix-Palop, A. Del Arco-Jiménez, A. Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-Kindelán, J.M. Reguera Iglesias, C. Armiñanzas-Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea-Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual-Hernández, J. Rodríguez-Baño
- E0163** **Simplified and rapid bacterial identification with antimicrobial resistance detection in bacteremia by on-chip multiplexed LAMP** C. Treille* (Saclay, France), K. Perez-Toralla, H. Boutal, X. Garcia Velasquez, L. Pommies, S. Simon, H. Volland
- E0164** **Community-onset bloodstream infection among people with oploid use disorders: A twenty-year population-based cohort study in Queensland, Australia** K. Laupland* (Herston, Australia), A. Stewart, F. Edwards, P. Harris, S. Coulter
- E0165** **Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgery** S. Soueges* (Lyon, France), A. Blanco, A. Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della-Schiava, U. Huvelle, A. Millon, F. Valour

EF024 13:30 - 14:30 Arena 4

ePoster Flash Session

AMR TRN

A never-ending evolution of antimicrobial resistance

Chair Antonio Oliver (Palma De Mallorca, Spain)

- E0166** **Gfa, a novel integron-born fosfomycin resistance mechanism** N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, J.A. Escudero
- E0167** **Regulons of Rama, RarA and SoxS mediated tigecycline resistance and oxidative stress among *in vitro* tigecycline resistant evolution trajectory of *Klebsiella pneumoniae*** X. Wang* (Beijing, China), J. Kuai, Y. Zhao
- E0168** **Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing *Escherichia coli*** C. Tellapragada* (Stockholm, Sweden), P. Jonsson, C. Giske
- E0170** ***Enterococcus faecalis* penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentration** O. Funk* (Brooklyn, United States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S. Brown, J. Cusumano
- E0171** **Uncommon genomic rearrangements drive vancomycin resistance in *vanB*-positive *Enterococcus faecium*** K. Xanthopoulou* (Cologne, Germany), J. Mellüh, R. Arazo Del Pino, L. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L. Maus, A. Klimka, P.G. Higgins
- E0172** **Heteroresistance in *Enterococcus faecalis*: prevalence and mechanistic insights across clinically relevant antibiotics** S. Heidarian* (Uppsala, Sweden), S. Lohsen, A. Gulliaev, K. Hjort, S. Satola, D. I. Andersson
- E0173** **Side effects of rifampicin resistance: transcriptome modulation by *rpoB* mutations in *Staphylococcus aureus*** M. Roch* (Geneva, Switzerland), R. Sierra, C. Colomer Winter, F. Bezrukov, O. Panasenka, A. Guisolon, U. Von Ah, M. Villanueva, P. Redder, K. Kline, J. Prados, W.L. Kelley
- E0174** **Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistance** T. Echelmeyer* (Greifswald, Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H. Fickenscher, G. Maschkowitz, D. Nurjadi, R. Podschun, K. Schaufler, E. Eger

OS018 13:30 - 14:30 Hall 11

1-hour Oral Session

ANT IPC

Battling the Spore: *C. difficile* epidemiology and management

Chairs Nicolas Benech (Lyon, France)
Fidelma Fitzpatrick (Dublin, Ireland)

- O0124** **Molecular epidemiology and antimicrobial resistome of *Clostridioides difficile* from private and public healthcare settings in three provinces in South Africa** H. Shirinda* (Pretoria, South Africa), A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers
- O0125** **Screening for *Clostridioides difficile* colonization at admission and during hospitalization** N. Khanafar* (Lyon, France), S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems
- O0126** **Revolutionizing CDI treatment: Are shorter antibiotic regimens the future** M. Duricek* (Prague, Czech Republic), J. Benes, K. Halmova
- O0127** **Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of *Clostridioides difficile* infection** E. Rubio-Martín* (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Diaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tacias, R. Blanes, M.Á. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella-Rodríguez, L. Ramos Merino, B. Castelo López, M.M.

ESCMID Global 2025 - Programme

00128 **Gut phageome profiling in *Clostridioides difficile* infection and faecal microbiota transplantation C.**
*Chen** (Lausanne, Switzerland), *T. Pillonel, J. Schaer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine*

Montero, D. Echeverría-Esnal, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo

OS019 **13:30 – 14:30** Hall 12

TRN

1-hour Oral Session

Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential

Chairs *Mauricio Farfan (Santiago, Chile)*
Eija Inkeri Könönen (Turku, Finland)

00129 **Multi-omics integrated analysis revealed the key role of *Fusobacterium periodonticum* in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis.**
*X. Chu** (Beijing, China), *Q. Yang*

00130 **Exploring the respiratory microbiome in COPD patients: The role of *Haemophilus* spp. in disease pathogenesis.**
*P. Camps-Massa** (Barcelona, Spain), *L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara-Nuñez, F. Tubau, J. Burgos, M. Lopez, A. González-Díaz, C. Ardanuy, M. Domínguez, S. Santos, S. Martí*

00131 **Using the in vitro MIGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes.**
*I. Moura** (Leeds, United Kingdom), *W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley*

00132 **Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human health.**
*M. Thorp** (Gent, Belgium), *C. Callewaert, B. De Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. Vereecke*

00133 **Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria?**
*K. Villageois-Tran** (Bobigny, France), *C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, E. Ruppé*

ME055 **13:30 – 14:30** Hall 14

CLN

Meet-the-Expert

Long acting injectables to treat and prevent infections: an example from HIV field

M0159 **13:30** *Monica Gandhi (Salt Lake City, United States)*

M0160 **13:42** *Pedro Cahn (Buenos Aires, Argentina)*

OS020 **13:30 – 14:30** Hall 15

ANT

1-hour Oral Session

How to evaluate AMS programs

Chairs *Esther Calbo (Terrassa, Barcelona, Spain)*
Sabiha Essack (Durban, South Africa)

00134 **Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data.**
*N. Nguyen** (Oxford, United Kingdom), *K. Pouwels, J.V. Robotham, S. Yu, S. Wordsworth*

00135 **Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study.**
*B. Moshy** (London, United Kingdom), *R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan*

00136 **Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital.**
*V. Huang** (Glendale, United States), *T. Pham, A. Vogler, H. Chhen, C. Vandenberg*

00137 **Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting.**
*A. Hopkins** (Livingston, United States), *A. Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime*

00138 **Timing of Novel β -Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings.**
*E. Yucel** (Rahway, United States), *J. Min, Y. Wang, M. Vendetti, Y. Emre, R.K. Shields*

ME054 **13:30 – 14:30** Hall 3

AMR TRN

Meet-the-Expert

How antimicrobial tolerance impacts polymicrobial biofilm-associated infections

M0157 **13:30** *Hans Steenackers (Leuven, Belgium)*

M0158 **13:42** *Brian Conlon (Chapel Hill, United States)*

OS017 **13:30 – 14:30** Hall 5

CLN

1-hour Case Session

Bad bacteria

Chairs *Maristela P. Freire (Sao Paulo, Brazil)*
Siegbert Rieg (Freiburg, Germany)

00119 **Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug?**
*R. Gupta (bagga)** (London, Canada), *R. Gupta, A. Cabrera, A. Kanyua, F. Almutawa, J. Delpont, K. Kavanoor Sridhar*

00120 **Whipple's disease: one of medicine's great imitators.**
*S. Kesavan** (Nottingham, United Kingdom), *F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos, R. Thomson*

00121 **Phage Therapy as a Rescue Treatment for Recurrent *Pseudomonas aeruginosa* Bental Infection.**
*V. Eiferman** (Paris, France), *P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu*

00122 **A clinical case of *Legionella longbeachae* pneumonia featuring unique epidemiological features in a major Italian hospital.**
*S. Guerriero** (Rome, Italy), *M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti*

00123 ***Francisella tularensis* – First autochthonous case in the UK.**
*G. Vanstone** (Truro, United Kingdom), *A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou*

ME061 **14:45 – 15:45** Hall 3

PHEI TRN

Meet-the-Expert

How to use large language models and machine learning for improving One Health

M0170 **14:45** *Javier Fernández (Oviedo, Spain)*

M0171 **14:57** *Nicolas Radomski (Teramo, Italy)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)

ESCMID Global 2025 - Programme

FO063 14:45 – 15:45 Arena 1
Open Forum

PRO

Science communication in a noisy world: podcasting and social media in ID/CM

Chair *Emily G. McDonald (Montreal, Canada)*

FO174 14:45 **The ID:IOTS guide to creating a successful CM/ID podcast**[†] *Callum Mutch (Edinburgh, United Kingdom)*

FO175 14:55 **Using social media for CM/ID education***Scott Jake (Oakland, United States)*

FO176 15:05 **Podcasting and social media for antimicrobial stewardship and pharmacy***Erin McCreary (Pittsburgh, United States)*

Co-organised with: CMI Communications Board of Editors

EF029 14:45 – 15:45 Arena 2
ePoster Flash Session

VAX

Vaccination uptake-challenges and opportunities

Chair *Joanne M. Langley (Halifax, Canada)*

E0195 **Electronic nudges to increase influenza vaccination uptake among patients with heart failure: insights from 3 nationwide randomized trials enrolling >2 million patients***N.D. Johansen* (Hellerup, Denmark), M. Vaduganathan, A.S. Bhatt, D. Modin, B.L. Claggett, K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, E.L. Dueger, S. Samson, M.M. Loiacono, R.C. Harris, L. Køber, S.D. Solomon, P. Sivapalan, J.U.S. Jensen, T. Biering-Sørensen*

E0196 **Psychological Predictors of Influenza Vaccination Intent Among Healthcare Workers in Bulgaria***P. Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, Y. Tcholakov, V. Borisova-Nenov[], D. Ivanov, A. Zasheva, A. Hori*

E0197 **Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort study***Q. Hofsink* (Amsterdam, Netherlands), T. Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J. Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg, C.E. Rutten, S. Haggenburg, P. Den Tex, A. Dinmohamed, J. Kemmeren, H. De Melker, S. Van Den Hof*

E0199 **Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programme***A.C.M. Breschel* (Copenhagen, Denmark), A.V. Søndergaard, S.K. Nørgaard, B. Søborg, P.H. Andersen*

E0200 **Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024***M. Hakim* (Hayat Abad Peshawar Kp Pakistan, Pakistan)*

E0201 **Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIV***D. Yaman* (Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu, D. Gökengin*

E0202 **Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018–2022A***Palmborg* (Stockholm, Sweden), F. Angulo, P. Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar*

E0203 **Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkey***C. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E. Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal*

EF030 14:45 – 15:45 Arena 3
ePoster Flash Session

CLN DX PHEI

Viruses crossing the blood-brain barrier

E0204 **Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort study***L. Duerlund* (Aarhus, Denmark), L. Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Andersen, H. Nielsen, J. Bodilsen*

E0205 **Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control study***S. Lant* (Liverpool, United Kingdom), R. Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea Carrera, M. Tullius, P. Brasil, C. Miguelote, A. Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim Rodrigues, R. Braga, L. Pamplona, C. Spitz, F. Militao, A. Rosala Hallas, G. Burnside, R. Vivancos, S. Leonhard, L. Rodrigues De Mendonça-Vieira, B. Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R. Franca, A. Bispo, T. Solomon*

E0206 **Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiology***C. Marin* (Bucharest, Romania), A. Paun, E. Nedu, S. Tetrado, S. Lazar, M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu, S.M. Ruta, C.P. Popescu*

E0207 **Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse model***Z. Ou* (Shenzhen, China), Z. Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng*

E0208 **Intrathecal immunoglobulin synthesis in tick-borne encephalitis***S. Grygorczuk* (Bialystok, Poland), P. Czupryna, D. Martonik, J. Dunaj-Małyszko, J. Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A. Moniuszko-Malinowska*

E0209 **B and T cell responses to Tick-borne Encephalitis Virus***N. Mayola Danes* (Stockholm, Sweden), R. Varnaité, N. Mayola Danés, K. Blom, H.G. Ljunggren, S. Gredmark-Russ*

E0210 **Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insights***D. Sharma* (Chandigarh, India), R. Pathania, P. Bhattacharya, M. Gautam, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh*

E0211 **Neuroimaging findings and their correlation with autopsy findings: Prospective study on Rabies encephalitis***M. Mohata* (New Delhi, India), V. Suri, P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K. Soni, K. Gupta*

E0212 **Toxoplasma gondii IgG Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era***T. Ou* (New Taipei City, Taiwan, China), T.Y. Tsai, S.H. Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C. Hung*

EF031 14:45 – 15:45 Arena 4
ePoster Flash Session

ANT CLN

AMS around the world: know your data!

Chair *Eoghan De Barra (Dublin, Ireland)*

E0213 **Duration of antibiotic treatment for respiratory tract infections in primary care***C. Llor* (Barcelona, Spain), M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H. Lindberg, I.K. Rebnord, R. Radzeviciene, L. Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk, C. Lionis*

E0214 **Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveys***N. Nguyen* (Oxford, United Kingdom), K. Pouwels, M. Sharland, S. Mangla, A. Cook, M. Thorn, P. Stephens*

E0215 **Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveys***N. Nguyen* (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland*

E0216 **Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescription***R. Koizumi**

ESCMID Global 2025 - Programme

(Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. Ohmagari

E0217	Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Survey. C. Palos* (Lisbon, Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa
E0218	Evaluating the impact on 28-day mortality of different empiric AWARe antibiotic treatment strategies for hospital-acquired infections across different hospital settings. C. Lim* (Oxford, United Kingdom), K.B. Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Walker, M. Sharland, B.S. Cooper
E0219	Update on WHO's Global antibiotic use surveillance system (GLASS-AMU) B. Huttner* (Geneva, Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Tong
E0220	Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPSA. Versporten* (Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe
E0221	Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa

KN056	14:45 - 15:45	Hall 1
	Keynote Lecture	

Defending against dengue: global epidemiology and strategies for prevention and control

Chairs Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)

K0161 14:45 Fernanda Boulos (São Paulo, Brazil)

OS026	14:45 - 15:45	Hall 11
	1-hour Oral Session	

Carbapenem resistance Gram-negatives, what's new in treatment?

Chairs Robin Howe
Maria Milagro Montero (Barcelona, Spain)

O0180	Ceftriaxone sulbactam disodium EDTA combination (CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be? Y. Verma* (Hisar, India), K. Narang, D. Bhandish, C. Sharma
O0181	Sulbactam-durlobactam as an effective alternative option against NDM-producing <i>Escherichia coli</i> including cefiderocol and aztreonam-avibactam-resistant isolates in Switzerland C. Le Terrier* (Fribourg, Switzerland), P. Nordmann, A. Delaval, L. Poirel
O0182	Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by <i>In vitro</i> Antibiotic Combination Testing T. Lim* (Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa
O0183	Management of infections caused by ST308 New Delhi metallo-β-lactamase-producing <i>Pseudomonas aeruginosa</i> with <i>In vitro</i>-guided combination antibiotic therapy J. Teo* (Singapore, Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa
O0184	<i>In vitro</i> activity of cefepime/enmetazobactam against clinical isolates of <i>Enterobacterales</i> in Portugal: A multicentre retrospective study H. Cruz* (Porto, Portugal), C. Chaves, L. Carneiro

OS027	14:45 - 15:45	Hall 12
	1-hour Oral Session	

Staphylococcus aureus: colonisation, virulence, and persistence

O0185	The nasal microbiome redefines and predicts <i>Staphylococcus aureus</i> nasal colonisation status D. Aggarwal* (London, United Kingdom), K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. McMahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison
O0186	Development of a <i>Staphylococcus aureus</i> human nasal colonisation model A. Hachani* (Melbourne vic), Australia), B. Tran, E. Cho, R. Guérillot, B. Howden, T. Stinear, E. Vincan
O0187	Selection-free, virulence gene promoter-controlled CRISPR interference system for <i>In vivo</i> pathogenesis study of <i>Staphylococcus aureus</i> - A proof of concept R. Miah* (Tromsø, Norway), M. Johannessen, M. Kjos, C. Lentz
O0188	Placebo-controlled study of competitive exclusion using <i>Lactococcus lactis</i> to reduce transmission of LA-MRSA from pigs to humans B. Duim* (Utrecht, Netherlands), A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar
O0189	Rifampicin-induced <i>Staphylococcus aureus</i> persister formation is driven by CodY and oxidative stress level N. Pordone* (Lyon, France), J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P.O. Verhoeven

SY059	14:45 - 15:45	Hall 13
	1-hour Symposium	

Value-based syndromic diagnostics in medical microbiology: Pro / Con debate

Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Eric Claas (Leiden, Netherlands)

S0166	14:45	Pro: clinical benefit and potential for improved patient outcomes Kirstine K. Søgaard (Aalborg, Denmark)
S0167	15:15	Con: limitations, costs, and possible overuse of syndromic panels Gilbert Greub (Lausanne, Switzerland)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française

SY060	14:45 - 15:45	Hall 14
	1-hour Symposium	

We need to talk about toilets...

Chairs Stephanie J. Dancer (Glasgow, United Kingdom)
Juliette Severin (Rotterdam, Netherlands)

S0168	14:45	Infection risks from sanitation engineering Davey Jones (Bangor, United Kingdom)
S0169	15:15	Ventilation in toilets: how can we improve it? Michael Gormley (Edinburgh, United Kingdom)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)

OS028	14:45 - 15:45	Hall 15
	1-hour Oral Session	

ESCMID Global 2025 - Programme

Unlocking the potential of the human microbiome for clinical diagnostics

Chairs John W. A. Rossen (Groningen, Netherlands)
Maria Vehreschild (Frankfurt Am Main, Germany)

- 00190** **Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions.**
*Nalbantoglu** (Kayseri, Türkiye), A. Gundogdu, B.H. Ermis
- 00191** **Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis.**
*E. Rubio García** (Barcelona, Spain), E. Rubio-García, A. Pulgarin, R. López-Aladid, L. Martínez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual
- 00192** **Donor for fecal microbiota transplantation: a challenging research.**
*B.S. Orena** (Milan, Italy), M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani
- 00193** **Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy.**
*N. Boutouchent** (Rouen, France), S. Kennedy
- 00194** **Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology.**
*A. Gundogdu** (Kayseri, Türkiye), O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestimur, U. Ture

ME062 **14:45 – 15:45** **Hall 16**

ANT CLN

Meet-the-Expert

Untangling the web: antimicrobial dose adjustments in renal impairment

- M0172** **14:45** *Claire Roger* (Nimes, France)
- M0173** **14:57** *Isabel Spriet* (Leuven, Belgium)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

SY057 **14:45 – 15:45** **Hall 2**

ANT CLN

1-hour Symposium

Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?

Chairs Marc J.M. Bonten (Utrecht, Netherlands)
Karin Thursky (Carlton, Australia)

- S0162** **14:45** **Pro: maximising outcomes with evidence-based use.**
Evangelos Giamarellos-Bourboulis (Athens, Greece)
- S0163** **15:15** **Con: the risks of routine (over)use.**
Aurélien Dinh (Garches, France)

SY058 **14:45 – 15:45** **Hall 4**

VAX

1-hour Symposium

Top papers in transplant ID

Chair Nicolas Mueller (Zurich, Switzerland)

- S0164** **14:45** **Top 10 papers in infections in SOT.**
Patricia Munoz (Madrid, Spain)
- S0165** **15:15** **Top 10 paper in infections in HCT and cellular therapy.**
Joshua Hill (Seattle, United States)

OS025 **14:45 – 15:45** **Hall 5**

DX IPC

1-hour Oral Session

Bacterial battles: a paediatric perspective on infections and interventions

Chairs Angelika Berger
Julie Toubiana (Paris, France)

- 00175** **Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Pediatric Infections.**
*D. Dona** (Padova, Italy), D. Donà, G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito
- 00176** **Correlation between antibiotic consumption and digestive colonization with multidrug-resistant *Enterobacteriales* in a paediatric haematology department.**
*S. Frigui** (Tunis, Tunisia), N. Fitouri, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour
- 00177** **Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study.**
*S. Whelan** (Dublin, Ireland), M. Eogan, N. McCallion, A. Walsh, F. Moriarty, M. Elsammak, R. Drew
- 00178** **Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center.**
*E. Vaugon** (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard
- 00179** **Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre.**
*M. De Luca** (Rome, Italy), R. Iacobelli, S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancellata, L. Galletti

EW071 **16:15 – 18:15** **Hall 15**

PRO

Educational Session

The rare art of writing scientific articles: from conception to submission

Chairs Marlieke De Kraker (Geneva, Switzerland)
Mical Paul (Haifa, Israel)

- W0205** **16:15** **Expressing yourself correctly: writing tips.**
Angela Huttner (Geneva, Switzerland)
- W0206** **16:35** **Constructing your manuscript for an original article.**
Jesús Rodríguez-Baño (Seville, Spain)
- W0207** **16:55** **The use of artificial intelligence tools for writing articles: what to do and not to do.**
Erlangga Yusuf (Rotterdam, Netherlands)
- W0208** **17:15** **Selecting the best journal for my manuscript.**
Andre Kalil (Omaha, United States)

Co-organised with: CMI Board of Editors

SY069 **16:15 – 18:15** **Hall 16**

TRN

2-hour Symposium

Controlled human infection models

Chairs Frederick Hayden (Charlottesville, United States)
Nikolai Siemens (Greifswald, Germany)

- S0197** **16:15** **Updates on the dengue human infection model.**
Kirsten Lyke (Baltimore, United States)
- S0198** **16:45** **CHIM in endemic countries.**
Melissa Kapulu (Kilifi, Kenya)
- S0199** **17:15** **Controlled human infection models of parasitic infections.**
Meta Roestenberg (Leiden, Netherlands)
- S0200** **17:45** **Controlled human infection models of non-typhoidal *Salmonella*.**
Malick Gibani (London, United Kingdom)

Co-organised with: British Infection Association (BIA)

EF033 **16:15 – 17:15** **Arena 2**

AMR ANT CLN

ePoster Flash Session

Current treatment options for invasive fungal infections

Chair *Andreas H. Groll (Münster, Germany)*

- E0232** **The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonates.** *Z.D. Pana* (Nicosia, Cyprus), A.H. Groll, A. Bal, R. Sprute, F. Carlesse, S. Mellinshoff, S. Butzer, D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A. Marek, U. Ristau-Schäfer, O. Cornely*
- E0233** **Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centers.** *C. Palamin Buonafine* (São Paulo, Brazil), C.P. Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Cogniali, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T. Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro, C.C. Baqueiro, E.C. Francisco, A.L. Colombo*
- E0234** **Rezafungin showed high *in vitro* activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024.** *J. Guinea* (Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, P. Muñoz*
- E0235** **Posaconazole Drug-Drug Interaction Potential is Similar Across Bodyweight.** *R.E. Wrishko* (Rahway, United States), P. Kothare, T.J. Bateman, M.G. Johnson, A. Stoch*
- E0236** **Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosis.** *H. Kang* (Seoul, Korea, Republic of), A.C. Arrieta, C. Dhooze, A. Kelemen, M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Waskin, M.G. Johnson*
- E0237** **Activity of manogepix against a worldwide collection of mould isolates from 2023.** *M. Winkler* (North Liberty, United States), S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira*
- E0239** ***Candida auris* displays an inoculum effect with multiple antifungal drug classes.** *R. Ben-Ami* (Tel Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi*
- E0240** ***In vitro* olorofim activity against *Aspergillus* spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (ASPEN II and III).** *J. Guinea* (Madrid, Spain), P. Escribano, J. Moraga, A. Gomez, P. Muñoz*

EF034 **16:15 - 17:15** **Arena 4**

AMR IPC

ePoster Flash Session

Surgical site infections: epidemiology, risk factors, and prevention strategies

Chair *Trisha Peel (Melbourne, Australia)*

- E0241** **Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, France.** *P. Astagneau* (Paris, France), B. Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat-Trannoy, J. Auroix, K. Lebascle*
- E0242** **Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patients.** *S. Largiadèr* (Lucerne, Switzerland), D. Berthod, A. Widmer, N. Troillet, C. Perdrieu, S. Harbarth, R. Sommerstein*
- E0245** ***Cutibacterium* species in Neurosurgical Infections: Not Such a "Cute" Pathogen After All.** *J. Donnelly* (Dublin, Ireland), B. Dinesh, S. O'donnell*
- E0246** **The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcome.** *K. Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y. Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands*

E0247 **Efficacy of Oxetidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative Analysis.** *A. Abialevich* (Beer Sheva, Israel), V. Benkovich, G. Benkovich*

E0249 **Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic doses.** *C.M. Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R. Gabunada, Z. Alano*

SY067 **16:15 - 18:15** **Hall 11**

2-hour Symposium

PHEI

STIs: an ongoing crisis

Chair *Dagmar Heuer (Berlin, Germany)*

- S0189** **16:15** **STI treatment options are running out due to AMR.** *Magnus Unemo (Örebro, Sweden)*
- S0190** **16:45** **Genomic surveillance of *Neisseria gonorrhoeae* strains.** *Petra Wolfs (Maastricht, Netherlands)*
- S0191** **17:15** **Evolutionary insights into syphilis and *Treponema pallidum*.** *Mathew Beale (Cambridgeshire, United Kingdom)*
- S0192** **17:45** **Challenges in chlamydial STI infections.** *Cecile Bebear (Bordeaux, France)*

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie

SY068 **16:15 - 18:15** **Hall 12**

2-hour Symposium

CLN DX VAX

Tick-borne encephalitis: contemporary diagnosis and management

Chairs *Joanna Maria Zajkowska (Białystok, Poland), Dace Zavadzka (Rīga, Latvia)*

- S0193** **16:15** **Tick-borne encephalitis: immune response and clinical experience.** *Sara Gredmark Russ (Stockholm, Sweden)*
- S0194** **16:45** **TBE immune responses and vaccine effectiveness.** *Karin Stiasny (Vienna, Austria)*
- S0195** **17:15** **NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection.** *Gerhard Dobler (Munich, Germany)*
- S0196** **17:45** **Treatment for TBE: where do we stand?** *Daniel Ruzek (Brno, Czech Republic)*

LB006 **16:15 - 18:15** **Hall 13**





2-hour Oral Session

The Trial Run: recent trials on *S. aureus* bacteraemia management

Chairs *Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)*

- L0031** **16:15** **Introduction.** *Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)*
- L0032** **16:20** **Description of SNAP trial**
- L0033** **16:30** **Benzylpenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible *Staphylococcus aureus* bacteraemia: a randomised controlled trial of the *S. aureus* network adaptive platform (SNAP).** *S. Tong* (Melbourne, Australia), S. Aureus Network Adaptive Platform Trial Group*
- L0034** **16:45** **Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible *Staphylococcus aureus* bacteraemia: a randomised controlled trial within the *S. aureus* network adaptive platform (SNAP).** *J. Davis* (Newcastle, Australia), S. Aureus Network Adaptive Platform Trial Group*
- L0035** **17:00** **Cloxacillin versus cefazolin for methicillin-susceptible *Staphylococcus aureus* bacteraemia (CloCeBa): a**

ESCMID Global 2025 - Programme

		randomised, controlled, non-inferiority trial. X. Lescure* (Paris, France), F. Vandenesch, X. Duval, S. Tubiana, C. Burdet, N. Saïdani, A. Lemaïgnien, E. Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, P. Tattevin			
L0036	17:15	Trial Discussion Julia Anna Bielicki (London, United Kingdom)			
L0037	17:30	Trial Discussion Vance Fowler (Durham, United States)			
L0038	17:45	Open Discussion and Q&A			
<hr/>					
OS032	16:15 – 18:15			Hall 14	
		2-hour Oral Session			
					
Unraveling respiratory viruses, 2025					
<i>Chairs</i> Eeva Broberg (Solna, Sweden) Florian Krammer (New York, United States)					
O0222		Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France P. Loubet* (Nîmes, France), S. Guitton, R. Simon, L. Lefrançois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foullogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay			
O0223		Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids F. Tarrés-Freixas* (Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez-Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert			
O0224		Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection B. Huckestein* (Memphis, United States), P. Thomas			
O0225		Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France S. Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace Dossou, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Bricler, V. Avettand-Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Deroche, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodriguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti			
O0226		Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort C. Geurts Van Kessel* (Rotterdam, Netherlands), M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Geurtsvankessel			
O0227		Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems J. Tan* (Singapore, Singapore), J.T. Lim, L.E. Wee, C. Chiew, B. Ong, D. Lye			
O0228		Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study S. Bratkovic* (Copenhagen, Denmark), Y. Çolak, M. Helleberg, M.J. Fonseca, S. Bratković, N. Vestergaard Dich, M. Pedersen, M. Kany, T. Pliakas, R. Reeves, A. Marijam			
O0229		The burden of respiratory syncytial virus in children <3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study E. Carter* (Liverpool, United Kingdom), H. Hill, D. Ferreira, A. Collins, C. Solórzano, L. Mclellan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N.			
O0230		Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers M. Knoll* (Hinxtton, United Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison			
O0231		Can changes in vital signs differentiate respiratory viruses in care home residents? J. Rudolph* (Providence, United States), N. Bhaskar, F. Devone, K. Mcconeghy, C. Halladay, Y. Abul, S. Gravenstein			
<hr/>					
SY064	16:15 – 18:15			Hall 2	
		2-hour Symposium			
					
PK/PD to avoid emergence of resistance?					
<i>Chairs</i> Anne-Grete Mårtson (Leiden, Netherlands) Joseph Meletiadis (Athens, Greece)					
S0177	16:15	PK/PD and antibacterial therapy Dolors Soy-Muner (Barcelona, Spain)			
S0178	16:45	PK/PD and antifungal therapy Roger Brüggemann (Nijmegen, Netherlands)			
S0179	17:15	PK/PD and antiviral therapy Joe Standing (London, United Kingdom)			
S0180	17:45	PK/PD considerations in anthelmintic treatment Jennifer Keiser (Allschwil, Switzerland)			
<hr/>					
EW070	16:15 – 18:15			Hall 3	
		Educational Session			
					
Malaria: when the drugs don't work Management of treatment failure in non-endemic countries					
<i>Chairs</i> Laura Nabarro (London, United Kingdom) Caroline Rönnberg (Stockholm, Sweden)					
W0201	16:15	Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure Emmanuel Bottieau (Antwerp, Belgium)			
W0202	16:35	Malaria resistance mutations in the non-endemic setting: role of genomic surveillance Anna Rosanas Urgell (Antwerp, Belgium)			
W0203	16:55	How to manage Plasmodium Knowlesi infection Giri Shan Rajahram (Kota Kinabalu, Malaysia)			
W0204	17:15	Epidemiology and control of Plasmodium Knowlesi Kimberly Fornace (Singapore, Singapore)			
Co-organised with: British Infection Association (BIA)					
<hr/>					
SY065	16:15 – 18:15			Hall 4	
		2-hour Symposium			
					
Gram-positives, are they still going?					
<i>Chairs</i> Diederik Bathoorn (Groningen, Netherlands) Stefania Stefani (Catania, Italy)					
S0181	16:15	The vanco chronicles: enterococci's global journey Guido Werner (Wernigerode, Germany)			
S0182	16:45	Pitfall in susceptibility testing of Gram-positives Helena Zemlickova (Prague, Czech Republic)			
S0183	17:15	Drivers for daptomycin and linezolid resistance in Gram-positives Glen Carter (Melbourne, Australia)			
S0184	17:45	What is new in treatment against MDR Gram-positives? Alex Soriano (Barcelona, Spain)			

ESCMID Global 2025 - Programme

SY066	16:15 – 18:15	Hall 5
	2-hour Symposium	
	CLN DX	
Biomarker testing to manage respiratory infections in primary care in low resource settings		
<i>Chairs</i>	<i>Sonia Lewycka (Hanoi, Vietnam)</i> <i>Heiman Wertheim (Nijmegen, Netherlands)</i>	
S0185	16:15	The Vietnamese experience with CRP testing in the community setting <i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i>
S0186	16:45	The Nigerian experience with CRP testing in the community setting <i>Augustine Onwunduba (Awka, Nigeria)</i>
S0187	17:15	CRP testing in diagnosing tuberculosis in Zambia and South Africa <i>Helen Ayles (Lusaka, Zambia)</i>
S0188	17:45	The health economics of CRP testing in LMICs <i>Yoel Lubell (Bangkok, Thailand)</i>

EF035	17:15 – 18:15	Arena 1
	ePoster Flash Session	
	DX PHEI	
Genomics in pathogen surveillance		
<i>Chair</i>	<i>Vitor Borges (Lisbon, Portugal)</i>	
E0250		Genomic Surveillance of Invasive Group A Streptococcus in Argentina's 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 Burden <i>L. Cipolla* (Capital Federal, Argentina), A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto</i>
E0251		Understanding the population structure of <i>Moraxella catarrhalis</i> using core-genome multilocus sequence typing <i>I. Yassine* (Oxford, United Kingdom), K.A. Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel, A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J. Maiden, M.P. Nicol, A.B. Brueggemann</i>
E0252		Impact of the COVID-19 pandemic on the <i>Streptococcus pyogenes</i> clones causing adult invasive infections <i>M. Ramirez* (Lisbon, Portugal), A. Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt, M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For The Study Of Streptococcal Infections</i>
E0253		Unveiling the Hidden Complexity of <i>Providencia</i>: Genomic Insights into Species Reclassification and Antibiotic Resistance <i>X. Dong* (Hangzhou, China)</i>
E0254		Genomic description of outbreak of VIM-1 carrying <i>Enterobacter</i> in Switzerland suggests plasmid transmission between sequence types <i>H. Seth-Smith* (Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte, L. Poirel, P. Nordmann, A. Egli</i>
E0255		Genomic epidemiology of <i>Klebsiella pneumoniae</i> bloodstream infections in a German tertiary centre: increased virulence in carbapenem-resistant strains <i>L. Knegendorf* (Hannover, Germany), M. Lindenberger, C. Baier, J. Erdmann, S. Häußler, D. Schlüter</i>
E0256		Phylogenetic mixing and undetected circulation of multiple <i>Candida auris</i> lineages following recognition of imported cases in Italy <i>V. Di Pilato* (Genoa, Italy), E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G. Daniele Roberto, M. Mikulska, B. Matteo, M. Anna</i>
E0257		Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital Wastewater <i>A.K. Bari* (Groningen, Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, T.T. Severs, M.J. Cardoso, M. Savin</i>
E0258		Screening for rectal colonization with multidrug-resistant pathogens: usage of rapid metagenomic long-read technology <i>S. Purushothaman* (Zurich, Switzerland), A.M. Rooney, S. Moser, A. Egli</i>

EF036	17:15 – 18:15	Arena 3
	ePoster Flash Session	
	CLN	

Heads up! CNS infections		
<i>Chair</i>	<i>Jacob Bodilsen (Aalborg, Denmark)</i>	
E0259		Central Nervous System Involvement by <i>Mycobacterium avium</i> Complex in Advanced HIV: A Rare and Underdiagnosed Challenge <i>E. Sienra Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A. Camiro Zuñiga, D.H. Martinez Oliva, A. Llamas Lopez, A.P. Rodriguez Zulueta</i>
E0260		Acute disseminated encephalomyelitis following bacterial meningitis – Two Case reports & Review of Literature <i>M. Priyadarshi* (Delhi, India), M. Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R. Bhatia</i>
E0261		<i>Streptococcus equi</i> Subspecies <i>zooepidemicus</i> Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature review <i>D. Chemello* (Modena, Italy), G. Franceschi, S. Alessandra, B. Andrea, S. Mario, M. Marianna, M. Cristina</i>
E0262		Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infections <i>F. Prativiera* (Udine, Italy), S. Giuliano, S. Flammini, J. Angelini, P.G. Cojutti, C. Tascini</i>
E0263		Multidrug-Resistant <i>Klebsiella pneumoniae</i> Meningitis in the Absence of Intracranial Devices: A Case Report <i>M. Chumbita* (Barcelona, Spain), E. Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A. Soriano</i>
E0264		Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with <i>Morganella morganii</i>, <i>Acinetobacter baumannii</i>, and Vancomycin-resistant <i>Enterococcus faecium</i> <i>Y. Çakir Kıymaz* (Sivas, Türkiye), Y. Çakir Kıymaz, E. Kıymaz, Z. Bulut, S.A. Büyüktuna, N. Elaldi</i>
E0265		Invasive pulmonary <i>Arthrographis kalrae</i> infection with cerebral abscesses in an immunocompromised child <i>B. Winkel* (Utrecht, Netherlands), J. Jans, M. Luesink, R.J. Nijvelstein, F. Hagen, J. Buil, T. Wolfs, T. Van Der Bruggen</i>
E0266		Treatment of herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient <i>A. Birkmann* (Wuppertal, Germany), C. Lueck, C. Rautenberg, S. Bonsmann, A. Marini, M. Sumner, T. Schroeder, S. Voigt</i>
E0267		A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adult <i>N.K. Midha* (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D. Kumar, G.K. Bohra</i>

Sunday, 13 April 2025

SY075	08:30 – 10:30	Hall 15
	2-hour Symposium	
	PHEI	
Diphtheria: from re-emergence to vaccine strategies		
<i>Chairs</i>	<i>Helena Seth-Smith (Zurich, Switzerland)</i> <i>Julie Toubiana (Paris, France)</i>	
S0221	08:30	Diphtheria: from clinical picture to medical management <i>Regina Oladokun (Oyo, Nigeria)</i>
S0222	09:00	The epidemiology of diphtheria worldwide over the last half-century: more than one comeback <i>Andreas Hofer (Solna, Sweden)</i>
S0223	09:30	There's more than one toxigenic <i>Corynebacterium</i>: the current genomics landscape of diphtheria-associated strains <i>Sylvain Brisse (Paris, France)</i>
S0224	10:00	Diphtheria vaccination: a reappraisal <i>Gayatri Amirthalingam (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Epidemiological Markers

ESCMID Global 2025 - Programme

(ESGEM), ESCMID Vaccine Study Group (EVASG)

EF039	08:30 - 09:30	Arena 1
<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="display: flex; gap: 5px;"> CLN PHEI TRN </div> <div>ePoster Flash Session</div> </div>		
Novel approaches to antiviral therapy		
<i>Chair</i> Pinyo Rattanaumpawan (Bangkok, Thailand)		
E0288	Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection.	<i>J. Pitts* (Foster City, United States), J.L.R. Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M. Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. Cihlar, S. Fletcher, J. Bilello</i>
E0289	EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge study.	<i>J. Devincenzo* (Watertown, Ma, United States), A. Ahmad, S. Chen, B. Löndt, A. Mann, J. Mori, A. Catchpole, S. Rottinghaus</i>
E0290	A Combined <i>In Silico</i> and <i>In Vitro</i> Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-CoV-2, WNV, and Influenza A Virus.	<i>C.L. Pierri* (Bari, Italy), G.C.M. Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, V. Scaglione, D.I. De Luca, F. Mastropirro, S. Spadone, L. Guerra, M. Volpicella, A. De Grassi</i>
E0291	Bernifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus <i>in vitro</i>.	<i>D. Grandgirard* (Bern, Switzerland), S. Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib</i>
E0292	Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA viruses.	<i>S. Ellis* (London, United Kingdom), A.I. Jacobs, M. Woodall, S. Zhang, J.F. Standing, J. Breuer</i>
E0293	The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants.	<i>A. Gaggar* (South San Francisco, United States), E. Gane, C. Schwabe, G. Wang, J. Liu, S. Knox, K. Kitrinis, K. Zomorodi</i>
E0294	Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time.	<i>L. Sudarsono* (Leiden, Netherlands), X. Liu, J.G.C. Van Hasselt, A.G. Mårtson</i>
E0295	Efficacy of molnupiravir and baloxavir against influenza A H1N1 infection <i>in vitro</i> and <i>in vivo</i>.	<i>Liu* (Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R. Zhang, Y. Fan, K.H. Chan, F.N.I. Hung</i>
E0296	Human defensin derived peptide showing broad antiviral activity against human adenoviruses.	<i>X. Wang* (Hongkong, China), H. Zhao</i>

EF040	08:30 - 09:30	Arena 3
<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="display: flex; gap: 5px;"> CLN TRN </div> <div>ePoster Flash Session</div> </div>		
New frontiers in parasitic disease and migrant health research		
E0298	Targeting metabolic bioenergetics: the 'Achilles' heel of <i>Leishmania</i>.	<i>D. Sarkar* (Kolkata, India)</i>
E0299	Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?	<i>M.D. Hernández Rabadán* (Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez López, D. López Parra, J. Llenas García</i>
E0300	<i>Schistosoma haematobium</i> infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatment.	<i>A. Mertelsmann* (Zürich, Switzerland), J.K. Maganga,</i>

J.A. Downs, J.M. Changalucha, M.H. Lee, M. Ward, A.Y. Tan, S.F. Bowers, L. Mhango, D. De Jong, P.L.A.M. Corstjens, G.J. Van Dam, S. Kapiga, K. Dupnik, H.D. Mazigo

E0301	Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?	<i>G. Lam* (London, United Kingdom), D. Dee, A. Edielu, E. Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P. Mawa, J. Friedman, A. Bustinduy</i>
E0302	Schistosomiasis detected by Screening of sub-Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024.	<i>G. Equihua Martinez* (Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T. Geppert, F. Mockenhaupt, B. Kampmann, F. Olgemöller</i>
E0303	NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgut.	<i>B. Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N. Buchon, O. Sparagano, P. Butaye</i>
E0304	Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in <i>Onchocerca volvulus</i>.	<i>A. Acheampong* (Sunyani, Ghana), J. Larbi, P.C. Kudzordzi, P. Nyarko, K.B. Otabil</i>
E0305	Tuberculosis outcomes among international migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysis.	<i>G. Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R. Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di Franco, M. Affronti, E. Piccione, G. Gualano, F. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F. Di Gennaro</i>

EW079	08:30 - 10:30	Hall 11
<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="display: flex; gap: 5px;"> CLN DX </div> <div>Educational Session</div> </div>		
New guidelines for management of brain infections		
<i>Chairs</i> Jacob Bodilsen (Aalborg, Denmark) Kartika Maharani (Jakarta, Indonesia)		
W0237	08:30	Tuberculous meningitis: what can we learn from the first global guidelines?
<i>Joseph Donovan (Ho Chi Minh City, Vietnam)</i>		
W0238	08:50	WHO guidelines on bacterial meningitis: change of clinical practice?
<i>Matthijs Brouwer (Amsterdam, Netherlands)</i>		
W0239	09:10	ESCMID encephalitis guidelines 2024: what's new?
<i>Tom Solomon (Liverpool, United Kingdom)</i>		
W0240	09:30	WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation.
<i>Nelesh Govender (Johannesburg, South Africa)</i>		
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)		

SY073	08:30 - 10:30	Hall 12
<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="display: flex; gap: 5px;"> AMR ANT </div> <div>2-hour Symposium</div> </div>		
Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship		
<i>Chairs</i> Bhanu Sinha (Groningen, Netherlands) Annelies Verbon (Bosch En Duin, Netherlands)		
S0213	08:30	A broad spectrum of possibilities: spectrum scores as a unifying metric.
<i>Céline Pulcini (Nancy, France)</i>		
S0214	09:00	Proxy indicators to estimate appropriateness of antibiotic prescriptions.
<i>Diane Ashiru-Oredope (London, United Kingdom)</i>		
S0215	09:30	How to bridge the gap between surveillance and antimicrobial stewardship.
<i>Mark G. J. De Boer (Leiden)</i>		

ESCMID Global 2025 - Programme

Netherlands
S0216 10:00 Health economics, surveillance and antimicrobial stewardship. Zhu Nina Jiayue (London, United Kingdom)

Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)

SY074 08:30 - 10:30 Hall 13
 2-hour Symposium

CLN IPC

Difficile to treat: advanced management strategies in difficult to treat CDI

Chairs Frédéric Barbut (Paris, France)
 Kerrie Davies (Leeds, United Kingdom)

S0217 08:30 Severe CDI: when standard protocols fail. Hynek Bartos (Prague, Czech Republic)

S0218 09:00 Therapies for complicated CDI. Emma Bishop (Clayton Vic, Australia)

S0219 09:30 Recurrent CDI: Breaking the cycle. Andrea Marino (Catania, Italy)

S0220 10:00 Live biotherapeutic products for Clostridioides difficile infection. Simon Goldenberg (London, United Kingdom)

Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)

OS038 08:30 - 10:30 Hall 14
 2-hour Oral Session

AMR DX

Making fast for making better: AMR rapid diagnostics

Chairs Giulia De Angelis (Rome, Italy)
 Onur Karatuna (Växjö, Sweden)

00278 Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections. J. Rogers* (Bedford, United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch

00279 Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria. C. Mogueet* (Guipry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas

00280 The NitroSpeed Taniborbactam NP test; easy detection of β -lactamase sensitivity to taniborbactam. O. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirer, P. Nordmann

00281 Rapid detection of β -lactamase-mediated resistance to aminopenicillins from urines. P. Nordmann* (Fribourg, Switzerland), N. Helsens, C. Duployez, L. Poirer, R. Dessein

00282 Rapid detection of antibiotic resistance in direct urine samples. M. Bot* (Arnhem, Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer

00283 Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIs. E. Iseri* (Stockholm, Sweden), W. Van Der Wijngaart, V. Özenci, R. Santini, A. Nakama, O. Ekelund, A. Van Belkum

00284 Screening for ceftriaxone-resistant Neisseria gonorrhoeae with the Urogenital and Resistance kit (AusDiagnost). A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Condamine, F. Caméléna, B. Berçot

00285 Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures. D. Squitieri* (Rome, Italy), G. Menchinelli, C. Magri, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti

00286 Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy. K. Chaudhary* (Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S.

Sood, B. Dhawan, B. Das Kumar

SY076 08:30 - 10:30 Hall 16
 2-hour Symposium

AMR

AMR Surveillance in low resource countries: Insights into clinical and policy translation

Chairs Kwame Ohene Buabeng (Ho, Ghana)
 H. Rogier Van Doorn (Hanoi, Vietnam)

S0225 08:30 New indicators in national monitoring and evaluation of AMR supported by improved data utilisation. Direk Limmathurotsakul (Bangkok, Thailand)

S0226 09:00 Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections. Stephen Mshana (Mwanza, Tanzania, United republic of)

S0227 09:30 A clinically-oriented AMR surveillance network: case-based surveillance and implementation. Paul Turner (Siem Reap, Cambodia)

S0228 10:00 National prescribing guidelines based on AMR surveillance data. Vilada Chansamouth (Vientiane, Lao People's democratic republic)

Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW077 08:30 - 10:30 Hall 2
 Educational Session

CLN DX

New tools in acute bacterial infections and sepsis: from machine learning to precision medicine

Chairs Benjamin Mcfadden (Perth, Australia)
 Rita Murri (Rome, Italy)

W0229 08:30 Differentiating acute infection, sepsis and sepsis mimics in the ED? Lisa Mellhammar (Lund, Sweden)

W0230 08:50 Machine learning for early recognition of sepsis. Karsten Borgwardt (Martinsried, Germany)

W0231 09:10 How to avoid common mistakes in randomised clinical study design. Yin Mo (Singapore, Singapore)

W0232 09:30 Improved clinical trials in community-acquired pneumonia using precision medicine. Lennie Derde (Utrecht, Netherlands)

Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro

SY072 08:30 - 10:30 Hall 3
 2-hour Symposium

PHEI VAX

Tackling the emergence of dengue and other Aedes-borne diseases in Europe

Chairs Fernanda Boulos (São Paulo, Brazil)
 Martin P. Grobusch (Amsterdam, Netherlands)

S0209 08:30 How dengue, chikungunya and zika virus disease became emerging threats to Europe. Celine Gossner (Solna, Sweden)

S0210 09:00 Surveillance of dengue in urbanised tropical regions. Vincent Junxiong Pang (Singapore, Singapore)

S0211 09:30 Mosquito surveillance and control: opportunities and challenges. Tba

S0212 10:00 Tracking autochthonous arboviral infection. Luisa Barzon (Padua, Italy)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

ESCMID Global 2025 - Programme

EW078	08:30 – 10:30	Hall 4
	Educational Session	
	DX	
Implementing metagenomics in my lab and mistakes to avoid		
Chairs	<i>Hege Vangstein Aamot (Lørenskog, Norway)</i> <i>Claudio Neidhöfer (Bonn, Germany)</i>	
W0233	08:30	Is metagenomics right for my lab? <i>Paula Mölling (Örebro, Sweden)</i>
W0234	08:50	Understanding the experimental and certification aspects of metagenomics <i>Mads Albertsen (Aalborg, Denmark)</i>
W0235	09:10	Navigating tools, techniques, and procurement <i>Basil Britto Xavier (Groningen, Netherlands)</i>
W0236	09:30	Setting realistic goals and outcomes for metagenomics integration <i>Claire Bertelli (Lausanne, Switzerland)</i>
Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee		
OS037	08:30 – 10:30	Hall 5
	2-hour Oral Session	
	DX IPC	
Whole genome sequencing: tracking transmission and reservoirs in outbreaks		
Chairs	<i>Eric Claas (Leiden, Netherlands)</i> <i>Paul G. Higgins (Cologne, Germany)</i>	
O0268	From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting <i>N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Hatcher, J. Brown, J. Breuer</i>	
O0269	Why do routine genome-oriented surveillance for <i>Pseudomonas aeruginosa</i>? <i>A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik-Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert</i>	
O0270	TreeTime estimation depicts transmission dynamics of clinical and environmental <i>Pseudomonas aeruginosa</i> from common reservoirs in healthcare environment through whole genome sequencing (WGS) <i>Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson</i>	
O0271	Understanding <i>Serratia</i> transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis <i>K. Jaakkola* (Lyon, France), C. Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Haijs, J.P. Rasigade</i>	
O0272	Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing <i>C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin</i>	
O0273	Genome-oriented analysis of the first outbreaks involving the novel <i>Serratia sarumanii</i> at a neonatal unit <i>A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-Brachert</i>	
O0274	Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTIPE Study <i>J. Price* (Brighton, United Kingdom), I. Sey, A. Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Mookerjee, M. Krutikov</i>	
O0275	Outbreak of Carbapenem-Resistant <i>Acinetobacter seifertii</i> in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance <i>D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antochewis, R. Paiva, K. Tragnago, A. Barth, A. Martins</i>	
O0276	Unveiling the Clonal Dynamics and transmission	

		mechanism of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the ICU environment <i>X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu</i>
O0277		Survey of Infection Prevention staff perception of WGS integration into routine IPC practice <i>D. Ling* (Melbourne, Australia), B. Baral, V. Madigan</i>
EF041	09:30 – 10:30	Arena 2
	ePoster Flash Session	
	AMR CLN DX	
Contemporary diagnostic approaches for fungal infections		
E0306	Evaluation of persistence of <i>C. auris</i> colonization in a cohort of patients discharged from a <i>C. auris</i> endemic area <i>M. Bavastro* (Genoa, Italy), L. Mezzogori, M. Bonaffini, L. Magnasco, F. Centorrino, V. Di Pilato, E. Willison, F. Fortunato, D.R. Giacobbe, A. Vena, A. Marchese, M. Mikulska, M. Bassetti</i>	
E0307	A pilot study of digital retinal photography (DRP) and tele-ophthalmology of patients with candidemia <i>C. Hadi* (Pittsburgh, United States), E. Waxman, J.A. Viehman, A. Eller, M. O'donnell, F. Silveira, P. Samantha, B. Smith, S. Padival, V. Nauriyal, M.H.T. Nguyen, C. Clancy</i>	
E0308	Epidemiology and diagnosis of Pneumocystis pneumonia : a 11 years-surveillance in France <i>A. Alanio* (Paris, France), K. Boukris-Sitbon, M. Desnos-Ollivier, D. Garcia-Hermoso, F. Lanternier, O. Lortholary</i>	
E0309	Chronic pulmonary aspergillosis coexisting with pulmonary cystic echinococcosis: a global systematic review <i>A. Adhikari* (Chame, Nepal), F. Bongomin, R. Olum, P. Baral, I. Osaigbovo, W. Kibone, B. Ekeng, L. Atulinda, S. Katwal, B. Morgan, N.V. Rhijn, D. Denning</i>	
E0310	Implementation and performance of a universal Mucorales PCR assay for diagnosis of mucormycosis <i>A. Haas* (Salt Lake City, United States), K. Hanson</i>	
E0311	Blood cultures (BCs) contain populations of genetically diverse <i>Candida</i> strains that may differ in antifungal resistance and tolerance <i>C. Clancy* (Pittsburgh, United States), S. Cheng, H. Badrane, B. Hao, G. Fleres, E. Driscoll, D. Chris, E. Josh, M.H. Nguyen</i>	
E0312	Clinical validation of a urinary antigen test as an aid to diagnose invasive aspergillosis in hematology patients <i>Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, T. Mercier, E. Boon, G. Gysember, E. Houben, K. Lagrou, J. Maertens</i>	
E0313	Genomic epidemiology of Greek <i>Candida auris</i> clinical isolates <i>M. Siopi* (Athens, Greece), B. Spruijtenburg, I. Anagnostakis, C. Anthoulaki, A. Argyropoulou, S. Varveraki, C. Vossou, A. Votsi, P. Giannopoulou, K. Gartzonika, M. Damala, I. Daskalakis, I. Dendrinos, V. Dimitriou, E. Dimitroulia, L.P. Drosopoulou, O. Zarkotou, L. Zachariadou, V. Ippa, A. Kampas, P. Karagiannidou, S. Karabela, A. Katsaka, A. Katsiiflaka, E. Kafkoulia, M. Kimouli, I. Lamprou, O. Legga, V. Mamali, M. Martsoukou, G. Mouratis, C. Mparka, T. Biniari, A. Xanthaki, E. Oikonomopoulou, M. Orfanidou, F. Paliogianni, E. Palla, A. Pantazatou, K. Panteli, E. Papadogeorgaki, M. Papadogianni, K. Papaefstathiou, P. Papanikolaou, J. Papaparaskevas, G. Parvouloskou, E. Perivolioti, S. Pournaras, C. Silleli, T. Skalidis, E. Souki, A. Spiliopoulou, C. Stergiou, S. Tsiplakou, P. Tsolakidou, N. Charalampaki, E. Chinou, G.S. Christodoulatos, G. Chronopoulou, E. Chrysou, E. Meijer, A. Tsakris, J. Meletiadis, G. Vrioni</i>	
E0314	A guanidine-functionalized anthranilamide peptidomimetic RK758 targets <i>Candida auris</i>: Integrative mechanistic insights from morphology to transcriptomics <i>S. Mishra (baishnab)* (Sydney, Australia), S.K. Mishra Baishnab, R. Kuppasamy, A. Hui, E. Wong, M. Willcox</i>	

ESCMID Global 2025 - Programme

EF042 09:30 – 10:30 Arena 4
ePoster Flash Session

CLN

Prosthetic and device-associated infections

Chair *Marjan Wouthuyzen-Bakker (Groningen, Netherlands)*

E0315 **Case series of gluteal Apophysomyces post intramuscular injection** *R. Sivasankaran* (Vellore, India), R. Bandyopadhyay*

E0316 **MIGRATING mesh - an unusual cause of pyogenic liver abscess** *M. Caris* (Leiden, Netherlands), J. Rutgers, A. Inderson, S.M. Arend, L.M.F. Kuijpers*

E0317 **Ceftaroline salvage monotherapy: successful treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant *Staphylococcus epidermidis* strain** *M.D. Di Trapani* (Bozen, Italy), T. Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinsler, R. Aschbacher*

E0318 **Timeline of early infections post porcine xenotymokidney transplant** *H. Neumann* (New York, United States), M. Ringer, R. Alpizar-Rivas, J. Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Griesemer, R. Montgomery, S. Williams, S. Mehta*

E0319 **Invasive Non-tuberculous mycobacteria infection in children undergoing Cardiac Surgery at the specialized Cardiology Hospital of Peshawar** *M. Khan* (Peshawar, Pakistan)*

E0320 **Use of multiplex PCR assay analysis in patients with suspected implant-based breast reconstruction infection: a single center experience** *A. Pagotto* (Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, A. Colombo, P.C. Parodi, C. Tascini*

E0321 **PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections** *C. Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering, A. Friedrichs*

E0322 **A complex case of pelvic bone infection caused by carbapenem-resistant *Acinetobacter baumannii* successfully treated with eravacycline** *M. Zagarrigo* (Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, A. Pozzi, E. Zamparini, P. Viale*

E0323 **Oritavancin in a patient with recurrent endocarditis by *Enterococcus faecalis*: a new therapeutic option?** *M. Bongiovanni* (Lugano, Switzerland), B. Barda, E. Bernasconi*

KN080 09:30 – 10:30 Hall 1
Keynote Lecture

VAX

Infections after solid organ transplantation: past, present and future

Chairs *Nina Khanna (Basel, Switzerland), Priscilla Rupali (Vellore, India)*

K0241 09:30 *Jay Fishman (Boston, United States)*

SY082 11:00 – 12:00 Hall 6
1-hour Symposium

PRO PHEI

How to address anti-science in our community?

Chair *Tyra Grove Krause (Copenhagen, Denmark)*

S0243 11:00 **The rise of anti-science: lessons for the future scientist** *Marion Koopmans (Rotterdam, Netherlands)*

S0244 11:30 **Open science for public trust** *Lisa Hansen (Ottawa, Canada)*

FO090 11:00 – 12:00 Arena 1

PRO

Open Forum

European CM/ID exam: going forward

Chair *Siri Goepel (Tuebingen, Germany)*

F0259 11:00 **View from medical microbiology** *Maeve Doyle (Waterford, Ireland)*

F0260 11:10 **view from infectious diseases** *Eoghan De Barra (Dublin, Ireland)*

F0261 11:20 **view from trainees (TAE)** *Christian Kraef (Copenhagen, Denmark)*

F0262 11:30 **European exam - how to prepare?** *Annelies Verbon (Bosch En Duin, Netherlands)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Professional Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section of Infectious Diseases

EF049 11:00 – 12:00 Arena 2
ePoster Flash Session

CLN DX VAX

Sometimes it's hard to be a woman

Chair *Debora Konopnicki (Brussels, Belgium)*

E0354 **Interleukins 17 and 18: Key players in Cervical Cancer Progression in Indian Population** *P. Gupta* (Bhopal, India), A. Vyas, A. Halder, S. Purwar*

E0355 **Risk evaluation of iatrogenic transmission of Human Papillomavirus (HPV) during gynaecological procedures** *B. Casini* (Pisa, Italy), F. Chiovelli, Y. Ferchichi, E. Esposito, M. Basile, G. Del Bravo, A. Giannini, T. Simoncini*

E0356 **Role of human herpesvirus 6 in unexplained infertility: among Indian women in a tertiary care hospital of north India** *V. Angra* (Chandigarh, India), P. Sharma, B. Joshi, S. Gainer, N. Gupta, S. Sethi, M. Singh, A. Ghosh, K. Goyal*

E0357 **Rubella screening in pregnancy – Slovakian one-center retrospective analysis around COVID-19 pandemic** *Z. Paraličová* (Kosice, Slovakia), D. Javorská*

E0358 **The impact of maternal influenza infection and vaccination during pregnancy on birth outcomes** *B. Goundappa* (Pittsburgh, United States), X. Zhang, B. Gk, H.E.A. D'agostino, H. Liu, A.M. Rick*

E0359 **Use of valaciclovir therapy during pregnancy for the prevention of congenital cytomegalovirus infection: a monocentric experience** *G. Lorenzetti* (Rome, Italy), S. Garattini, L. Romani, M. Di Giuseppe, M. De Luca, L. Cursi, S. Bernardi, S. Chiurchiù, S. Mercadante, C. Tripiciano, A. Krzysztofiak, C. Vassallo, I. Fabietti, L. Caforio, L. Lancella, F.I. Calò Carducci*

E0360 **Multi-systemic long-term sequelae following SARS-CoV-2 Omicron infection in pregnancy: a population-based cohort study** *Y.Y. Tan* (Singapore, Singapore), E.X.H. Loy, A.T. Tay, J.T. Lim, C.J. Chiew, D.C.B. Lye, L.E. Wee*

E0361 **The Impact of OAS1 rs4766664 and OAS3 rs10735079 Polymorphisms on the Clinical Course of COVID-19 in Pregnant Women** *S. Kirik Yilmaz* (Konya, Türkiye), S. Kirik Yilmaz, S. Sumer, N. Demir Aktug, O. Ural, E. Ozdemir Marzioglu, O. Secilmis, T. Cora*

E0362 **Sex-stratified analysis of T cell activation, exhaustion, proliferation and HIV reservoir among PLWH** *L. Santinelli* (Rome, Italy), M. Andreotti, L. Maddaloni, Z. Michelini, G. Bugani, F. Romano, E. Gentili Cacciola, G. Antonelli, C.M. Mastroianni, C. Scagnolari, G. D'ettore*

EF050 11:00 – 12:00 Arena 3
ePoster Flash Session

DX

Expanding MALDI-TOF applications

ESCMID Global 2025 - Programme

Chair *Belen Rodriguez-Sanchez (Madrid, Spain)*

- E0363** Application of MALDI-TOF Mass Spectrometry and Machine Learning for the Detection of Vancomycin-Resistant *Enterococcus faecium* M. Sánchez Cueto* (Madrid, Spain), M. Sánchez-Cueto, M. Blázquez-Sánchez, M. Marín, E. Cercenado, P. Muñoz, B. Rodríguez-Sánchez, D. Rodríguez-Temporal
- E0364** Early detection of ampicillin susceptibility in *Enterococcus faecium* with MALDI-TOF MS and machine learning T. Pichl* (Munich, Germany), L. Miranda, N. Wantia, K. Borgwardt, J. Sattler
- E0365** Rapid antifungal resistance prediction based on MALDI TOF mass spectrometry D. Duroux* (Zurich, Switzerland), Y. Yang, J. Sattler, A. Egli
- E0366** Rapid prediction of fluconazole resistance by machine-learning analysis of *Candida parapsilosis* MALDI-TOF mass profiles C. Magri* (Rome, Italy), C. Magri, V. Ivagnes, M. Sanguinetti, E. De Carolis
- E0367** Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification R. Huang* (Shenzhen, China), Y. Li, Y. He, T. Ma, F. Lu
- E0368** Rapid detection of colistin resistance in *Acinetobacter baumannii* by a MALDI-TOF MS-based assay E. Kirbaş* (Van, Türkiye), I.D. Nix, K. Sparbier, O. Drews, B. Oberheitmann, M. Kostrzewa, G. Hasçelik, B. Sancak
- E0369** Discrimination of clinical *Pseudomonas* strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MSK. Teramoto* (Kyoto, Japan), Y. Sekiguchi, L. Sellami, M. Tohya, T. Kirikae
- E0370** Automatic differentiation of *Clostridioides difficile* ribotypes using MALDI-TOF MS and web-based classification models M. Blázquez Sanchez* (Madrid, Spain), M.C. Blázquez-Sánchez, J.M. Moreno, A. Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. Muñoz, M. Marín, L. Alcalá, D. Rodríguez-Temporal, B. Rodríguez-Sánchez
- E0371** Identification of sepsis-causing bacteria using shotgun proteomics L. Meekes* (Rotterdam, Netherlands), D. Rustad, C. Güzel, T.K. Jenssen, H. Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, W. Goessens

EF051 11:00 – 12:00 **Arena 4**
ePoster Flash Session

The enemy of my enemy: From jumbo phages to cocktails for difficult to treat infections

- E0372** Anti-K2 recombinant phage depolymerases as anti-virulence agents against hypervirulent *Klebsiella pneumoniae* M. Roch* (Geneva, Switzerland), R. Sierra, D. Andrey
- E0373** Jumbo *Klebsiella* bacteriophage demonstrates efficient multidrug-resistant *Klebsiella pneumoniae* killing and significant clinical potential Y. Liu* (Singapore, Singapore), Y. Zhong, S. Thong, L.H.A. Kwa
- E0374** A new phage cocktail targeting at *Klebsiella pneumoniae* X. Yin* (Chengdu, China), Y. Feng, H. Luo, Z. Zong
- E0375** Bacteriophages against pulmonary infection and colonization of the gut by multidrug-resistant *Klebsiella pneumoniae* in murine models A.M. Örmälä-Tiznado* (Stockholm, Sweden), S. Patpatia, J. Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske
- E0376** A novel broad-spectrum phage cocktail effective for carbapenem resistant *Acinetobacter baumannii* of capsular type 104/2/7 in vitro L. Wei* (Chengdu, China), Y. Feng, Z. Zong
- E0377** Proteomic and Genomic Characterization of a Novel Bacteriophage of a New Genus Infecting *Pseudomonas aeruginosa* S. Unlu* (Ankara, Türkiye),

A. Uskudar Guclu

- E0378** Phages as innovative adjuvants of antibiotics therapy against *S. aureus* and *P. aeruginosa* in the context of Cystic Fibrosis A. Glorieux* (Brussels, Belgium), S. De Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Bambeke
- E0379** Evaluation of bacteriophages against *Staphylococcus aureus* strains isolated from orthopaedic infections S. Patpatia* (Helsinki, Finland), A. Camporeale, S. Kiljunen, C. Giske, A.M. Örmälä-Tiznado
- E0380** Anti-*Staphylococcus aureus* phages: assessing the risk of bacterial resistance emergence through selective pressure M. Degreze* (Lyon, France), M. Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, C. Kolenda

KN081 11:00 – 12:00 **Hall 1**
Keynote Lecture

The new frontiers in antimicrobial stewardship
Chairs *Jose Ramon Pano-Pardo (Zaragoza, Spain)*
Jeroen Schouten (Nijmegen, Netherlands)

K0242 11:00 *Karin Thursky (Carlton, Australia)*

SY084 11:00 – 12:00 **Hall 10**
1-hour Symposium

Sleeping sickness and Chagas: a tale of the two trypanosomes
Chairs *Hanne Brekke (Oslo, Norway)*
Irene Losada Galvan (Barcelona, Spain)

S0247 11:00 **Human African Trypanosomiasis: recent diagnostic and medical practices** Jean-Mathieu Bart (Conakry, Guinea)

S0248 11:30 **American Trypanosomiasis: Diagnosis, screening and management** Tba

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

OS047 11:00 – 12:00 **Hall 11**
1-hour Oral Session

Clinical studies in UTI
Chairs *Iva Butic (Zagreb, Croatia)*
Paul Christoffer Lindemann (Bergen, Norway)

O0344 **Short versus long antibiotic treatment for pyelonephritis and complicated UTIs: an updated systematic review and meta-analysis of RCTs!** Zahavi* (Haifa, Israel), D. Kunwar, J. Olchowski, H. Dallasheh, M. Paul

O0345 **Antibiotic treatment duration of complicated urinary tract infection patients in Europe: results from the Ecraid POS-cUTI study** C. Kats* (Utrecht, Netherlands), J.M. Bravo-Ferrer, T.T. Doesschate, P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio, P. Clevenbergh, A. Barac, A. Cano, E. Merino, P. Andrade, L. Jacquin, B. Koprivica, R. Espindola, P. Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D. Viglino, A. Ternhag, J. Rupp, A. Hernandez-Torres, D. Chadwick, B. Carevic, M. Bonten, E. Tacconelli, J. Rodríguez-Baño

O0346 **Prevalence and impact of multidrug resistance in a cohort of patients admitted to emergency department for urinary tract infections: the UTILITY study, a prospective multicentre study** L. Onorato* (Naples, Italy), E. Allegorico, M. Macera, C. Monari, B. Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R. Sciorio, G. Guiotto, M. Giordano, R. Raucchi, F. Dello Vicario, R. Nasti, A. Voza, N. Coppola

O0347 **Weekly sequential antibioprohylaxis for UTI in**

ESCMID Global 2025 - Programme

neurogenic bladder *R. Calin* (Paris, France), C. Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F. Adda, C. Palacios, G. Amarenco, G. Pialoux*

00348 Evidence for the duration of antibiotic therapy for chronic bacterial prostatitis: a systematic review *L. Cordes* (Geneva, Switzerland), A. Huttner, R. Calin, K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B. Trautner*

OS048 **11:00 – 12:00** **Hall 12**
1-hour Oral Session

AMR CLN

Complexities of infections in solid organ transplantation

Chairs *Silvia Corcione (Turin, Italy)*
Michael G Ison (Derwood (MD), United States)

00349 Solid Organ Transplants from donors with positive blood cultures: watch out for carbapenem-resistant Enterobacterales *A. Cona* (Palermo, Italy), C. Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni*

00350 Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers *M. Rinaldi* (Bologna, Italy), B. Miani, M. Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella*

00351 Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors. *O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette*

00352 Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients *A. Dahl* (København V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup, J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning, J. Lundgren, N. Mueller, M. Helleberg*

00353 Burden of non-microbiologically confirmed infections in solid organ transplant recipients *M. Zou* (Basel, Switzerland), M. Koller, O.J. Manuel, N. Mueller, K. Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos*

SY085 **11:00 – 12:00** **Hall 13**
1-hour Symposium

DX PHEI

Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination

Chairs *Mojca Maticic (Ljubljana, Slovenia)*
Snjezana Zidovec Lepej (Zagreb, Croatia)

S0249 11:00 Role of reflex testing strategies in identifying patients with chronic viral hepatitis *Oana Sandulescu (Bucharest, Romania)*

S0250 11:30 Management and elimination of hepatitis in hard-to-reach persons *Suda Tekin (Istanbul, Türkiye)*

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS

SY086 **11:00 – 12:00** **Hall 14**
1-hour Symposium

DX

Impact on including a measure of viability in molecular diagnostic tests

Chairs *Fusun Can (Istanbul, Türkiye)*
Denise O'sullivan (Teddington, United Kingdom)

S0251 11:00 Viability markers in support of development of

Chlamydia screening recommendations *Petra Wolffs (Maastricht, Netherlands)*

S0252 11:30 Measuring viability to improve the correlation of AMR markers and clinical outcomes in *Neisseria gonorrhoeae* *Tatum Mortimer (Athens, United States)*

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

ME089 **11:00 – 12:00** **Hall 15**
Meet-the-Expert

PRO

How to teach Medical Mycology

M0257 11:00 *Katrien Lagrou (Leuven, Belgium)*

M0258 11:12 *Mihai Mares (Iasi, Romania)*

Co-organised with: European Confederation of Medical Mycology (ECMM)

SY087 **11:00 – 12:00** **Hall 16**
1-hour Symposium

ANT TRN

Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology

S0253 11:00 Bacterial PROTACs: Do proteolysis-targeting degraders represent a viable strategy for new antimicrobials? *Morreale Francesca Ester (London, United Kingdom)*

S0254 11:30 Activity-based protein profiling of bacterial pathogens: new enzymes and their functions at the host-microbe interface *Christian Stephan Lentz (Tromsø, Norway)*

ME088 **11:00 – 12:00** **Hall 2**
Meet-the-Expert

AMR

Global AMR Policy after UNGA: what do we do now!

M0255 11:00 *Gisela Robles Aguilar (Oxford, United Kingdom)*

M0256 11:12 *Mike Sharland (London, United Kingdom)*

OS043 **11:00 – 12:00** **Hall 3**
1-hour Oral Session

AMR IPC

Navigating disinfection challenges: resistance, outbreaks, and efficacy

Chairs *Hillary A. Craddock (Dublin, Ireland)*
Stephanie J. Dancer (Glasgow, United Kingdom)

00324 Prolonged disinfectant exposure impacts the antimicrobial resistance of healthcare-associated microorganisms: a systematic review *Á.R. Fernandes* (Porto, Portugal), A. Gonçalves Rodrigues, L. Cobrado*

00325 Sink-associated outbreak of verona integron-encoded metallo-β-lactamase-producing carbapenem-resistant *Pseudomonas aeruginosa* in a Dutch intensive care unit *M. Van Den Bos Kromhout* (Zwolle, Netherlands), S. Debast, M. Van Den Bos-Kromhout, S. De Vries-Van Rossum, S. Abma-Blatter, B. Immeker, K. Zuur, M. Hijmering, J.W.A. Rossen*

00326 Carbapenemase-producing Enterobacterales outbreak control by replacement of toilets or long-term disinfection? A real-life experience. *A.L. Engsbros* (Slagelse, Denmark), K.H. Hansen, M.F.J. Larsen, N. Kling, H.T. Larsen, R. Kjølsten, B. Hansen, L.K. Vejrum, A.L. Laugesen, M. Kemp*

00327 Tolerance of *Klebsiella pneumoniae* biofilms to disinfection with peracetic acid *M. Arvand* (Berlin,*

ESCMID Global 2025 - Programme

Germany), A.M. Richter, D. Csertő, K. Konrat
00328 **Bringing balance to the formulation: disinfection efficacy and material compatibility.** J. Jennings* (Halifax, United Kingdom), T. Langford, H. Mansbridge, E. Fraser, I. Poles, J. Clarke

LB002 **11:00 – 12:00** **Hall 4**
 1-hour Oral Session

Investigation of intriguing outbreaks

L0006 **Molecular surveillance of artemisinin and sulfadoxine-pyrimethamine resistance in *Plasmodium falciparum* isolates from Uganda: results of ERASE study.** M. L'episcopia* (Rome, Italy), F.V. Segala, J. Ictho, R. Papagni, I. Obua, E. De Vita, N. Olang, R. Novara, V. Totaro, L. Olal, G. Patti, C. Bignom, C. Agaro, G. Dall'oglio, B. Ngole, S. Okori, P. Lochoro, G. Putoto, F. Di Gennaro, C. Severini, A. Saracino

L0007 **Investigation of an international pseudo-outbreak involving *Paraburkholderia fungorum* blood culture contamination.** J. Moran-Gilad* (Jerusalem, Israel), J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Palavecino, P. Snippes Vagnone

L0008 **Evolving cluster of severe infective endocarditis with non-toxicogenic *C. diphtheriae* amongst people experiencing homelessness and substance misuse in the UK.** R. Cordery* (London, United Kingdom), T. Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Primus, S. Das, K. Paranthaman, G. Amirthalingham

L0009 **AI-driven live cough rate tracking for public health surveillance.** M. Kågeback* (Göteborg, Sweden), E. Carlsson

OS044 **11:00 – 12:00** **Hall 5**
 1-hour Case Session

Unusual presentations of unusual parasites

Chairs Emmanuel Bottieau (Antwerp, Belgium)
 Marcelo Victor Radisic (Buenos Aires, Argentina)

00329 **Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting.** D. Ekwem Amarachi* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum

00330 **An itchy awakening due to *Dermanyssus* infestation.** J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque

00331 **Uterine Myiasis: A Rare Case of External Genitourinary Myiasis.** R.L. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua

00332 **Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation.** C. Norsungnern* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong

00333 **If at first, you don't succeed... Treatment-resistant Fascioliasis: case report.** W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro

SY083 **11:00 – 12:00** **Hall 7**
 1-hour Symposium

Lyme neuroborreliosis: challenges in diagnosis and treatment

Chairs Alexandra Mailles (Paris, France)
 Joanna Maria Zajkowska (Białystok, Poland)

S0245 **11:00** **Challenges in diagnosis of Lyme neuroborreliosis.** Rick Dersch (Freiburg, Germany)

S0246 **11:30** **Challenges in treatment of Lyme neuroborreliosis.** Anne Marit Solheim (Kristiansand, Norway)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)

OS045 **11:00 – 12:00** **Hall 8**
 1-hour Oral Session

Social behavioural dynamics of antibiotic use and AMR

Chairs Sonia Lewycka (Hanoi, Vietnam)
 Filippo Mediolì (Milan, Italy)

00334 **Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey.** A. Abbara* (London, United Kingdom), H. Alhosni, F. Alahdab

00335 **Gamified Intervention to Enhance Antimicrobial Stewardship: Improving Knowledge and Practices on the Rational Use of Antimicrobials Among Medicines and Therapeutics Committee Members ????** S. Mahadevaiah* (Mysore, India), C. Es, K. Anil, Y. Maheshwarappa, S.S. Sc, S. Srinivas, V. Swamy Gs, K. Gautam

00336 **Healthcare providers' perspectives on antibiotic use and resistance in pregnancy, childbirth, and children under five years of age across four levels of hospitals in Lao PDR, 2024.** S. Vantava* (Vientiane Capital, Lao People's democratic republic), K. Thilakoun, D. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B. Phetsamone, S. Bangthong, K. Sengchanh, S. Latsamy, S. Vanphanom, L. Annick, S. Somphou

00337 **High gender gap in female labour force participation and reduced gender inequality linked to high antibiotic consumption: Evidence from a global analysis.** D. Samrìa* (Bangalore, India), D. Batheja, A. Nandi

00338 **Gender gaps in knowledge of antibiotics and antimicrobial resistance: Evidence from India.** D. Batheja* (Delhi, India), S.R. Umenthala, S. Goel, D. Samrìa, R. Bhagawati, B. Deepshikha

OS046 **11:00 – 12:00** **Hall 9**
 1-hour Oral Session

Vaccines and prophylaxis against respiratory viral infections

Chair Sophie Schneitler (Homburg, Germany)

00339 **Public health impact of universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. Full 2023-24 season analysis of the NIRSE-GAL study (www.nirsegal.es/en).** F. Martínón-Torres* (Santiago De Compostela, Spain), N. Mallah, J. Pardo-Seco, O. Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, I. Rivero-Calle, Á. Manzaneres-Casteleiro

00340 **Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial.** K. Feldballe Bernholm* (Copenhagen, Denmark), N. Dyrby Johansen, C. Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon, S. Samson, M.M. Loiacono, R. Harris, C. Schade Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B.L. Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, J.U. Stæhr Jensen, T. Biering-Sørensen

00341 **Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19**

ESCMID Global 2025 - Programme

vaccine versus mRNA-1273: subgroup analyses C. Grassi* (Cambridge, United States), S. Chalkias, P. Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R. Handforth, N. Vacic, A. Rossi, R. Wahid, D. Edwards, J. Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B. Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das

00342 Effectiveness of RSV vaccine in lung transplant recipients: neutralizing antibody response against reference and seasonal strains N. Shirin* (Ramat Gan, Israel), L. Levy, D. Yahav, M. Benzimra, Y. Bezalel, T. Hoffman, T. Sinai, M. Jurkiewicz, O. Deri, N. Matalon, M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M. Mandelboim

00343 Novavax investigational COVID-19 Influenza Combination nanoparticle vaccine phase 2 study safety evaluation C. Bennett* (Gaithersburg, United States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M. Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F. Mahkhou, A.M. Marchese, I. Cho, L. Fries, W. Woo

SY093 13:30 - 14:30 Hall 11
1-hour Symposium

Immunosenescence and immune response to vaccination

Chairs Petar Velikov (Sofia, Bulgaria)
Dafna Yahav (Ramat-Gan, Israel)

S0267 13:30 How immunosenescence impacts vaccine response Andrea Cossarizza (Modena, Italy)

S0268 14:00 Strategies to tackle immunosenescence and improve immune response to vaccination in the elderly Inna Ovsyannikova (Rochester, United States)

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)

EW096 13:30 - 15:30 Hall 15
Educational Session

Tools for successful development as a medical educator

Chairs Giorgia Caruana (Sion (Switzerland), Switzerland)
Yoav Keynan (Winnipeg, Canada)

W0273 13:30 Developing your educator professional identity Todd Cassese (Bronx, United States)

W0274 13:50 What do IPC doctors need to learn to be prepared Simone Scheithauer (Göttingen, Germany)

W0275 14:10 Communities of practice: successful experience of a transformative collaboration and roadmap Erin Bonura (Portland, United States)

W0276 14:30 The critical need for ongoing innovations in medical education Clémentine Schilte (Paris, France)

Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology

FO097 13:30 - 14:30 Arena 1
Open Forum

Essential diagnostics in Low-Resource Settings: why are we still talking?

Chair Truls Michael Leegaard (Lørenskog, Norway)

F0277 13:30 Training skilled personnel in LMIC and brain drain: is the solution the problem? Siphon Kenneth Dlamini (Observatory, South Africa)

F0278 13:40 Leveraging surveillance networks to strengthen basic bacteriology Dissou Affolabi (Cotonou, Benin)

F0279 13:50 TBA Makeda Semret (Montreal, Canada)

Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity

Commission, Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiologie

FO098 13:30 - 14:30 Arena 2
Open Forum

Best of ID Week

Chair Tina Tan (United States)

F0280, Seth Cohen (Seattle, United States), Erin McCreary (Pittsburgh, United States), Ilan Youngster (Beer Yaakov, Israel)

EF054 13:30 - 14:30 Arena 3
ePoster Flash Session

Beware the sink! Pathogen reservoirs in drains and waste water

Chair Stephan Juergen Harbarth (Geneva, Switzerland)

E0391 Genomic Epidemiology to Investigate Healthcare Environment as Reservoir for Carbapenem-Resistant Organisms in an Academic Hospital in Miami, Florida. A. Jimenez* (Miami, United States), S. Hawken, S. Arenas, K. Mokoban, D. Pronty, O. Martinez, J. Colson, A. Richardson, T. Ferreira, B. Shukla

E0392 Two clusters of carbapenemase-producing Enterobacterales linked to hospital wastewater drainage in utility rooms – an outbreak investigation. I. Vock* (Basel, Switzerland), G. Capoferri, P. Urwyler, P. Domene, D. Roy, S. Kuster, N. Gürtler, B. Ivan, P.M. Keller, S. Tschudin-Sutter

E0393 Assessing the burden of carbapenemase and colistin antimicrobial resistance genes in hospital wastewater. E. Au* (Calgary, Canada), N. Acosta, B. Waddell, J. Lee, K. Du, R.B. Weyant, B. Dalton, M. Bautista, J. Mccalder, R. Clark, J. Pitout, J. Kim, B. Missaghi, O. Larios, J. Vayalumkal, J. Leal, E. Rennert-May, J. Kanji, P. Westlund, B. Lee, X.L. Pang, K. Frankowski, C. O'grady, J.M. Conly, C.R. Hubert, M. Parkins

E0394 Hospital wastewater as a reservoir for carbapenemase-producing organisms. A. Anantharajah* (Brussels, Belgium), C. Altintas, T. Lavalleye, A. Delaunoy, I. Meyts, E. Dumitreasa, A. Bennert, C. Schirvel, A. Verroken, H. Rodriguez-Villalobos

E0396 Reversing and controlling microbial proliferation in the water system of a high-risk hospital ward after extended closure and reconstruction. D. Chaput* (Glasgow, United Kingdom), K. Clarkson, L. Bagrade, A. Marek, D. Kelly, D. Watson, A. Leanord, T. Steele

E0397 Whole-genome sequencing as part of the tracking and managing Carbapenemase producing Enterobacterales transmission in an acute hospital setting. D. Coffey* (Cork, Ireland), R. Waldron, D. Neshev, M. Cormican, C. Clarke, L. Hayes

E0398 Is there a solution for hospital acquired infections due to the aquatic reservoir in the near patient environment? H. Zayyad* (Poriya, Israel), R. Khouri, N. Saleh, A. Peretz

E0399 Reducing Antimicrobial Resistance (AMR) across the One Health Landscape: Diverse Perspectives on AMR risks and their mitigation in sinks, drains, and wastewater. H.A. Craddock* (Dublin, Ireland), A. Kearney, F. Fitzpatrick, C. Finn, M.T. Pryce, D. Fitzgerald-Hughes

EF055 13:30 - 14:30 Arena 4
ePoster Flash Session

The cutting edge in tuberculosis

ESCMID Global 2025 - Programme

Chair Graeme Ayton Meintjes (Observatory, South Africa)

E0400	Personalised risk predictions for incident TB and preventive treatment uptake. <i>R. Rose-Key* (London, United Kingdom), R. Gupta, M. Noursadeghi</i>
E0401	Programmatic migrant screening for tuberculosis identifies a spectrum of clinical phenotypes and outcomes: cohort data from a national migrant screening programme. <i>M. Gohar* (Leicester, United Kingdom), C. Martin, A. Ayobami, H. Patel, M. Patel, L. Ahyow, B. Srinj, G. Rishi, P. Mark, S. Nilesch, C. Trevithick, K. Pierun, M. Wiselka, L. Gray, I. Abubakar, R. Baggaley, A. Cooper, P. Haldar, M. Pareek</i>
E0402	An investigation into the relationship between human and animal <i>Mycobacterium bovis</i> isolates using whole genome analysis. <i>M. Mansfield* (Dublin, Ireland), E. Roycroft, S. Mok, P. Flanagan, M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers</i>
E0403	Distinguishing relapse from reinfection in tuberculosis patients from Lithuania. <i>L. Vasiliauskaitė, A. Zinola, F. Di Marco, V.E. Davidavičienė, B. Nakčeriėnė, A. Vaitulionytė, D.M. Cirillo, T. Kačergius</i>
E0404	Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study. <i>P. Chheda* (Mumbai, India), S. Shivaprakash, T. Dama, G. Thandassery</i>
E0405	Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment. <i>A. Van Laarhoven* (Nijmegen, Netherlands), L. Kurver, E. Klein Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Ingen, E. Ardiansyah, C. Van Arkel, R. Vullingsh, C. Magis Escurra, W. Hoefsloot, R. Van Crevel</i>
E0406	Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis. <i>C. Kim* (London, United Kingdom), S. Sweeney, H. Sohn, G.M. Knight, C.F. Mcquaid</i>
E0407	A longitudinal study on the evolution of drug resistance during tuberculosis treatment. <i>E. Danso* (Accra, Ghana), P. Asare, P. Tetteh, A. Tetteh, A.A. Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah-Manu</i>
E0408	Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers. <i>A.K. Pandey* (Chandigarh, India), N. Shafiq, S. Malhotra, C. Mothsara, G. Khuller, J. Verma, L. Verma</i>

SEL 13:30 - 15:30 Hall 1
Special Session

Selective Pressure
Chairs Jacob Moran-Gilad (Beer Sheva, Israel)
Joshua Nosanchuk (Bronx, United States)
Jose Ramon Pano-Pardo (Zaragoza, Spain)
Jesús Rodríguez-Baño (Seville, Spain)
Anja Šterbenc (Ljubljana, Slovenia)
Suzanne Van Asten (Nijmegen, Netherlands)
David Van Duin (Chapel Hill, Nc, United States)

JS1 13:30 - 14:30 Hall 12
Journal Session

Late-breaker research from CMI and CMI Communications

J001 13:30 Measuring the impact of hospitalization for infectious

diseases on the quality of life of older patients in four European countries: the AEGUI longitudinal matched cohort study (2020–2023) *Gaetan Gavazzi (Grenoble, France)*

J002	13:45	Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial <i>Thomas Holland (Durham, United States)</i>
J003	14:00	The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study <i>Elise Mitri (Heidelberg, Australia)</i>

LB003 13:30 - 14:30 Hall 13
1-hour Oral Session

New solutions for difficult-to-treat infection

L0011	Antimicrobial CRISPR-Cas9-based treatment against antibiotic resistant extraintestinal pathogenic <i>E. coli</i> (ExPEC) ST131C. <i>Morros-Bernaus* (Penryn, United Kingdom), J. Westley, E. R. Wyrsh, S. P. Djordjevic, A. F.C. Leonard, D. Sünderhauf, S. Van Houte</i>
L0012	Ultra-narrow spectrum antibiotic against multi-drug resistant gonococci with novel mode of action. <i>N. Nguyen* (Vienna, Austria), N. Nhung, A.K. Mix</i>
L0013	Multivalent OMV-based vaccine against Klebsiella pneumoniae. <i>B. Cano Castaño* (Madrid, Spain), B. Cano-Castaño, A. Tajuelo Moreno-Palancas, S. Prieto Martin-Gil, D. Fouteris, L. Del Pozo Acebo, F. Docando Sánchez, E. Gato, A. Pérez, M.J. McConnell</i>
L0014	Epidermicin NI01, a first-in-class peptide antibiotic candidate, has potent efficacy in a robust MRSA wound infection model and low allergic reaction liabilities. <i>M. Upton* (Plymouth, United Kingdom), G. Barker, V. Bennett, I. Fotheringham, S. Baxter, H. Curry</i>
L0015	Minimum inhibitory concentrations of quabodepistat in Mycobacterium tuberculosis clinical isolates from patients with drug-susceptible pulmonary tuberculosis. <i>I. Kontsevaya* (Munich, Germany), Y. Hayashi, D. Towle, N. Hariguchi, Y. Liu, S. Takuva</i>

SY094 13:30 - 14:30 Hall 14
1-hour Symposium

Farm to fork: food-borne antimicrobial resistance
Chairs Beatriz Guerra Román (Parma, Spain)
Joel Mossong (Luxembourg, Luxembourg)

S0269 13:30 **Foodborne risk in meat and fishery products and impact on AMR** *Anders Dalsgaard (Frederiksberg C, Denmark)*

S0270 14:00 **Control challenges associated with food-borne multidrug resistance** *Luisa Maria Vieira Peixe (Porto, Portugal)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG)

ME095 13:30 - 14:30 Hall 16
Meet-the-Expert

Local antimicrobials for deep infections

M0271	13:30	<i>Karolina Akinosoglou (Patra, Greece)</i>
M0272	13:42	<i>Pierre Tattevin (Rennes, France)</i>

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ESCMID Global 2025 - Programme

OS052 13:30 – 14:30 Hall 2
1-hour Oral Session

CLN DX

AI in infectious diseases: the lab and beyond

Chair *Miranda Langendam (Amsterdam, Netherlands)*

00381 **Accurate strain typing of key bacterial pathogens through artificial intelligence analysis of MALDI-TOF mass spectra** *N. Macesic* (Melbourne, Australia), H.A. Nguyen, A. Peleg, J. Song, J.A. Wisniewski, D.L. Dowe*

00382 **CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacteriales Using Disk-Diffusion** *L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht*

00383 **AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE)** *G. Danoe* (Groningen, Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brillman, L.L. Peters, M.S. Berends*

00384 **Predicting potentially infection-related findings in structured radiology reports** *J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D. Eyre*

00385 **Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections** *H. Zhang* (Shanghai, China), X. Xu, J. Ai*

OS053 13:30 – 14:30 Hall 3
1-hour Oral Session

TRN

Immune evasion and intracellular survival strategies

Chairs *Juliane Bubeck Wardenburg (St. Louis, United States), Giovanni Delogu (Italy)*

00386 **Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in *Acinetobacter baumannii*** *H. Wang* (Beijing, China), C. Jiang*

00387 **Intracellular lifestyle of *Acinetobacter baumannii*. Role of phospholipase A2 and transcriptional factor EB (TFEB)** *Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha*

00388 **The role of p_{eg344} of hypervirulent *Klebsiella pneumoniae* on suppressing autophagy responses of macrophages** *Z.E. Kuloğlu* (Istanbul, Türkiye), Ö. Albayrak, D. Güllü, G. Ekinci, F. Can*

00389 **c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection** *C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth*

00390 **Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology** *J. Kutschenreuter* (London, United Kingdom), D. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong*

SY091 13:30 – 14:30 Hall 4
1-hour Symposium

PHEI

Emerging infectious diseases: staying informed and prepared in a globalised world

Chairs *Nitin Gupta (Manipal, India), Pikka Jokelainen (Copenhagen, Denmark)*

S0263 13:30 **Lessons learnt from previous outbreaks *Tba***

S0264 14:00 **Disease X: preparedness for the next pandemic** *Yee Sin Leo (Singapore, Singapore)*

Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

SY092 13:30 – 14:30 Hall 5
1-hour Symposium

CLN

Sex differences in management and outcome of patients with serious bacterial infections

Chairs *Michele Bartoletti (Milan, Italy), Merel Lambregts (Leiden, Netherlands)*

S0265 13:30 **Sex Impacts incidence, management, and outcome in bacteraemia** *Annette Westgeest (Leiden, Netherlands)*

S0266 14:00 **The complex interplay between gender and sepsis** *Ines Lakbar (Montpellier, France)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

ME101 14:45 – 15:45 Hall 14
Meet-the-Expert

PRO

How to master conflict management and negotiation in healthcare

M0285 14:45 *Esther Calbo (Terrassa, Barcelona, Spain)*

M0286 14:57 *Jan A.J.W. Kluytmans (Utrecht, Netherlands)*

FO102 14:45 – 15:45 Arena 1
Open Forum

PHEI

Navigating the future of pandemics across One Health

Chair *Xavier Lescure (Paris, France)*

F0287 14:45 **Status of the One Health Joint Plan of Action by the Quadripartite** *Chadia Wannous (Paris, France)*

F0288 14:55 **National surveillance responsibilities under the updated international health regulations** *Tba*

F0289 15:05 **Long-term consequences of emerging viral diseases** *Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID Study Group for Public Health Microbiology (ESGPHM), Trainee Association of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases (SBI), Latin American Society for Travel Medicine

EF059 14:45 – 15:45 Arena 2
ePoster Flash Session

CLN PHEI

Bacterial infections in the post pandemic era

Chair *Özlem Kurt Azap (Ankara, Türkiye)*

E0424 **Genomic epidemiology of invasive meningococcal disease in Scotland: The impact of the COVID-19 pandemic** *N. Ahmad* (London, United Kingdom), C. Rodrigues, A. Smith, C. Cameron, L. Macdonald, R. Ure, M. Maiden*

E0425 **Targeted probe-capture culture-independent sequencing identifies emergence of Macrolide-Resistant *Bordetella pertussis* in Australia** *W. Fong* (Westmead, Australia), R. Rockett, K. Tam, T. Nguyen, E. Sim, C. Suster, J. Agius, S. Chandra, A. Watt, D. Speers, M. Graham, T. Tran, C. Lim, M. Wehrhahn, A. Ginn, D. Gray, J. Robson, L. Papanicolas, I. Gardner, A. Howard-Jones, A. Outhred, K. Kennedy, L. Cooley, Q. Wang, N. Jeffreys, S. Chen, K. Basile, T. Golubchik, J. Kok, V. Sintchenko*

ESCMID Global 2025 - Programme

E0426	Invasive pneumococcal disease in Spanish adults. Multicenter analysis of serotypes and lineages in the post-pandemic period. <i>R. España Bonilla* (Barcelona, Spain), R. España-Bonilla, A. González-Díaz, J.M. Marimón, A. Manzanal, E. Cercenado, S. De La Villa, B. Viñado, M. Bernat-Sole, M. Campos-Ruiz, M.D. Quesada, A. Casabella, M.L. Machado, R. Tejero, M.Á. Galán, S. Calvo-Silveria, D. Berbel, J. Yuste, S. Martí, J. Càmara, C. Ardanuy</i>	E0439	Risk factors for antimicrobial resistance in community commensal <i>Staphylococcus aureus</i> isolates, a sub-analysis of the AMRIC project. <i>M. Joyce* (Manchester, United Kingdom), Z. Aiken, N. Zhu, A. Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown, D.M. Lecky</i>
E0427	Group A streptococcal infections in Germany from 2017 to 2024: a post-pandemic rebound above expected numbers? <i>A. Von Laer* (Berlin, Germany), J. Mutevelli, A. Dörre, S. Haller, M. Feig, S. Buda, A. Hoffmann, I. Noll</i>	E0440	Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014-2023) <i>A. Mcgeer* (Toronto, Canada), A. Shigayeva, A. Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W. Gold, R. Lovinsky, M. Muller, K. Ostrowska, D. Ricciuto, D. Richardson, C. Vermeiren, K. Hassan, M. Lefebvre, A.X. Li, N. Malik, M. Pejkovska, A. Sultana, T. Vikulova, C. Kandel, Z. Zhong</i>
E0428	Invasive group A streptococcus infections is often preceded by seasonal influenza. <i>J. Westin* (Gothenburg, Sweden), M. Nygren, U. Snygg-Martin, L. Gustavsson, N. Sundell</i>	E0441	Antimicrobial resistance in <i>Streptococcus pneumoniae</i> in the Netherlands: an 11-year trend analysis of surveillance data <i>I. Nauta* (Bilthoven, Netherlands), W. Altorf-Van Der Kuil, D.W. Notermans, A.F. Schoffelen</i>
E0429	Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates <i>A. Cannas* (Rome, Italy), V. Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, E. Girardi, C. Fontana</i>	E0442	Impact of Donor Colonization or Infection, or preservation fluid contamination with Multiresistant Bacteria and Fungi in Solid Organ Transplantation. Multicenter registry of Argentina <i>L. Barcan* (Buenos Aires, Argentina), A. Smud, P. Giorgio, R. Gago, N. Pujato, M. Martinez, S. Villamandos, C. Niveyro, N. Lasserre</i>
E0430	Treatment outcomes of bedaquiline-based longer oral regimens in Indian children above 5-years of age <i>D. Gandhi* (Mumbai, India), I. Shah, R. Ansari, H. Warse, S. Kalawadia, T. Yangchen, D. Shah, V. Puri, S. Mattoo, M. Bodhanwala</i>	E0443	Analysis of viral load kinetics and risk factors for Epstein-Barr virus DNAemia and Post-transplant lymphoproliferative disorders in pediatric liver transplant recipients - a single centre experience <i>B. Kasztelewicz* (Warsaw, Poland), K. Skrok, I. Jankowska, P. Kaliciński, K. Dzierzanowska-Fangrat</i>
E0431	Incidence of Invasive <i>Escherichia coli</i> Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records <i>M. Blum* (Leuven, Belgium), C. Onwuchekwa, M.A. Schmidt, J. Poolman, T. Verstraeten, J. Geurtsen</i>	E0444	Impact of pre-transplant infection on post-transplant morbidity and graft survival in liver transplant recipients: a prospective cohort study <i>L. Mani-Perren* (Bern, Switzerland), S.F. Perrodin, A. Berzigotti, V. Banz, C. Hirzel, L.N. Walti</i>
E0432	A prospective controlled cross-sectional study demonstrates significantly higher IgG seroprevalence of leptospirosis among Munich's Eisbach river surfers <i>F. Voit* (München, Germany), D. Schult-Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider</i>	E0445	Risks of live-attenuated vaccines in children with primary immunodeficiency <i>S. Frigui* (Tunis, Tunisia), S. Ben Jaafar, Y. Chebbi, M. Ouederni, W. Achour</i>
E0433	Socio-demographic factors associated with community-acquired extended spectrum β-lactamase producing <i>E. coli</i> urinary tract infections at intermunicipal level in France <i>M. Prime* (Nantes, France), O. Lemenand, S. Thibaut, T. Coeffic, B. Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand</i>	E0446	Chagas reactivation/ transmission in kidney transplantation <i>M. Radisic* (Buenos Aires, Argentina), N. Pujato, M.C. Lopez-Albizu, R. Del Grosso</i>
E0434	Prolonged community outbreak of OXA-48-producing <i>Escherichia coli</i> linked to a food premises: Lower Hutt, New Zealand, 2018-2022 <i>C. Thornley* (Lower Hutt, New Zealand), M. Kelly, M. Bloomfield, A. Nesdale, R. White</i>	E0447	Clinical presentation and treatment of tuberculosis in solid organ transplant recipients: a multicentric retrospective analysis <i>J. Moltó* (Barcelona, Spain), I. Los-Arcos, D. Ruiz Cabrera, L. López González, M. Fayos Pérez, R. Rodríguez-Alvarez, M. Murga De La Fuente, V. Pomar, E. García Vázquez, T. Tórtola, J. Espinosa, O. Len, A. Sánchez-Montalva</i>
E0435	Low rates of macrolide resistance found in <i>Mycoplasma pneumoniae</i> cases in Australia <i>R. Rockett* (Westmead, Australia), J. Kok, K.G. Tam, T. Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, V. Sintchenko, S.C.A. Chen</i>	E0448	Clinical presentation, risk factors and outcome of non-tuberculous mycobacteria infection in hematopoietic stem-cell transplant recipients: a multinational case-control study <i>M. Fernandez Ruiz* (Madrid, Spain), M. Fernández-Ruiz, J.T. Silva, P.L. Carver, S. Rutjanawech, L.F. Aranha-Camargo, R. Fernandes, S. Belga, A. Alghamdi, N.J. Mueller, S. Burkhard, N.M. Theodoropoulos, D.F. Postma, P.J. Van Duijn, F. Arnaiz De Las Revillas, C. Pérez Del Molino-Bernal, J. Hand, A. Lowe, M. Bodro, E. Vanino, A. Fernández-Cruz, A. Ramos-Martínez, M.J. Makek, R. Bou Mjehed, O. Manuel, N. Kamar, A. Calvo-Cano, L. Rueda-Carrasco, P. Muñoz, A. Álvarez-Uría, S. Pérez-Recio, N. Sabé, R. Rodríguez-Álvarez, A. Mularoni, E. Vidal, J. Alonso-Titos, T. Del Rosal, A. Y. Classen, C. Mejía-Chew, F. López-Medrano</i>
E0436	Epidemiology of antibiotic resistance associated with <i>E. coli</i>/Klebsiella pneumoniae bloodstream infections in England 2012-2023 <i>S. Lipworth* (Oxford, United Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, T. Katy</i>		
E0437	The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in children <i>C. Brand* (Cape Town, South Africa), R. Ocloo, D. Wilck, P. Dube, A. Hesselung, J. Seddon, A. Demers, M. Newton-Foot, A. Whitelaw</i>		
E0438	Risk factors and prevalence of AntiMicrobial Resistant microbes In the English Community (AMRIC) <i>D. Lecky* (Gloucester, United Kingdom), Z. Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S.</i>		
E0439			
E0440			
E0441			
E0442			
E0443			
E0444			
E0445			
E0446			
E0447			
E0448			
EF061	14:45 – 15:45	Arena 4	
			ePoster Flash Session
			CLN DX
			Infections in the immunocompromised: a multifaceted overview
			Chair <i>Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)</i>
E0442			
E0443			
E0444			
E0445			
E0446			
E0447			
E0448			
EF060	14:45 – 15:45	Arena 3	
			ePoster Flash Session
			AMR CLN
			AMR in the community
			Chair <i>Camilla Wiuff Coia (Copenhagen, Denmark)</i>
E0433			
E0434			
E0435			
E0436			
E0437			
E0438			

ESCMID Global 2025 - Programme

E0449	<p>Impact of bronchoalveolar lavage results on clinical decision-making among immunocompromised, critically ill patients. C. Fanelli* (Sassari, Italy), R. Mondaca, R. Colima, D. Prado, R.R. Abud, S. Morales, M.M. Vera, E. Kattan</p>
E0450	<p>Campylobacter spp. bloodstream infections: preliminary results from a multicenter differential clinical analysis in immunocompromised and immunocompetent patients. M. Paniagua-García* (Seville, Spain), J.M. Bernal-Aznar, S. Herrera-Espejo, S. Salto-Alejandre, A. Valiente, M.C. Domínguez, M.Á. López-Zúñiga, F. Cobo, L. Alsina-Manrique De Lara, C. Martí-Castellote, M. Monsonis-Cabed, V. García-López, A. Polo, J. Laporte-Amargos, G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. Galán, M. Chávez-Caballero, M.O. Mohamed-Balghata, S. Winderickx, J.M. García De Lomas, F.J. Martínez-Marcos, M. Giannella, M. Garzaro, M. Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. López Cardenas, E. Cendejas, A.V. Halperin Benito, A. Romero Palacios, M. Navarro, C.A. Alonso, A. Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. Pachón-Ibáñez, E. Cordero-Matía</p>

SY100	<p>14:45 - 15:45 Hall 12</p> <p>1-hour Symposium</p>
-------	---

TRN

The challenge of a healthy microbiota in neonates

Chairs	<p>Maria Vehreschild (Frankfurt Am Main, Germany) Walter Zingg (Zurich, Switzerland)</p>
--------	--

S0283	<p>14:45 Infant gut microbiome development. Debby Bogaert (Edinburgh, United Kingdom)</p>
S0284	<p>15:15 Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates. Gautam Dantas (Saint Louis, United States)</p>

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)

OS058	<p>14:45 - 15:45 Hall 16</p> <p>1-hour Case Session</p>
-------	--

CLN

In the field with fungi

Chairs	<p>Beatriz L. Gomez (Bogota, Colombia) Leonardo Nimrichter (Rio De Janeiro, Brazil)</p>
--------	---

O0419	<p>Fosmanogepix expanded access in patients with Fusarium infections. S. Dadwal* (Duarate, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner</p>
O0420	<p>Voriconazole's hidden toll: unvelling periostitis in a heart transplant recipient and a hematologic patient. G. Motoa* (Boston, United States), A. Woolley, N. Issa</p>
O0421	<p>Unvelling the Uncommon: Managing Geotrichum candidum in Pancreatic Necrosis. L. Kriegl* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause</p>
O0422	<p>Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections. V. Havlicek* (Prague, Czech Republic), R. Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. Stevens</p>
O0423	<p>Efficacy of novel antifungal therapies in refractory Candida and Aspergillus infections: insights from compassionate use and clinical trials. S. Sedik* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl, J. Prattes</p>

OS056	<p>14:45 - 15:45 Hall 2</p> <p>1-hour Oral Session</p>
-------	---

PHI

Emerging trends in viral hepatitis across Europe

Chairs	<p>Federico Garcia (Granada, Spain) Neven Papic (Zagreb, Croatia)</p>
--------	---

O0409	<p>One of the largest outbreak of hepatitis A in the 21st century in Europe. I. Hockickova* (Slovakia, Slovakia), I. Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. Vasilová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian</p>
O0410	<p>Higher prevalence of Cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure – cause or consequence? J. Sonnenberg* (Muenster, Germany), K. Thiyagarajah, E. Görgülü, P. Lembeck, M. Glitscher, F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein, M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N. Kraus, M. Prakinjo, J. Fischer, H.P. Erasmus, J. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka, S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer</p>
O0411	<p>Delta in Denmark: current prevalence of hepatitis delta virus infection. H. Watson* (Lyon, France), P. Jepsen, H. Vilstrup, H. Krarup</p>
O0412	<p>RatHEV as an aetiological agent of acute hepatitis in Europe: results from the ESGHV-RHEV Study. A. Rivero-Juarez* (Córdoba, Spain), M. Casares, B. Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Rios-Muñoz, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-Álvarez De Luna, I. Viciana, M.D.C. Domínguez, M. Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez</p>
O0413	<p>Understanding the incidence and risk factors of low-level viremia in chronic hepatitis B: A propensity-matched comparison of tenofovir and entecavir. I. Hasanoglu* (Ankara, Türkiye), R. Guner, E. Zerdali, A. Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I. Yilmaz Nakir, O. Gunal, N. Eser, H. Yaqoobi, O. Tabki, T. Turunc, U. Balci, S. Komur, E.E. Tutuncu, L.N. Altunal, N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz, S. Kaya, O. Karabay, S. Alkan, F. Tabak</p>

OS057	<p>14:45 - 15:45 Hall 3</p> <p>1-hour Oral Session</p>
-------	---

ANT

Precision Medicine: from models to patient care

Chairs	<p>Anouk Edwina Muller (The Hague, Netherlands) Sebastian Wicha (Hamburg, Germany)</p>
--------	--

O0414	<p>Pharmacokinetics and pharmacodynamics of BPaLM, BPaLC and BPaL regimens for treatment of RR-TB. F. Kloprogge* (London, United Kingdom), B.T. Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S. Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D. Moore</p>
O0415	<p>Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data. Y. Chen* (Shanghai, China), J. Zhao, J. Zhang</p>
O0416	<p>Context-specific genome-scale metabolic modelling reveals metabolic alterations in multidrug-resistant Klebsiella pneumoniae in response to polymyxin B/zidovudine combination. J. Zhao* (Melbourne, Australia), Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li</p>
O0417	<p>Agent-based model predictions of polymyxin B activity on Acinetobacter baumannii. H. Soeorg* (London, United Kingdom), Y. Yuan, J. Readman, J.F. Standing</p>
O0418	<p>Monthly dalbavancin dosing for suppressive therapy: a case series and pharmacokinetic estimation analysis. C. Volk* (Madison, United States), W. Kufel, P. Hutson, R. Mahapatra, W. Rose</p>

SY099	<p>14:45 - 15:45 Hall 4</p> <p>1-hour Symposium</p>
-------	--

AMR IPC

How innovations of AMR and HAI surveillance systems help the clinical practice

ESCMID Global 2025 - Programme

Chairs
Pascal Astagneau (Paris, France)
Mandy Wootton (Cardiff, United Kingdom)

S0281 14:45 The EUCAST system in surveillance of AMR *Sören G. Gatermann (Bochum, Germany)*

S0282 15:15 Insights into developments in the surveillance of HAIs *Diamantis Plachouras (Solna, Sweden)*

Co-organised with: EUCAST Steering Committee, EUCIC Steering Committee, European Centre for Disease Prevention and Control (ECDC)

SY107 16:15 – 17:15 Hall 15

1-hour Symposium

PRO PHEI

Communicating (your) ID science for policy and societal impact

Chairs
Leonard Leibovici (Petah-Tiqva, Israel)
Ines Steffens (Solna, Sweden)

S0297 16:15 Communicating to policy makers and for societal impact *Balázs Babarczy (Budapest, Hungary)*

S0298 16:45 Influencing behaviour through the media and a multichannel communications strategy *Charlotte Hutchinson (London, United Kingdom)*

Co-organised with: CMI Board of Editors

EW109 16:15 – 18:15 Hall 2

Educational Session

GLN VAX

Infections in cancer patients: tips for daily practice

Chairs
José Molina Gil-Bermejo (Sevilla, Spain)
Stefan Schwartz (Berlin, Germany)

W0301 16:15 Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi *Janne Vehreschild (Frankfurt, Germany)*

W0302 16:35 Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours *Tba*

W0303 16:55 The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients *Şiran Keske (Istanbul, Türkiye)*

W0304 17:15 HTLV-1 and T-cell lymphoma - predict & prevent *Lucy Cook (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EF065 16:15 – 17:15 Arena 1

ePoster Flash Session

ANT TRN

The Antibiotic bakery: Novel compounds in the pipeline

Chair
Susanne Haeussler (Germany)

E0471 *In vitro* activity and *in vivo* proof-of-efficacy of epimutilin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens *S. Paukner* (Vienna, Austria), W.W. Wicha*

E0472 SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections *Y. Hui Hui* (Taipei, Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang, Y.S. Lu, H.C. Chiu*

E0473 *In vitro* potency of ceftibuten with xeruborbutam against β -lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme *O. Lomovskaya* (San Diego, California, United States), M. Castanheira, J. Lindley*

E0474 Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on *Pseudomonas aeruginosa* biofilm formation *A. Fontanot* (Rotterdam, Netherlands), W. Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani,*

A. Pini, R. Ecker, I. Ellinger

E0475 Broad spectrum coverage of serine β -lactamase and high *in vitro* potency against KPC- and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabicyclooctane β -lactamase inhibitor ANT3310 *L. Sánchez-Peña* (A Coruña, Spain), S. Rodríguez-Pallares, T. Blanco-Martín, L. González-Pinto, M. Outeda-García, P. Aja-Macaya, I. López-Hernández, J.C. Vázquez-Ucha, G. Bou, A. Beceiro, J. Arca-Suárez*

E0476 Antibacterial potential of D-limonene and diallyl disulfide and their interaction with gentamicin against multidrug-resistant *Pseudomonas aeruginosa* in rat pneumonia model *Y. Almuhanha* (Shaqra, Saudi Arabia), M. Asad*

E0477 *In vivo* pharmacokinetic/pharmacodynamic targets of a novel macrolide antibiotic naffithromycin, determined in neutropenic murine lung infection model of *Streptococcus pneumoniae* *A. Muller* (The Hague, Netherlands), R. Chavan, S. Takalkar, V. Zope, K. Umkar, P. Tayde, M. Tellis, S. Bhagwat, M. Patel, B. Veerarghavan*

E0478 NiPharmins: novel low resistance-inducing antimicrobials with antibiofilm activity against *Staphylococcus aureus* *A. Nunes* (Lisbon, Portugal), B. Alves, J.P. Carrilho, N.R. Candeias*

EF066 16:15 – 17:15 Arena 2

ePoster Flash Session

VAX

Modelling infectious disease burden and impact of vaccination

Chair
David Fisman (Toronto, Canada)

E0480 Evaluating the Impact of Re-vaccination on Pneumococcal Disease in Individuals Previously Vaccinated with PPSV23 in Germany: Comparative Approach *O. Sharomi* (Pennsylvania, United States), S. Oluwaseun, M. De Lepper, S. Mihm, T.C. Reuter, C. Solleder, G. Meleleo, T. Malik, K. Bakker, R. Oidtman*

E0481 Modeling the public health impact of a 21-valent PCV in the Canadian adult population *O. Sharomi* (Rahway, United States), R. Oidtman, M.C. Meilleur, S. Weinrich, K. Bakker*

E0482 Estimating the health and economic burden of pneumococcal diseases attributable to PCV21 (V116) vs. PCV20 or PPSV23 serotypes among adults in Norway *Z. Yi* (Rahway, United States), A.A. Tajik, S.T. Klitkou, E. Tsoumani, K. Owusu-Edusei*

E0483 Shifting from risk-based to age-based approach for pneumococcal vaccination in adults in France: a comprehensive evaluation *O. Sharomi* (Pennsylvania, United States), S. Oluwaseun, M. Breau-Brunel, F. Gaëlle, B. Lionel, C. Jérémy, M. Giulio, N. Robert, O. Rachel, M. Tufail, B. Kevin*

E0484 The socio-economic value of adult respiratory immunisation programmes in the United Kingdom – Are we measuring what matters to society? *C. Harrison* (Tadworth, United Kingdom), T. Hu, J. Yang, J. Vietri, D. Mendes, S. Chowdhury, C. Theakston, S. Brassel, L. Steuten*

E0485 Improving Danish all-cause mortality monitoring by nowcasting weekly deaths *A. Kalnæs* (Copenhagen, Denmark), J. Nielsen, L. Vestergaard, S. Nørgaard*

E0486 Modelling to identify an optimal ring vaccination strategy to mitigate a smallpox outbreak *V. Costantino* (Sydney, Australia), M. Kunasekaran, T. Leroyd, K. Yeo, R.C. Macintyre*

E0487 The impact of introducing meningococcal C/ACWY booster vaccination among adolescents in Germany: a dynamic transmission modelling study *F. Günther* (Berlin, Germany), U. Reinacher, S. Chisholm, M. Griskaitis, M. Höhle, S. Scholz, V. Schönfeld, O. Wichmann, T. Harder, F.G. Sandmann*

E0488 Potential public health impacts of gonorrhoea vaccination programmes under declining incidences: a modelling analysis *L. Geng* (Singapore, Singapore)*

ESCMID Global 2025 - Programme

EF067 16:15 – 17:15 Arena 3

ePoster Flash Session

CLN

Blood parasitology at its best

Chair *Miriam José Álvarez-Martínez (Barcelona, Spain)*

E0489 **Unexepected P.malariae diagnosis in Italian woman with no history of travel to endemic areas.** *A. Busni** (Milan, Italy), *L. Tartaglione, S. Torri, A. Longhi, E.M. Zavaroni, F. Crippa, C.S. Vismara*

E0490 **A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with Plasmodium vivax and Plasmodium falciparum.** *U.A. Zainulabid** (Pahang, Malaysia), *X.K. Cheong, P. Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris*

E0491 **Trick or Treat? An unrelenting malaria case.** *C. Uhomobhi** (Dublin, Ireland), *E. De Barra, C. Leddy, A. Brown*

E0492 **"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis"** *F. Murphy** (Dublin, Ireland), *A. Albadí, P. Coakley, C. McNally*

E0493 **Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy)** *F. Sabaini** (Milan, Italy), *A. Giacomelli, M. Beltrami, L.R. Galimberti, S. Antinori*

E0494 **The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients.** *S. Vita** (Rome, Italy), *A. D'abramo, A. Corpolongo, M.V. Tomassi, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastri*

E0495 **Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study.** *J. De Larminat** (Paris, France), *N. Dahane, N. Argy, M. Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Pineau, P. Picherit Steinbrucker, S. Azohana, S. Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye*

E0496 **Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement.** *A. Mohita** (Bikaner, India)

E0497 **Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV co-infection.** *N. T R** (Jodhpur, India), *T. Kanagiri, S. Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit, G.K. Bohra*

EF068 16:15 – 17:15 Arena 4

ePoster Flash Session

AMR PHEI

A global perspective on antimicrobial resistance surveillance

Chair *Mirfin Mpundu (Lusaka, Zambia)*

E0498 **Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS).** *O. Tosas Auguet** (Geneva, Switzerland), *E. Van Kleef, S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. Cooper, A.S. Dean, S. Bertagnolio*

E0499 **Comparative analysis of antimicrobial resistance (AMR) burden across European countries.** *A. Dörre** (Berlin, Germany), *A. Meinen, S. Haller, G. Robles Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns*

E0500 **Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities.** *C. Van Rossum** (Nijmegen, Netherlands), *C. Meijer, P. Koopman, D. Van Der Veegt, T. De Groot, M. Nabuurs-Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. Bowles, A. Gostmann, C. Van Der Veer, S. Pas*

E0501 **Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade.** *R. Janssen** (Bilthoven, Netherlands), *S. Woudt, D.*

Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O. Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M. Gelormini

E0502 **Global, regional, and national temporal trends in mortality for carbapenem-resistant bacteria from 1990 to 2021: An age-period-cohort analysis.** *C. Zhihui** (Shanghai, China), *Z. Mingchen, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong*

E0503 **Global Trends and Impact of Antimicrobial Resistance in Paediatric Populations: An Analysis Using WHO AWaRe Classification and Priority Pathogens.** *J. Harwell** (Boston, United States), *Y. Hu*

E0504 **Antibiotic resistance profile and comparative evaluation of WHO AWaRe Guidelines at the Emergency's Children's Surgical Hospital in Uganda.** *L. Barcellini** (Milan, Italy), *F. Riccaboni, V. Fabiano, F. Forlanini, A. Banfi, E. Crivellaro, A. La Mendola, A. Mohammed Zain, G.V. Zuccotti, L. Folgiori, L. Napolitano*

E0505 **Initiatives in antimicrobial resistance surveillance: Using automated bacteraemia surveillance for hospital-wide multidrug resistance monitoring.** *F.D. Ruether** (Berlin, Germany), *L.A. Peña Diaz, M. Behnke, C. Geffers, S.J.S. Aghdassi*

E0506 **Global and regional prevalence of antimicrobial resistance in GLASS target bacterial pathogens for bloodstream, urinary tract and gastrointestinal infections: a systematic review of the global literature (2019-2024).** *B. Caddey** (Calgary, Canada), *G. Lazarus, S. Bertagnolio, D.B. Nobrega, R.L. Hamers, A. Dean, V.K. Wangsaputra, F. Febrina, J.M. Conly, H.W. Barkema, E. Van Kleef, O. Tosas-Auguet*

KN103 16:15 – 17:15 Hall 1

Keynote Lecture

CLN

Tuberculosis: where are we now and where should we be

Chairs *Jon S. Friedland (London, United Kingdom)*
Delia Goletti (Rome, Italy)

K0290 16:15 *Guy Thwaites (Ho Chi Minh City, Vietnam)*

OS063 16:15 – 17:15 Hall 11

1-hour Oral Session

DX

Improving blood culture diagnostics: rethinking the basics

Chairs *Direk Limmathurotsakul (Bangkok, Thailand)*
Pilar Retamar Gentil (Seville, Spain)

O0461 **Blood culture volume, guideline adherence and pathogen yield of 35,433 paediatric blood cultures in Germany.** *J. Forster** (Würzburg, Germany), *A.L. Sieg, V. Rücker, H. Haefner, T. Bähr, S. Rössler, J. Held, V. Le Saout – Chapot, M. Hogardt, B. Spielberg, E.A. Idelevich, M. Christner, S. Zimmermann, S. Schneiter, M. Mauritz, C.S. Stingu, M. Gerlach, U. Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M. Krone*

O0462 **Changing the paradigm: are two sets of blood cultures always needed?** *R. Rosa** (Miami, United States), *J. Somani, K. Manzanillo, H. Dinh, G. Rosello, L. Abbo*

O0463 **Evaluating clinical and economic impact of reducing blood culture incubation timings: Time to shift the paradigm?** *R. Gupta (bagga)** (London, Canada), *R. Gupta, J. Delpont, T. Mazzulli*





O0464 **Revolutionizing hospital workflows with blood culture-free ultra-rapid antimicrobial susceptibility testing: A clinical pilot study.** *S. Kwon** (Seoul, Korea, Republic of), *K. Sunghoon, K. Dong Young, J. Jisung, K. Tae Hyun, K. Junwon, J. Hyelyun, L. Gi Yoon, P. Wan Beom*







O0465 **Human *In vivo* footprints from blood plasma for improved diagnostics in sepsis.** *M. Sonntag** (Stuttgart, Germany), *J. Mueller, A. Von Haeseler, Y.*

ESCMID Global 2025 - Programme

Vainshtein, S.O. Decker, T. Brenner, K. Sohn

J. Butler, F. Uhel, O. Cremer, T. Van Der Poll

ME108	16:15 – 17:15	Hall 12
	Meet-the-Expert	
		
Navigating travel medicine: expert tips for safe international travel		
M0299	16:15	Sophie Schneitler (Homburg, Germany)
M0300	16:27	Andreas Neumayr (Basel, Switzerland)
OS062	16:15 – 18:15	Hall 13
	2-hour Oral Session	
	  	
Heterogeneity and complexity of sepsis		
Chairs	Despoina Koulenti (London, United Kingdom) Sylvain Meylan (Lausanne, Switzerland)	
00451	A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium. Moore* (Stanford, Ca, United States), T. Sweeney, A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer	
00452	BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study C. Genovese* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri	
00453	Deciphering the Dynamics of <i>Klebsiella pneumoniae</i> Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients W. Yu* (Beijing, China)	
00454	Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients S. Taylor* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas	
00455	Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups M.H. Øvre* (Herlev And Gentofte, Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknacht	
00456	Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam - results from SPECTRA.E Yucel* (Rahway, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul	
00457	Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series J. Underwood* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed	
00458	Is transthoracic echocardiography required in all patients with <i>Staphylococcus aureus</i> bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis M.Á. Verdejo* (Barcelona, Spain), D. Malano-Barletta, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. García-Vidal, P. Puerta, A. Del Río, M. Espasa, J.A. Martínez, L. Morata, A. Soriano	
00459	DNA methylation changes in Sepsis: Potential use as biomarkers I. López-Cruz* (Valencia, Spain), J.L. García-Giménez, L. Piles, M. Madrazo, G. Judit, M. López-Torres, A. Artero	
00460	Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia S. Doeleman* (Amsterdam, Netherlands), D. Susanne, E. Michels,	

SY106	16:15 – 17:15	Hall 14
	1-hour Symposium	
	 	
Strain dynamics in determining gut microbial colonisation resistance		
Chairs	Silvio Daniel Brugger (Zurich, Switzerland) Li Yang Hsu (Singapore, Singapore)	
S0295	16:15	Strain dynamics in serious bacterial infections in infants Drew Schwartz (Saint Louis, United States)
S0296	16:45	Long-term colonisation dynamics of carbapenemase-producing Enterobacteriales Niranjan Nagarajan (Singapore, Singapore)
OS064	16:15 – 17:15	Hall 16
	1-hour Oral Session	
	  	
Viral immune response - nature or nurture? Exploring the limits of immune response		
Chairs	Malin Flodström-Tullberg (Stockholm, Sweden) Florian Krammer (New York, United States)	
00466	Orthopoxvirus-specific antibody dynamics up to two years after monkeypoxvirus infection or vaccination C. Van Dijk* (Antwerp, Belgium), N. Berens-Riha, L. Zaeck, I. Brosius, R. De Vries, J. Marien, L. Liesenborghs	
00467	DENG-VAC study: preliminary data on immunogenicity and reactogenicity of Qdenga vaccine versus natural infection A. D'abramo* (Rome, Italy), S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle, G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M. Fabrizio, N. Emanuele	
00468	Long-Lasting Immunity Followed by Natural CCHFV Infection H. Karakoc* (Trabzon, Türkiye), H.N. Karakoç Parlayan, A. Aslanabadi, D. Yapar, Q. Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A. Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M. Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D. Pegan, É. Bergeron, G. Lewis, N. Baykam, M.M. Sajadi	
00469	Why does rabies virus not induce an anti-viral immune response : insights from experimental models and a human cohort C. Geurts Van Kessel* (Rotterdam, Netherlands), C. Embregts, A. Gohar, B. Verstrepren, J. Aijaz, N. Salahuddin, C. Geurtsvankessel	
00470	Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses N. Noulin* (London, United Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt, K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C. Chiu, A. Catchpole	
SY104	16:15 – 17:15	Hall 3
	1-hour Symposium	
		
Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant with MDR Gram-negative colonisation		
Chairs	Elda Righi (London, United Kingdom) David Van Duin (Chapel Hill, Nc, United States)	
S0291	16:15	Standard prophylaxis Maddalena Giannella (Bologna, Italy)
S0292	16:45	Targeted approaches Maristela P. Freire (Sao Paulo, Brazil)
Co-organised with: European Association for the study of the liver (EASL)		
SY105	16:15 – 17:15	Hall 4

ESCMID Global 2025 - Programme

1-hour Symposium

Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach

Chairs Robert A. Bonomo (Cleveland, United States)
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0293 16:15 Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics Anna Sramkova (Pilsen, Czech Republic)

S0294 16:45 Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors Parikshit Prayag (Pune, India)

Co-organised with: EUCAST Steering Committee

LB004 16:15 - 18:15 Hall 9

2-hour Oral Session

Trials in severe infections

L0016 Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial F. Cogliati Dezza* (Seville, Spain), L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin García, S. Lopez Cardenas, M.C. Gomez Sanchez, I. Pérez Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M.C. Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero Sanchez, S. De La Villa, J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez-Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño Álvarez, Z.R. Palacios Baena, L. López Cerero, J. Rodríguez-Baño

L0017 High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trial R. Van Crevel* (Nijmegen, Netherlands), D. Meya, R. Rovina, D. Boulware, B. Dai, N. Engen, F. Cresswell, K. Naidoo, A. Rizal, D. Imran, R. Lessels, L. Tugume, R. Hamers, M. Kabahubya, S. Marais, Y. Moosa, N. Bahr, E. Svensson, L. Te Brake, R. Aarnoutse

L0018 HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study M. Ju* (Shanghai, China), M. Wang, J. Yuan, H. Huang, G. Bi, J. Lv, X. Lv, L. Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Zhang

L0019 Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant *Acinetobacter baumannii* G. Dale* (Basel, Switzerland), F. Fratzeskaki, I. Tsagkaris, A. Armaganidis, M. Katsiashvili, D. Kazaishvili, T. Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Kapanadze, T. Kachibaia, A. Sarkany, E. Zakyntinos, P. Delique, M. Davila, L. Husband, P. Timofeev, F. Jung, C. Kemmer

L0020 Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trial M. Canetti* (Tel Aviv, Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Magiel, N. Baharav, A. Belkin, I. Margalit, V. Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. Wieder-Finesod, N. Maggio, D. Yahav

L0021 Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network

remodelling and enteric pathogen reduction L.A. Edwards* (London, United Kingdom), B. Auch, T. Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. Tranah, J.M. Blanco, L. Meoli, A. Clavé Llaval1, V.T. Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. Liachko, S. Goldenberg, D.L. Shawcross

L0022 Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients coinfecting with HIV and tuberculosis: a multicentre, open-label, randomised trial Y. Shen* (Shanghai, China), X. Le

L0023 Initial vancomycin taper for the prevention of recurrent *Clostridioides difficile* infection: the TAPER-V randomised controlled trial E.G. Mcdonald* (Montreal, Canada), Y. Chen, B. Coburn, N. Daneman, S. Hota, C. Frenette, C.E. Kandel, L. Kong, Y. Longtin, V.G. Loo, D. Macfadden, M. Muller, T.S. Steiner, L. Valiquette, T.C. Lee

L0024 Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial S. Bastrup Israelsen* (Hvidovre, Denmark), L. Hagens Mygind, F. Al-Zergani, B. Lindegaard, A. Knudsen, S. Tingsgård, L. Thorlacius-Ussing, I. S. Johansen, H. Nielsen, P. Ravn, T. Benfield

L0025 Beneficial effects of a clinical metagenomics intervention on clinical outcomes, healthcare economics, and quality of life in patients with sepsis/septic shock: results of the DigiSep-trial T. Brenner* (Essen, Germany), A. Skarabis, S.J. Schaller, T. Von Groote, C. Putensen, U. Günther, M. Sauer, S.O. Decker, F. Dusse, M. Weiss, K. Suchodolski, T.P. Simon, P. Rosenberger, O. Moerer, M. Unterberg, J.C. Schewe, H. Bracht, S. Hutzl, M. Feißt, U. Marschall, P. Brandenburg, J. Englisch, P. Stevens, J. Schmidt, M.W. Pletz, J. Brands, A. Antinoro, L.O. Warner, M.A. Weigand, D.M. Hart, G. Marx, J. Mossanen, T. Breuer, H. Häberle, K. Nitzsche, P. Thalmann, J. Brezinski, J. Saam, T. Schwerhoff, S. Grumaz, M. Steinmann, M. Gaasch, B. Pasieka, U. Jaekel, T. Brandenburg, F. Bach, H. Mutlak, S. Utzolimo, M.M. Berger

SY112 17:30 - 17:30 Hall 1

PHEI

1-hour Symposium

Year in public health

Chairs Ziad A. Memish (Riyadh, Saudi Arabia)
Catherine Moore (Cardiff, United Kingdom)

S0309 17:30 Li Yang Hsu (Singapore, Singapore)

S0310 18:00 Rita Oladele (Lagos, Nigeria)

EF074 17:30 - 18:30 Arena 1

ePoster Flash Session

DX PHEI

New methods for rapid pathogen detection and typing

Chair Sylvain Brisse (Paris, France)

E0532 Rapid detection of Shiga toxin-producing *Escherichia coli* (*stx2a* and *stx2d*) in Korean diarrheal stool samples: a performance evaluation L. Hyeonji* (Seoul, Korea, Republic of), H.J. Lee, H.J. Kim, S.S. Choi, H.J. Choo, H.J. Huh, E.J. Won

E0533 Global prevalence of O-serotypes and antibiotic resistance among extraintestinal pathogenic *Escherichia coli* isolated from older adult patients with bacteraemia (2011–2021) J. Geurtsen* (Leiden, Netherlands), M. De Been, O. Go, M. Aitabi, C. Willame, E. Weerdenburg

E0534 Strategy for the rapid typing of *Salmonella* spp using infrared spectroscopy: a one health perspective J. Jiménez* (Santiago, Chile), D. Fredes, A. Piña, I. Mercado, J. Miranda, S. Henríquez, T. González, A. Adell, A. Moreno-Switt, A. Wozniak, P. García

ESCMID Global 2025 - Programme

E0535	WGS-based surveillance as a paradigm shift in outbreak detection, AMR monitoring and source attribution in <i>Campylobacter</i> . <i>A. Nunes*</i> (Lisbon, Portugal), <i>M.L. Lemos, S. Ortiz, I. Santos, S. Ramos, M. Oleastro</i>
E0536	Prevalence of <i>Staphylococcus aureus</i> clonal complex 97 amongst BORSA isolates in a large UK hospital. <i>H. Gareth*</i> (Birmingham, United Kingdom)
E0537	The effectiveness of clinical laboratory tools in the surveillance of nontuberculous mycobacterium isolations within different counties in Taiwan. <i>H.W. Chu*</i> (Taipei, Taiwan, China), <i>T.F. Lee, C.C. Shu, Y.T. Huang</i>
E0538	Rapid detection of oxazolidinone-resistance-related mutations in <i>Enterococcus</i> spp. by using High Resolution Melting-qPCR-typing analysis. <i>R. Musumeci*</i> (Monza, Italy), <i>E. Giordano, M. Martinelli, M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Congedo, C.E. Cocuzza</i>
E0539	An automated pipeline to genotype bacteriophages using third generation sequencing. <i>Z. Halász*</i> (Debrecen, Hungary), <i>E. Szoták, L. Dr. Laczkó, G. Dr. Kardos</i>
E0540	Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy. <i>N. Mauder*</i> (Bremen, Germany), <i>M. Cordovana, M. Kostrzewa</i>

EF075	17:30 – 18:30	Arena 2
	ePoster Flash Session	
		
	Healthcare (workers') safety revisited	
Chair	<i>Daniel Diekema</i> (Harpswell, United States)	

E0541	Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study. <i>B. Beishuizen*</i> (Bilthoven, Netherlands), <i>M. Stein, A. Tostmann, C. Rovers, A. Timen</i>
E0542	Preparing First-Line health care workers for 'Virus X' through targeted training (FILI-VI-X). <i>A. Mondelaers*</i> (Antwerp, Belgium), <i>Y. Somers, K. Vanden Driessche, I. Brosius, L. Liesenborghs, C. Rovers, L. Zweers, M. Wieland, E. Vlieghe</i>
E0543	Analysis of the current situation of hospital inspection practices by German health authorities. <i>A. Schwabe*</i> (Bonn, Germany), <i>J. Dannenberg, A.D. Wollkopf, F. Droop, S. Engelhart, N.T. Mutters</i>
E0544	A nationwide survey on the status and implementation of infection prevention and control practice on behalf of INSIEME Project (Italian National project for contrast antibiotic resistance a cooperation between Simit (Italian society of infectious diseases) E (&) Ministry of hEalth). <i>M. Meschiarì*</i> (Modena, Italy), <i>F.V. Segala, E. Ricchizzi, A. Gallerani, V. Scaglione, R. Castoldi, F. Almerigogna, I. Spalliera, A. Parente, S. Coladonato, P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S. Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. Murri, C. Mussini</i>
E0545	High level of measles immunity among Dutch healthcare workers with self-reported "unknown" measles immunity status. <i>C. Meijer*</i> (Nijmegen, Netherlands), <i>J. Leijser, M. Mccall, C. Rovers, E. Bowles, N. Van Der Geest, A. Tostmann</i>
E0546	Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland. <i>C. Anderson*</i> (Dublin, Ireland), <i>D. Mcgee, M. Coleman, A. Hehir, L. Dolan, N. Noonan, V. Tormey, C. Bergin, C. Fleming, L. Townsend</i>
E0547	Systematic review of determinants of vaccine hesitancy among healthcare workers. <i>V. Gabbellone*</i> (Lecce, Italy), <i>F. Nuccetelli, R. Prato, E. Gabrielli, P.L. Lopalco</i>

E0548	Post-pandemic questions on vaccine usage: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines. <i>P. Shamsrizi*</i> (Hamburg, Germany), <i>S. Eitze, D. Heinemeier, A. Tänzer, M.A. Jenny</i>
E0549	Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits? <i>A. Kearney*</i> (Dublin, Ireland), <i>H. Humphreys, D. Fitzgerald Hughes</i>

EF076	17:30 – 18:30	Arena 3
	ePoster Flash Session	
		
	Knowing me, knowing you: behaviour influencing AMS	
Chair	<i>Elena Carrara</i> (Verona, Italy)	

E0550	Exploring determinants in deciding the optimal antimicrobial dose in patients receiving CRRT: a mixed method study. <i>T. Yanik Yalçın*</i> (Ankara, Türkiye), <i>A. Pehlivanlı, İ. Yeşiler, H. Şahintürk, Ö. Azap, H. Arslan, B. Başgüt, P. Zeyneloğlu</i>
E0551	Behaviour change vs policy change: Key drivers of inappropriate antibiotic use among health care professionals in LMICs – insights from Indian community setting. <i>N. P. Mathew*</i> (Manipal, India), <i>U. B. M. Varma, V. K E, R. Ruiter, G. Thunga, C. Mukhopadhyay</i>
E0552	Contextual determinants to antimicrobial stewardship implementation in 16 hospitals: a four-country analysis in Asia. <i>H. Vu Thi Lan*</i> (Ha Noi, Vietnam), <i>R. Limato, H.Y. Duong, S. Manandhar, D. Limmathurotsakul, A. Apisarnthanarak, N.T. Pham, V.C. Nguyen, R.L. Hamers, E.J. Nelwan, S. Sakinah, A. Karkey, M.K. Upadhyaya, E. Dodds Ashley, D. Anderson, H.R. Van Doorn, H. Vu</i>
E0553	SpeakAB, a pilot study to encourage nurses to speak up about antibiotic care. <i>M. Bos*</i> ('s Hertogenbosch, Netherlands), <i>J. Schouten, H. Vermeulen, M. Hulscher, C. De Bot</i>
E0554	Understanding what matters to patients in antimicrobial stewardship in hospitals. PERSPECT study update. <i>B. Jacob*</i> (Dublin, Ireland), <i>E. De Barra</i>
E0555	Determinants of antibiotic prescribing in hospitals from low, middle and high-income countries in Asia. <i>S. Chhabra*</i> (Singapore, Singapore), <i>S. Nair, A. Bramley, J.Y. Chee, K. Vignesvaran, R.E.D. See, L.J. Sun, A.H. Ching, B.S. Cooper, E. Charani, Y. Mo</i>
E0556	Riding "the antimicrobial rollercoaster": The behavioural and phenomenological science of antimicrobial use in haemato-oncology. <i>C. Eades*</i> (London, United Kingdom), <i>L. Byrne-Davis, R. Rautemaa-Richardson, T. Felton</i>
E0557	Addressing Antimicrobial Resistance: Expert Insights and Policy Recommendations for Effective Interventions. <i>B. Madran*</i> (Istanbul, Türkiye), <i>F. Almeida, E. Carrara, D. Kofteridis, N. Rocha-Pereira, G. Pieve, N. Tziolos, İ. Kayı, Ş. Keske, E. Önder, S. Sakarya</i>
E0558	Implementation of hospital antimicrobial stewardship in Europe using a data-driven behaviour change approach: insights from the drive-AMS EU project!. <i>Pauwels*</i> (Antwerp, Belgium), <i>R. Janssen, E. Iosifidis, N. Milevska-Kostova, M. Lupşu, J.A. Paiva, E. Roilides, T. Schoffelen, R. Valinteliene, A. Versporten, E. Vlieghe, J. Schouten</i>

EF077	17:30 – 18:30	Arena 4
	ePoster Flash Session	
		
	Viral aphroditis	
Chair	<i>Rémi Charrel</i> (Marseille, France)	

E0559	Potential for international spread of Oropouche virus via commercial air travel. <i>M. Torres Portillo*</i>
-------	---

ESCMID Global 2025 - Programme

		(English, Canada), A. Marwah, M. Kraemer, A. Thomas, K. Khan, I. Bogoch
E0560		Estimating mpox Clade 1b outbreak size in the Democratic Republic of the Congo to attenuate surveillance gaps during the early stages of the 2024 outbreak. M. Torres Portillo* (English, Canada), A. Marwah, A. Thomas-Bachli, I. Bogoch, K. Khan
E0561		Disparate epitope recognition between MPXV-infected and Smallpox-vaccinated individuals. A. Otter* (Salisbury, United Kingdom), S. Jones, B. Hicks, B. Hallis, C. Rowe
E0562		Diverse residual and late-onset symptoms of severe fever with thrombocytopenia syndrome: insights from a multicenter questionnaire study in Western Japan. R.M. Sada* (Osaka, Japan), S. Yamamoto, T. Toyokawa, T. Takahashi, A. Yamanaka, M. Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Tanizaki, K. Iwata, S. Kutsuna
E0563		Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study. J.T. Lim* (Singapore, Singapore), I. Wee, W.Z. Tan
E0564		Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina. G.A. Méndez* (Posadas, Argentina), J. Salmanton-García, C. Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Bernard, C.P.L. Fernández, M.F. Tosin, M.F. Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely
E0565		Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever. D. Yigci* (Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. Yetişgen, M. Özgüler, A. Şenol, Ö. Gündoğ, M. Çağlar Özer, F. Soyak, B. Tanır, İ.D. Alırcı, G. Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkuçcu, Ö. Ergönül
E0566		Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India. P. Venkata Swathi Kiran* (Udupi, India), P.K. Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K. Pothumarthy
E0567		Unravelling the aetiology of summer flu-like illness in Czechia. M.F. Křihá* (Ceske Budejovice, Czech Republic), V. Hönig, J. Kamiš, M. Dvořáková, L. Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek

SY111	17:30 - 18:30	Hall 11
	1-hour Symposium	

PK/PD in drug development: what's in it for me?		
Chairs	Sandrine Marchand (Poitiers, France) Sebastian Wicha (Hamburg, Germany)	

S0307	17:30	PK/PD from the EUCAST/regulatory perspective: what tools do we need? Joseph Meletiadis (Athens, Greece)
S0308	18:00	PK/PD for new anti-TB drugs Elin Svensson (Uppsala, Sweden)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

OS070	17:30 - 18:30	Hall 12
	1-hour Oral Session	

What's new in antifungal guidelines and management		
Chairs	Sharon Chen (Sydney, Australia) Helmut Salzer (Linz, Austria)	

O0512		Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASMR. Sprute*
-------	--	--

(Cologne, Germany), O.A. Cornely, M. Bassetti, C. Sharon, A. Groll, O. Kurzai, C. Lass-Flörl, L. Ostrosky-Zeichner, R. Rautemaa-Richardson, G. Revathi, M.E. Santolaya, L. White, L.P. Zhu

O0513		Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay. M. Bassetti* (Genoa, Italy), G.R. Thompson, A. Soriano, S. Dickerson, I. Bielicka, O.A. Cornely
-------	--	---

O0514		An open-label study of ibrexafungerp in patients with refractory fungal infections (FURI). O.A. Cornely* (Cologne, Germany), B.D. Alexander, P.G. Pappas, T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A. Spec, G.R. Thompson, L. Ostrosky-Zeichner, R.S. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo
-------	--	---

O0515		Novel immunotherapy approach using pan-Candida monoclonal antibodies to treat life-threatening invasive candidiasis and tackle global AMR. Y. Zhao* (Aberdeen, United Kingdom), C.A. Munro, S. Palliyil
-------	--	--

O0516		Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis. K. Stott* (Liverpool, United Kingdom), D. Tembo, C. Kajanga, A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T. Harrison, J. Jarvis, D. Namakhwa, D. Lalloo, W. Hope, H. Mwandumba
-------	--	---

OS071	17:30 - 18:30	Hall 14
	1-hour Oral Session	

Intestinal parasitic uncovered: epidemiology and treatment success		
Chairs	Kurt Hanevik (Bergen, Norway) Pavla Tůmová (Praha, Czech Republic)	

O0517		Giardia- Does the treatment work? The experience from a national tertiary referral centre. A. Boté Casamitjana* (London, United Kingdom), A. Boté-Casamitjana, S. Eisen, L. Nabarro, N. Longley, G. Godbole
-------	--	--

O0518		Giardiasis: Who gets it? Experience from a Central London Teaching Hospital. A. Boté Casamitjana* (London, United Kingdom), A. Boté-Casamitjana, S. Eisen, L. Nabarro, N. Longley, G. Godbole
-------	--	--

O0519		Assessing the Effect of Antimicrobial Treatment on the Accuracy of Serial Serum and Urine Testing for Detecting E. histolytica cfDNA. P. Datta* (Chandigarh, India), D. Rattan, A. Duseja, N. Sharma, N. Kalra, S. Khurana
-------	--	---

O0520		Longitudinal observation of Blastocystis sp. and Dientamoeba fragilis in children: a very rare occurrence in chronic diseases with gut dysbiosis. J. Hurych* (Prague, Czech Republic), J. Havlova, V. Neuman, K. Litosova, K. Hubackova, L. Hlinakova, M. Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P. Saavalainen, H. Malcova, D. Cebecauerova, P. Dřevínek, Z. Sumnik, O. Cínek
-------	--	---

O0521		High prevalence of the zoonotic Angiostrongylus cantonensis in rats in Spain. J. Caballero Gómez* (Córdoba, Spain), T. Fajardo-Alonso, I. García-Bocanegra, M. González, A. Beato-Benítez, R. Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R. Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A. González, P. Foronda, J. Caballero-Gómez
-------	--	---

OS072	17:30 - 18:30	Hall 15
	1-hour Oral Session	

Training models - a new model for training		
Chairs	Erin Bonura (Portland, United States) Cassandra Bulescu (Bucharest, Romania)	

O0522		Can ChatGPT4o help build Objective Structured Clinical Examination (OSCE) stations in infectious diseases? S. Villard* (Paris, France), Y. Guedj, L. Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B.
-------	--	---

ESCMID Global 2025 - Programme

Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, M. Thy, N. Peiffer-Smadja

00523	Large language model in real-world clinical infectious diseases: are we there yet? <i>G. Carra*</i> (Switzerland, Switzerland), <i>M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat-Blanco</i>
00524	Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3 <i>S. Ahmad*</i> (Tampere, Finland)
00525	A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines. <i>J. Molina Gil-Bermejo*</i> (Sevilla, Spain), <i>J. Molina, J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller</i>
00526	Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis <i>S. Angirekula*</i> (Jodhpur, India), <i>R. Modi, R. Bora, R. Lohiya, S.K. Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K. Bohra</i>

OS073	17:30 - 18:30	Hall 16
	1-hour Case Session	

CLN

Still going viral

<i>Chairs</i>	<i>Ursula Hofer</i> (London, United Kingdom) <i>Yee Sin Leo</i> (Singapore, Singapore)
00527	Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions. <i>A. Tessitore*</i> (Trieste, Italy), <i>N. Maximova, S. Braidotti, M. Granzotto, R. Simeone</i>

00528	Histopathological proof of herpes simplex pneumonia in a patient with severe COVID-19 pneumonia. <i>J. Heylen*</i> (Leuven, Belgium), <i>B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters</i>
-------	--

00529	Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina. <i>L. Barcan*</i> (Buenos Aires, Argentina), <i>S. Villamandos, R. Gago, M. Aguirre, A. Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán</i>
-------	---

00530	Rash without borders: waning immunity in a travelling physician. <i>R. Ville Benavides*</i> (Mexico City, Mexico), <i>R. Ville-Benavides, I. Avendaño-Gutiérrez</i>
-------	--

00531	A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient. <i>A. Kaya*</i> (Izmir, Türkiye), <i>G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan</i>
-------	---

SY110	17:30 - 18:30	Hall 3
	1-hour Symposium	

VAX

Immune reconstitution syndrome in infectious diseases: Who. Are. You?

<i>Chair</i>	<i>Justyna Kowalska</i> (Warsaw, Poland)
--------------	--

S0305	17:30	IRIS in HIV immunocompromised hosts: a failure of success <i>Paola Maria Cinque</i> (Milan, Italy)
-------	-------	---

S0306	18:00	Dysregulated host responses to infection <i>Michal</i>
-------	-------	---

Holub (Praha, Czech Republic)

OS069	17:30 - 18:30	Hall 4
	1-hour Oral Session	

AMR ANT

Determining new and revising old breakpoints

<i>Chairs</i>	<i>Jaroslav Hrabak</i> (Plzen, Czech Republic) <i>Erika Matuschek</i> (Växjö, Sweden)
---------------	--

00507	EUCAST disk diffusion testing of ten additional species of anaerobic bacteria. <i>J. Ahman*</i> (Växjö, Sweden), <i>J. Åhman, E. Matuschek, B.J. Holzkecht, P.C. Lindemann, H. Marchandin, S. Copsy-Mawer, T. Morris, G. Kahlmeter</i>
-------	---

00508	Standardised antimicrobial susceptibility testing protocol for <i>Legionella pneumophila</i> validated across ten European reference laboratories. <i>M. Sewell*</i> (Cardiff, United Kingdom), <i>C. Farley, A.V. Krøvel, M. Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B. Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M. González-Rubio, F. González-Camacho, M. Petzold, M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L. Jones, O.B. Spiller</i>
-------	--

00509	Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods. <i>L. Chan*</i> (Kennedy Town, Hong-Kong SAR, China), <i>D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung, V.C.Y. Chow</i>
-------	--

00510	Determination of optimal disk diffusion mass for zosurabalpin. <i>M. Castanheira*</i> (North Liberty, United States), <i>J. Maher, Y. Edah, A. Trauner</i>
-------	---

00511	The clinical significance of aminoglycoside susceptibility breakpoints modification. <i>O. Henig*</i> (Tel Aviv, Israel), <i>M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-Ami</i>
-------	---

Monday, 14 April 2025

SY116	08:30 - 10:30	Hall 15
	2-hour Symposium	

PHEI

Climate Change: changing risks and adaptation strategies for a world on the move

<i>Chairs</i>	<i>Rachel Lowe</i> (Barcelona, Spain) <i>Giacomo Stroffolini</i> (Lausanne, Switzerland)
---------------	---

S0323	08:30	Vector-borne diseases in Europe and clinical consequences <i>Tuba Dal</i> (Ankara, Türkiye)
-------	-------	--

S0324	09:00	Rising temperatures and risks of fungal disease <i>Anuradha Chowdhary</i> (New Delhi, India)
-------	-------	---

S0325	09:30	Strategies for climate prevention and adaptation in a moving world <i>Kristie Ebi</i> (Seattle, United States)
-------	-------	---

S0326	10:00	AMR in climate change-affected countries <i>Esmita Charani</i> (London, South Africa)
-------	-------	--

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

EF079	08:30 - 09:30	Arena 1
	ePoster Flash Session	

CLN


AMS around the world: what we can learn from each other

<i>Chair</i>	<i>Benedikt Huttner</i> (Geneva, Switzerland)
--------------	---

E0578	Battlefield Stewardship: Implementing Antimicrobial Management in the Ukrainian Trauma Pathway. <i>H. Uren*</i> (Lviv, Ukraine), <i>N. Aliieva, O. Voitovysh</i>
-------	---

E0579	Evaluating a Tailored Antimicrobial Stewardship
-------	--

ESCMID Global 2025 - Programme

		Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study <i>M. Alyazji* (Abudhabi, United Arab Emirates), A. Sadeq, J. Shamseddine, Z.O.E. Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. Alhebsi, S. Alawlaqi, F. Aljamsi, A. Aitamimi, S. Shaabani, A. Alhosani, S. Shawish, R. Ali</i>
E0580		Antimicrobial stewardship program for antibiotic use in the community: impact of multidisciplinary local guidelines during the 2023-2024 influenza a H1N1 season in northern Italy <i>R. Corsini* (Reggio Emilia, Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, S. Mezzadri</i>
E0581		Effectiveness of Clinical Algorithms combined with Point-of-Care testing to improve Antibiotic Prescribing practices of physicians in outpatient setting of low middle-income country <i>S. Qureshi* (Karachi, Pakistan), S. Ahmed, N. Nasir, F.N. Qamar</i>
E0582		Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study <i>M.S. Kabir* (Dhaka, Bangladesh), R. Farzana, S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Humayra, M. Sultana, M.N. Haque, T.R. Walsh</i>
E0583		Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital <i>P. Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti Salik, M. Quipildor, M.M. Maresca, I.A. Falco</i>
E0584		Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment <i>M. Krauss* (Vienna, Austria), C. Labut, G. Brunhofer-Bolzer, G. Laml-Wallner, B. Unterkoefler, M. Andtisch, E. Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. Starzengruber, F. Loetsch, H. Lagler</i>
E0585		Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CARbapenem Sparing Antimicrobial Stewardship) Project <i>M. Bongiovanni* (Lugano, Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di Benedetto, N. Ramponi, M. Mombelli, N. Centemero, A. Colombo, D. Destefani, M. Bissig, E. Bernasconi</i>
E0586		"Prescribing antibiotics is a gamble...": A mixed-methods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital <i>L. Jung* (Leipzig, Germany), L. Atikoro, D. Owachi, A. Schneider, S. Schönherr, A. Von Braun, C. Kabugo</i>
EF080	08:30 - 09:30	Arena 3 ePoster Flash Session 
		Acinetobacter baumannii, still a strong knight to be knocked <i>Chair Parikshit Prayag (Pune, India)</i>
E0587		Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against Acinetobacter baumannii <i>H. Haddad* (Sousse, Tunisia)</i>
E0588		Clonal dissemination of highly resistant Acinetobacter baumannii/ST2: Insights from the BALANCE study <i>C. Abdellaoui* (Oxford, United Kingdom), R. Farzana, M.N. Haque, M. Sultana, A. Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S. Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh</i>
E0589		Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant Acinetobacter baumannii in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam <i>D. Nurjadi* (Luebeck, Germany), S. Boutin, Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P. Velavan</i>
E0590		In vitro activity of nitroxoline among Acinetobacter

		baumannii and Stenotrophomonas maltophilia clinical isolates <i>E. Wohlfarth* (51105 Cologne, Germany), P.G. Higgins, M. Kresken</i>
E0591		Assessing biocide resistance genes and susceptibility to biocides in carbapenem-resistant Acinetobacter baumannii isolates from Thai hospitals <i>M.R.D. Wiradiputra* (Bangkok, Thailand), K. Thirapanmethee, P. Khuntayaporn, M.T. Chomnawang</i>
E0592		Epidemiological and Genomic Characteristics of Acinetobacter baumannii in a Hospital in Zhejiang, China: A Study from 2015 to 2020 <i>Y. Zhang* (Hangzhou, China), X. Hua</i>
E0593		Evaluation of the susceptibility of Carbapenem-resistant Acinetobacter baumannii to sulbactam-durlobactam <i>J. Caierão* (Porto Alegre, Brazil), L. Silva Dornelles, G. Da Silva Collar, M. Preussler Mott, A. Luís Barth</i>
E0594		Clonal dissemination of Acinetobacter baumannii International Clone 2 Carrying ArmA and emergence of OXA-23-NDM1 co-producers in India <i>G. Nagaraj* (Bangalore, India), N. Geetha, S. Varun, K. Ravikumar</i>
E0595		Insight into Acinetobacter baumannii's phenotypic and genotypic traits in oncological patients <i>F. Sivori* (Rome, Italy), I. Cavallo, M. Truglio, G. Fabrizio, M. Francalancia, F. Fraticelli, E. Abril, E.G. Di Domenico, F. Pimpinelli</i>
EW119	08:30 - 10:30	Hall 11 Educational Session 
		This bacterium might harbour AmpC, what should I do? <i>Chairs Sören G. Gatermann (Bochum, Germany) Pranita Tamma (Ellicott City, United States)</i>
W0335	08:30	Laboratory Identification of AmpC and its impact on /in vitro resistance <i>Ana Gales (Sao Paulo, Brazil)</i>
W0336	08:50	Divergent levels of AmpC expression in Gram-negative pathogens <i>Antonio Oliver (Palma De Mallorca, Spain)</i>
W0337	09:10	Rational choice of antimicrobial therapy against AmpC-producing pathogens <i>Patrick Harris (Herston, Australia)</i>
W0338	09:30	Novel antimicrobials active against AmpC: what RCTs tell us in support of their use? <i>Amy Mathers (Charlottesville, United States)</i>
SY114	08:30 - 10:30	Hall 13 2-hour Symposium 
		Sepsis Global 2025 <i>Chairs Brigitte Lamy (Bobigny, France) Willem Joost Wiersinga (Amsterdam, Netherlands)</i>
S0315	08:30	The ESCMID-ISF Sepsis Award Lecture <i>Andrew Moore (Emerald Hills, Ca, United States)</i>
S0316	08:45	The WHO Global Maternal Sepsis Study <i>Carolina Carvalho Ribeiro Do Valle (Sao Paulo, Brazil)</i>
S0317	09:15	Sepsis: year in review <i>Sylvain Meylan (Lausanne, Switzerland)</i>
S0318	09:45	How to design and implement a Sepsis National Action Plan (SNAP) <i>Erika Viteghe (Edegem, Belgium)</i>
		Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)
SY115	08:30 - 10:30	Hall 14 2-hour Symposium 
		Challenges in infection management, prevention and antimicrobial stewardship in long-term care facilities <i>Chairs Gaetan Gavazzi (Grenoble, France)</i>

ESCMID Global 2025 - Programme

Giusy Tiseo (Pisa, Italy)

- S0319 08:30** **The burden of nosocomial infections in long-term facilities** *Virginie Prendki (Genève-Thônex, Switzerland)*
- S0320 09:00** **Pneumonia in the elderly: management and prevention** *Marcos Restrepo (San Antonio, United States)*
- S0321 09:30** **Challenges in the clinical diagnosis of infection in the elderly** *Maheen Abidi (Denver, United States)*
- S0322 10:00** **Challenges in implementing antimicrobial stewardship in long-term care facilities** *Elena Carrara (Verona, Italy)*

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

SY117 08:30 - 10:30 Hall 16

2-hour Symposium

AMR CLN

Survival of the parasites: is treatment failure due to antimicrobial resistance?

Chairs Hanne Brekke (Oslo, Norway) Jaco J. Verweij (Tilburg, Netherlands)

- S0327 08:30** **Nitroimidazole refractory *Giardia intestinalis* infection** *Pavla Tůmová (Praha, Czech Republic)*
- S0328 09:00** **Treatment failure in scabies** *Francisco Bravo (Lima, Peru)*
- S0329 09:30** **Recurrent *Enterobius* infections** *Sarah Eisen (London, United Kingdom)*
- S0330 10:00** **Recent advances in the treatment of Visceral Leishmaniasis and PKDL** *Shyam Sundar (Varanasi, India)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EW118 08:30 - 10:30 Hall 2

Educational Session

DX IPC

How can we infer and track plasmid outbreaks?

Chairs Alessandra Carattoli (Rome, Italy) Jacob Moran-Gilad (Beer Sheva, Israel)

- W0331 08:30** **Evolutionary modelling of plasmids** *Manuel Ares Arroyo (Paris, France)*
- W0332 08:50** **How plasmids shape the emergence of nosocomial pathogens** *Jukka Corander (Oslo, Norway)*
- W0333 09:10** **Understanding the complexity of plasmid outbreaks using bioinformatics** *Torsten Seemann (Melbourne VIC, Australia)*
- W0334 09:30** **Plasmid transmission at the One Health interface** *Nicole Stoesser (Oxford, United Kingdom)*

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

SY113 08:30 - 10:30 Hall 3

2-hour Symposium

PHEI

Haemorrhagic viral infections

Chairs Önder Ergönül (Istanbul, Türkiye) Catherine Houlihan (Porton Down, United Kingdom)

- S0311 08:30** **Filovirus disease: evolving therapeutic strategies** *Jan Crozier (Frederick, United States)*
- S0312 09:00** **Jack in the box: Re-emergence of Kyasanur Forest Disease in India** *Kavitha Saravu (Manipal, India)*
- S0313 09:30** **Crimean Congo Haemorrhagic Fever: Newer insights into pathogenesis leading to new vaccines and**

therapeutics *Ali Mirazimi (Stockholm, Sweden)*

S0314 10:00 **Venezuelan Equine Encephalitis: Impact of newer strategies for vector control** *Carlos Seas (Lima, Peru)*

OS078 08:30 - 10:30 Hall 5

2-hour Oral Session

CLN DX TRN

Trending topics in tuberculosis

Chairs Delia Goletti (Rome, Italy) Sean Wasserman (London, United Kingdom)

O0568 **Lineage-specific Immune responses to *Mycobacterium tuberculosis*: Insights into L4 and L6 pathogenesis** *M. Silva* (Porto, Portugal), J. Couto, M. Cardoso, B. Cá, M. Saraiva*

O0569 **Deciphering the functional role of distinctive *Mycobacterium tuberculosis* peptidoglycan modifications in modulating antibiotic resistance and the immune response** *C. Silveiro* (Lisbon, Portugal), F. Olivença, M. Mandal, D. Pires, E. Anes, M.J. Catalão*

O0570 **Increased innate immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 tuberculous meningitis** *J. Barnacle* (London, United Kingdom), A. Davis, R.J. Wilkinson, K. Wilkinson, C. Stek, M. Maxebengula, N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S. Wasserman, G. Meintjes, A. O' Garra*

O0571 **Subpopulations in clinical samples of *Mycobacterium tuberculosis* can give rise to rifampicin resistance and shed light on how resistance is acquired** *V. Brunner* (Oxford, United Kingdom), P. Fowler*

O0572 **A systematic comparison of automated *Mycobacterium tuberculosis* complex whole genome sequencing analysis pipelines** *R. Spies* (Ho Chi Minh City, Vietnam), D. Crook, T. Peto, P. Fowler, R. Turner, H. Thai, J. Watson, T. Walker*

O0573 **Lung ultrasound for the detection of pulmonary tuberculosis using expert and AI-guided interpretation** *V. Suttels* (Lausanne, Switzerland), T. Brokowski, J. Wolleb, P. Wachinou, A. Hada, G. Makpemikpa, E. Garcia, T. Brahier, O. Opota, D. Affolabi, M.A. Hartley, N. Boillat-Blanco*

O0574 **Nanomotion Technology for Rapid Antimicrobial Susceptibility Testing of *Mycobacterium tuberculosis*: Evaluating Novel Benzothiazinone Derivatives** *A. Vocat* (Lausanne, Switzerland), A. Luraschi-Eggemann, C. Antoni, G. Cathomen, D. Cichocka, G. Greub, O. Riabova, V. Makarov, O. Opota, A. Mendoza, S. Cole, A. Sturm*

O0575 **Rapid drug susceptibility testing of *Mycobacterium tuberculosis* directly from clinical samples using targeted next-generation sequencing** *E. Rosendal* (Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo*

O0576 **Enhancing cerebral tuberculosis therapy with an innovative particulate nose-to-Brain drug delivery system: Insights from pharmacokinetic and pharmacodynamic studies** *K. Jadhav* (Sas Nagar, India), K. Sudhakar Jadhav, A.K. Singh, R.K. Verma*

O0577 **Multi-drug resistant tuberculosis among migrants in Europe** *S. Hayward* (London, United Kingdom), K. Rustage, L.B. Nellums, J.S. Friedland, S. Hargreaves*

SY120 09:30 - 10:30 Hall 1

1-hour Symposium

DX

Year in clinical microbiology

Chairs Fidelma Fitzpatrick (Dublin, Ireland) Maurizio Sanguinetti (Rome, Italy)

S0339 09:30 *Mario Ramirez (Lisbon, Portugal)*

S0340 10:00 *Anna Papa-Konidari (Thessaloniki, Greece)*

Session ID	Time	Venue
EF081	09:30 - 10:30	Arena 2
ePoster Flash Session		
<div style="display: flex; align-items: center;"> ANT DX </div>		
Clinical features and outcome of invasive fungal infections		
Chair <i>Marcus De Melo Teixeira (Brasília, Brazil)</i>		
EF0596	Management, outcomes and predictors of mortality of <i>Cryptococcus</i> infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand J. Coussement* (Melbourne, Australia), C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O'kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O'hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen	
EF0597	Incidence of invasive fungal infections in hospitalised paediatric patients in England A. Warris* (Exeter, United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz, M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J. Owczarek, C. Castillo, I. Jimenez	
EF0598	Invasive fungal disease in critically ill patients with cirrhosis: an autopsy study L. Maessen* (Leuven, Belgium), A. Wilmer, P. Meersseman, J. Wauters, J. Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, M. Peetermans, G. Hermans, Y. Debaveye, E. Van Wijngaerden, S. Van Der Merwe, G. De Hertogh	
EF0599	Non-<i>Aspergillus</i> mould infections in Australia and New Zealand: a multi-centre study on epidemiology and clinical outcomes C.F. Neoh* (Melbourne, Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Douglas, K. Urbancic, M. Menon, A. Stewart, P. Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, K.Y. Yong, A. Crowe, M. England, O. Robinson, S. Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong, T. Spelman, L. Worth, M. Slavin	
EF0600	Leveraging natural language processing (NLP) for early detection of aspergillosis: A retrospective study L. Nwankwo* (London, United Kingdom), N. Pinnock, A. Shek, C. Hemsley, J. Periselnieris, S. Schelenz, D. Armstrong-James	
EF0601	How often does Mucormycosis (MCM) contribute to mortality in Hematologic Malignancy (HM) patients? Analysis of 103 patients over 20 years S. Wurster* (Houston, United States), T.M. John, J. Ying, D.P. Kontoyiannis	
EF0602	Emergence of <i>Wickerhamomyces anomalus</i> invasive infections in injecting drug users M. Lefranc* (Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K. Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S. Imbert	
EF0603	Prevalence and risk-factors for secondary localizations during candidemia in intensive care unit patients: the French Candida ICU multicenter study J.P. Gangneux* (Rennes, France), F. Reizine, J. Henry, L. Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban, G. Eustache, T. Belleville, A. Marc, J. Malherbe, P. Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A. Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G. Nevez, L. Delhaes, S. Imbert, H. Guegan, J. Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y. Launey, C. Aubron	
EF0604	Population-based longitudinal study over two decades of <i>Candida</i> and <i>Candida</i>-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance A. Stewart* (Boston, United States), K. Laupland, F. Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson, M. Slavin, S. Chen	

Session ID	Time	Venue
FO129	11:00 - 12:00	Arena 1
Open Forum		
Predatory Journals in CM/ID: from symptoms to cure		
Chair <i>Emily G. McDonald (Montreal, Canada)</i>		
FO356	11:00	The genesis of predatory Journals: symptoms and root problems Leonard Leibovici (Petah-Tiqva, Israel)
FO357	11:10	The role of editors and publishers of 'reputable journals': what can they do to stop predatory journals? Till Bärnighausen (Heidelberg, Germany)
FO358	11:20	The roles of authors and academic Institutions: towards governance and regulation Luigia Scudeller (Pavia, Italy)
FO359	11:30	Bibliometric literacy in scientific publication Lauren Maggio (Chicago, United States)
Co-organised with: CMI Communications Board of Editors		
EF089	11:00 - 12:00	Arena 2
ePoster Flash Session		
Emerging Infectious Diseases, Zoonoses and Outbreaks		
EO640	Seasonality of Influenza and Respiratory Syncytial Virus related hospital contacts in Denmark (1999-2021) O. Reza Hosseini* (Hillerod, Denmark), C.L. Burrett, M.F. Eiberg, M.P. Andersen, M.F. Howitz, C. Roed, J.G. Holler, B. Lindegaard Madsen, D.M. Weinberger, T.K. Fischer, C. Torp-Pedersen, Z.B. Harboe	
EO641	Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us? I. Sanz-Muñoz* (Valladolid, Spain), J. Sánchez-Martínez, C. Rodríguez-Crespo, I. Arroyo-Hernández, C.S. Concha-Santos, M.L. De Dlego, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, A. Martín-Toribio, A. Mostafa, L. Martínez-Sobrido, J.M. Eiros, A. Nogales	
EO642	The UK Imported Fever Service (IFS): National VHF testing 2023-2024 A. Belfield* (Salisbury, United Kingdom), A. Thompson, H. Umpleby, B. Hack, S. Poole, J. Furneaux, J. Owen, J. Osborne, C. Petridou, T. Brooks, N.C. Gordon, T. Rampling, C. Houlihan, C.E. Warrel	
EO643	Reemergence of Poliovirus in Pakistan: Challenges and Implications for Global Health Security S. Ahmad* (Tampere, Finland)	
EO644	Preparing an emerging infectious diseases unit for high-consequence infectious diseases A. Silva-Pinto* (Porto, Portugal), C. Silva, A.S. Santos, M. Teixeira, L. Santos	
EO645	Correlation between clinical and wastewater measles positivity rate in three towns of Karachi, Pakistan F. Naz Qamar* (Karachi, Pakistan), F.N. Qamar, S. Qureshi, M. Larik, F. Kabir, J. Iqbal, K. Begum, J. Gauld, S. Kroiss, J. Giles	
EO646	<i>Salmonella</i> serovars in wild European hedgehogs (<i>Erinaceus europaeus</i>): an over 12-year monitoring in the Ferrara Province, Italy E. Massella* (Piacenza, Italy), M. Munari, S. Russo, L. Cirasella, C. Torreggiani, R. Taddei, A. Luppi, S. Rubini	
EO647	Clinico-epidemiological and Microbiological Investigation of Diphtheria Outbreak in Odisha, India, 2024 I. Prahara* (Bhubaneswar, India), S. Panda, S. Subhadra, J. Sabat, S. Mallik, S. Xalxo, N. Manisha, S. Priyadarshini, S. Nayak, N. Ray, S. Mallick, S. Pati	
EO648	Seroprevalence of nine causes of acute febrile illness in rural Cambodia and Thailand using a multiplex assay M. Zhang* (Bangkok, Thailand), R. Tripura, L. Dysoley, C. Perrone, E. M. Batty, J. Wongsantichon, S. D. Blacksell, S. S. Y. Kang, N. P. J. Day, R. J. Maude, S. J. Lee, Y. Lubell, T. J. Peto	

ESCMID Global 2025 - Programme

EF090	11:00 – 12:00	Arena 3	
	ePoster Flash Session		
	DX		
Addressing the need for speed: advances in point-of-care testing			
<i>Chair</i>	<i>Jennifer Dien Bard (Los Angeles, United States)</i>		
E0649	Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT. <i>Brown* (Bristol, United Kingdom), A.D. Hay, S. Abbs, M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. Mitchell, L. Zhu, L. Yardley, C. Metcalfe</i>	O0622	Molecular epidemiological characterization of enterotoxigenic and enteroaggregative <i>Escherichia coli</i> causing traveller's diarrhoea and their relationship with clinical features. <i>P. Oliveras Julia* (Barcelona, Spain), P. Oliveras, E. Riera, L. Horvath, R.M. Albarracin, M.E. Valls, M.J. Alvarez-Martinez, M. Alguacil, E. Guiral, M. Espasa, D. Camprubi-Ferrer, J. Vila</i>
E0650	Evaluation of the prototype BIOFIRE® nasal HR panel (nHRP) in children with acute respiratory illness, a nasal swab-based rapid host gene expression test. <i>G. Storch* (Saint Louis, Missouri, United States), M. Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin</i>	O0623	Bites and bytes – can digital surveillance of travellers' illness predict outbreaks? <i>N. Hedrich* (Zürich, Switzerland), T. Lovey, P. Schlagenhaut</i>
E0651	Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnosis of bacterial intestinal infections. <i>P. Lehours* (Bordeaux, France), Q. Beauvils, L. Benejat, A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain</i>	O0624	Travel-associated infections and diseases: a retrospective cross-sectional study. <i>M. Trojanek* (Prague, Czech Republic), M. Trojanek, V. Grebenyuk, V. Jegorova, P. Hubacek, A. Briksi, J. Havlova, K. Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O. Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, B. Pisova, R. Šindlerová, M. Tulach, Z. Uhříková, M. Vidlička, M. Štefan, F. Stejskal</i>
E0652	Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance Analysis. <i>N. Younes* (Doha, Qatar), G. Nasrallah</i>	OS086	11:00 – 12:00 Hall 11 1-hour Oral Session
E0653	A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE). <i>S.Y. Choi* (Daejeon, Korea, Republic of), C. Lee, H.O. Park</i>		DX TRN
E0654	Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing device. <i>A. Van Der Linden* (Eindhoven, Netherlands), Y. Deurloo, N. Doomen, D. Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko</i>	Marker based diagnostics: forget the pathogen	
E0655	Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogens. <i>C. Singhal* (Faridabad, India), S. Chatterjee, S. Gupta, M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, A. Tyagi, N. Kumar, S. Chaudhuri</i>	<i>Chair</i>	<i>Suzanne Van Asten (Nijmegen, Netherlands)</i>
E0656	Multianalyte POCT device for a sample-to-result detection of nucleic acid and protein. <i>L. Pommiers* (Gif Sur Yvette, France), H. Boutal, D. Fras, H. Volland</i>	O0625	A 29-mRNA molecular host response test demonstrates enhanced accuracy compared to a protein-based host response test for the diagnosis of bacterial and viral infections. <i>N. Whitfield* (Sunnyvale, United States), C. Lu, O. Liesenfeld</i>
E0657	A smartphone app for point-of-care quantification of lateral flow assays. <i>R. Armiger* (London, United Kingdom), R. Reid, P. Georgiou, A. Holmes, J. Herberg</i>	O0626	Diagnostic accuracy of a bacterial versus viral host-protein test for pediatric inpatients with acute infection. <i>T. Gottlieb* (Tirat Carmel, Israel), L. Bont, A. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, E. Eden, B.P. Muller</i>
KN121	11:00 – 12:00	Hall 1	
	Keynote Lecture		
	PHEI		
HIV: from needle parks to injectables			
<i>Chairs</i>	<i>Mary Horgan (Dublin, Ireland) Gülsen Özkaya Sahin (Lund, Sweden)</i>		
K0341	11:00	<i>Huldrych Günthard (Zürich, Switzerland)</i>	
OS085	11:00 – 12:00	Hall 10	
	1-hour Oral Session		
	CLN PHEI		
Planes, Pains, and Pathogens: The Perils of Travel Medicine			
<i>Chairs</i>	<i>Anu Kantele (Helsinki, Finland) Carlos Seas (Lima, Peru)</i>		
O0620	Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology. <i>S. Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori</i>	O0627	Diagnostic accuracy of combined urine lipocalin 2 and copper test in acute pyelonephritis or cystitis. <i>V. Havlicek* (Prague, Czech Republic), J. Hrbacek, T. Pluhacek, J. Houst, A. Palyzova, D. Luptakova, D.A. Stevens, J. Novak, R. Dobias, R. Zachoval</i>
O0621	Tracing the itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data. <i>S. Gupta* (Auckland, New Zealand), S. Thornley, G. Sundborn, C. Grant</i>	O0628	Diagnostic Performance of Whole-Blood RNA Signatures for Tuberculosis Diagnosis in a Cohort of Patients with Non-Tuberculous Mycobacterial Lung Disease. <i>P. Escalante* (Rochester, Mn, United States), B. Piatkowski, B. Pathakumari, V. Van Keulen, N. Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T. Peikert</i>
		O0629	Diagnostic utility of MxA and MxA/CRP ratio in differentiating viral and bacterial infections: a prospective cohort study. <i>O. Beránek* (Praha 5, Czech Republic), R. Prusa, M. Trojanek, O. Beranek, Z. Uhříková, J. Illner, P. Lehnert, P. Bukovska, M. Štefan, V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, R. Šindlerová, M. Tulach, M. Vidlička, V. Grebenyuk</i>
		PM2	11:00 – 12:00 Hall 12 Panel Discussion
		AMR and vaccines	
		<i>Chairs</i>	<i>Charlotte Vernhes (Brussels, Belgium) Ghada Zoubiane (London, United Kingdom)</i>
L005	11:00	Overview of the current evidence of the impact of vaccines on AMR. <i>Adam Cunningham (Birmingham, United Kingdom)</i>	
L006	11:20	Panel discussion: gaps, needs, and opportunities to leverage vaccines against AMR. <i>Adam Cunningham (Birmingham, United Kingdom), Siphokenneth Dlamini (Observatory, South Africa), Erin Duffy (Boston, United States), Mateusz Hasso-Agopsowicz (Geneva, Switzerland)</i>	
SY126	11:00 – 12:00	Hall 13	

ESCMID Global 2025 - Programme

1-hour Symposium

CLN

Why is the concept of complicated UTI so complicated?

Chairs Gernot Bonkat (Basel, Switzerland)
Maeve Doyle (Waterford, Ireland)

S0350 11:00 **The concept of complicated UTI: underlying conditions matter** Suzanne Geerlings (Amsterdam, Netherlands)

S0351 11:30 **The concept of complicated UTI: the site of infection matters most** Jesús Rodríguez-Baño (Seville, Spain)

Co-organised with: ESCMID Education Subcommittee

ME128 11:00 – 12:00 **Hall 14**
Meet-the-Expert

TRN

How to apply organoid models to study infectious disease

M0354 11:00 Jennifer Rohn (London, United Kingdom)

M0355 11:12 Nathalie Sauvonnnet (Paris, France)

OS087 11:00 – 12:00 **Hall 15**
1-hour Oral Session

AMR TRN

Antimicrobial resistance around birth

Chairs Julia Anna Bielicki (London, United Kingdom)
Surbhi Malhotra-Kumar (Antwerp, Belgium)

O0630 **Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs** A. Sharma* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray

O0631 **Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk** A. Chakraborty* (Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora

O0632 **Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units** A. Braspenning* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar

O0633 **Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut** V. Pettersen* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg

O0634 **Dynamics of gut resistome and mobilome in early life: A meta-analysis** V. Pettersen* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov

OS088 11:00 – 12:00 **Hall 16**
1-hour Oral Session

CLN DX VAX

Advancing diagnostics and preventive measures in hemato-oncological patients

Chair Dina Averbuch (Jerusalem, Israel)

O0635 **Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy** M. Freire* (Sao Paulo, Brazil), A. Villani, Jr, M. P. Freire, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L.S. Nunes, A.S. S. Levin

O0636 **Viral metagenomics in patients with persistent unexplained neutropenic fever- some clues to the**

cause of fever? A. Douglas* (Melbourne, Australia), L. Caly, M.A. Slavín, I. Savic, J. Moselen, A. Aziz, G. Papadakis, G. Ng, J. Druce, K. Thursky

O0637 **Results of Optifill study: 18F-FDG-PET/CT guided antifungal stewardship in invasive pulmonary aspergillosis** F. Lanternier* (Paris, France), C. Maunoury, F. Montravers, F. Marquant, S. Poiree, C. Elie, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E. Blanchard, O. Lortholary

O0638 **Long-term immunogenicity and boostability of the 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation: a prospective cohort study** S. Haggenburg* (Amsterdam, Netherlands), J. Schnyder, H. Garcia Garrido, M. Schoordijk, A. Reiners, B. Meek, M. Hazenberg, A. Goorhuis

O0639 **Humoral and cellular immune response to adjuvanted respiratory syncytial virus vaccine RSVPreF3 in adults after allogeneic hematopoietic cell transplantation** J. Lötscher* (Basel, Switzerland), C.S. Walti, J. Halter, N. Khanna, S. Heller, S. Schmid, K. Leuzinger

OS082 11:00 – 12:00 **Hall 2**
1-hour Oral Session

CLN DX

New insights in bloodstream infections and endocarditis

Chairs Barbara Hasse (Zurich, Switzerland)
José M. Miro (Barcelona, Spain)

O0605 **Different from the start – Sex differences in Staphylococcus aureus bacteremia mortality** A. Westgeest* (Leiden, Netherlands), M. Lambregts, F. Ruffin, V.G. Fowler, J.T. Thaden

O0606 **Tracking evolution in action during invasive Staphylococcus aureus infections: the BARISTA study** S. Giulieri* (Melbourne, Australia), D. Daniel, M. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A. Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen, M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S. Tong, J. Kwong, B. Howden

O0607 **Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection – an exploratory post-hoc analysis of the BALANCE randomized clinical trial** S. Ong* (Melbourne, Australia), R. Pinto, A. Rishu, S. Tong, R. Commons, J.M. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-Wiens, T. Lee, S. Lothar, D. Macfadden, J. Marshall, V. Martel-Laferrrière, M. Mayette, E. McDonald, J. Neary, J. Prazak, E. Raby, A. Regli, B.A. Rogers, S. Smith, L. Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young, R.A. Fowler, N. Daneman

O0608 **Bloodstream infection pathogen diversity and clinical impact revealed through unbiased whole genome sequencing: a prospective genomic epidemiology study** N. Macesic* (Melbourne, Australia), J. Hawkey, J.A. Wisniewski, A. Peleg

O0609 **Risk of infection of intracardiac devices in patients with valvular infective endocarditis who carry cardiovascular implanted electronic devices. Analysis on a national cohort** A. Blanco Arévalo* (Barcelona / Singapore, Spain), A. Blanco-Arevalo, E. Calbo, P. Muñoz, D. Monzón, M. Valerio, M. Hernandez Meneses, J.M. Miró, M. Cobo Belastegui, A. De Alarcón, R. Rodríguez, I. Villanueva Benito, J.C. Lopez-Azor, L. Garcia-Alvarez, L. Boix

SY122 11:00 – 12:00 **Hall 3**
1-hour Symposium

DX VAX

Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days?

Chairs Pavel Drevinec (Prague, Czech Republic)
Helle Krogh Johansen (Copenhagen, Denmark)

S0342 11:00 **The lung microbiome of people with cystic fibrosis**

ESCMID Global 2025 - Programme

S0343 11:30 **receiving modulator therapy** *Sebastien Boutin (Lübeck, Germany)*
Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary? *Alessandra Bragonzi (Milano, Italy)*
 Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology

SY123 11:00 – 12:00 **Hall 4**
 1-hour Symposium

Infection prevention and control and intensive care: challenges and solutions
Chairs Antonios Katsounas (Bochum, Germany) Claire Roger (Nimes, France)

S0344 11:00 **Intensive care unit (ICU) and infection: two sides of a coin** *Reto Schuepbach (Zurich, Switzerland)*

S0345 11:20 **Ventilator-associated pneumonia (VAP) and ICU environment: how can we improve practices?** *Despoina Koulenti (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee

OS083 11:00 – 12:00 **Hall 5**
 1-hour Oral Session

Don't 'rash' it
Chairs Heli Harvala (Turku, Finland) Catherine Moore (Cardiff, United Kingdom)

O0610 **Current Prevalence of Parvovirus B19 Infections: Ankara Bilkent City Hospital Experience 2019-2024** *B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kirca, A. Toyran, S. Aydoğan, B. Dinç*

O0611 **Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study** *M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo Artimagnella, C. Saffiotti*

O0612 **The dark side of the „fifth disease“ endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases** *B.G. Szabo* (Budapest, Hungary), D. Korozs, P. Remenyi, J. Sinko*

O0613 **Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024** *A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey*

O0614 **Measles virus in the context of subacute sclerosing panencephalitis (SSPE)** *J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous*

SY124 11:00 – 12:00 **Hall 6**
 1-hour Symposium

Antimicrobial prescribing: myths or pearls?
Chairs Massimo Fantoni (Roma, Italy) Spyros Pournaras (Athens, Greece)

S0346 11:00 **Why treat IV when PO is possible?** *Bradley Spellberg (Los Angeles, United States)*

S0347 11:30 **De-escalation of antibiotic therapy to narrow-spectrum IV drugs** *Flaminia Olearo (Hamburg, Germany)*

Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee

SY125 11:00 – 12:00 **Hall 7**
 1-hour Symposium

Cutting edge methods in mycology
Chairs Katrien Lagrou (Leuven, Belgium) Antonio Vena (Genova, Italy)

S0348 11:00 **Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT** *Ana Fernández-Cruz (Majadahonda (Madrid), Spain)*

S0349 11:30 **Exploring the intersection of fungal metagenomics and medical mycology** *Marcus De Melo Teixeira (Brasília, Brazil)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Education Subcommittee, Medical Mycology Study Group (GEMICOMED) within the SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP), Società Italiana per la Terapia Antinfett

OS084 11:00 – 12:00 **Hall 8**
 1-hour Case Session

Weird and unusual infections
Chair Muge Cevik (St Andrews, United Kingdom)

O0615 **Vertical Transmission of Clade Ib monkeypoxvirus during Pregnancy: Clinical and Histopathological description of 3 cases** *E. Hasivirwe Vakaniaki* (Kinshasa, Congo, the Democratic Republic of the), N.R. Swar Kuispond, H. Yuichiro, S. Tadaki, R. Bulakali Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni, E. Bangwen, I. Brosius, T. Wawina-Bokalanga, S. Sabiti Nundu*

O0616 **First case of Oropouche fever in the South of Spain** *I.A. Pérez-Hernández* (Malaga, Spain), E. Basallote Leal, M.A. Sempere Alcocer, B. O'donnell Cortés*

O0617 **Wild hippopotamus bite and *Aeromonas* spp. infection: a treatment challenge. First case report.** *J. Alza Arcila* (Medellín, Colombia), N.M. Daza Alarcon, M.V. Montoya Garcia, A. Múnera-Echeverri, F.F. Jiménez Quiroz, J. Alza-Arcila*

O0618 **From the sea to the land: an emerging species** *K. Rodríguez Martínez* (Santo Domingo, Dominican Republic), K. Rodríguez, A. Fernández, K. Espallat, J. Cruz, X. Rodríguez, T. Flores*

O0619 **The first findings of *Wohlfahrtiimonas chitiniclastica* and *Ignatzschineria* species bacteremia in two cases with maggot infested wounds in Scandinavia** *A.L. Engsbros* (Slagelse, Denmark), C. Mortensen, R. Jul, W. Cebula, A.L. Laugesen, J.T. Møller, M. Kemp*

ME127 11:00 – 12:00 **Hall 9**
 Meet-the-Expert

EUCAST: What's new in susceptibility testing

M0352 11:00 *Erika Matuschek (Växjö, Sweden)*

M0353 11:12 *Rafael Canton (Madrid, Spain)*

Co-organised with: EUCAST Steering Committee

ME134 13:30 – 14:30 **Hall 16**
 Meet-the-Expert

The older solid organ transplant recipient: between frailty, immunosenescence and infection

M0367 13:30 *Maheen Abidi (Denver, United States)*

ESCMID Global 2025 - Programme

M0368 13:42 *Alaa Atamna (Petah-Tikva, Israel)*
 Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)

SY131 13:30 - 14:30 **Hall 2**

1-hour Symposium

AMR PHEI VAX

Vaccines and antimicrobial resistance

Chairs *Iva Butic (Zagreb, Croatia)*
Zitta Barrella Harboe (Hillerød, Denmark)

S0361 13:30 **The impact of current and future vaccines on AMR: from pneumococcal to COVID-19** *Mateusz Hasso-Agopsowicz (Geneva, Switzerland)*

S0362 14:00 **Can vaccines against AMR be translated into policy?** *William Hausdorff (Washington DC, United States)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)

EW135 13:30 - 15:30 **Hall 3**

Educational Session

PRO

Transforming your research idea into an appropriate study design

Chairs *Casandra Bulescu (Bucharest, Romania)*
Mary Horgan (Dublin, Ireland)

W0369 13:30 **Designing high-quality research studies: methodological skills and knowledge** *Mical Paul (Haifa, Israel)*

W0370 13:50 **How to design and run scientific studies using AI agents as research assistants** *Alyssa Bilinski (Cambridge, United States)*

W0371 14:10 **Designing your first study: how to construct a workable project when your work environment may not help** *Thomas Tängdén (Uppsala, Sweden)*

W0372 14:30 **Bridging early-career professionals with partners and seniors** *Giorgia Caruana (Sion (Switzerland), Switzerland)*

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee

FO136 13:30 - 14:30 **Arena 1**

Open Forum

PRO

Diversity in CM and ID: gender gaps and policy traps

Chair *Andre Fuchs (Augsburg, Germany)*

F0373 13:30 **How to avoid parity traps in ID/CM research?** *Muge Cevik (St Andrews, United Kingdom)*

F0374 13:40 **Gender gaps in visibility at scientific conferences** *Sarah Dellièrè (Paris, France)*

F0375 13:50 **Psychological determinants of empowerment at individual and societal level** *Tba*

Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission

EF093 13:30 - 14:30 **Arena 2**

ePoster Flash Session

CLN DX

Real world experience with modern HIV treatment: the art of ART

E0668 **Use of long-acting cabotegravir/rilpivirine in HIV-viraemic individuals: a metanalysis** *M. Bongiovanni* (Lugano, Switzerland), B. Barda, G. Barilaro, E. Bernasconi*

E0669 **Assessment of HIV-DNA, immune activation and senescence biomarkers during injectable cabotegravir/rilpivirine treatment** *M. Mazzitelli* (Padua, Italy), M.R. Petrara, C. Cozzolino, L. Sasset, D. Leoni, S. Gardin, E. Ruffoni, A. De Rossi, A. Cattelan*

E0670 **Impact of Cabotegravir plus Rilpivirine Long-Acting on Body Composition: Results from a Prospective Study** *A. De Vito* (Sassari, Italy), A. Marongiu, A. Cano, M. Puci, A. Colpani, A. Mura, M.G. Catte, M.A. Deledda, S. Uzzau, S. Babudieri, G. Sotgiu, F. Deriu, A. Spanu, G. Madeddu*

E0671 **Real-World Efficacy and Tolerability of Long-Acting Cabotegravir/Rilpivirine in Older Woman with Polypharmacy and Comorbidities** *M. Rosas Cancio-Suárez* (Madrid, Spain), A. Moreno, S. Del Campo Terrón, M.J. Vivancos, A. G. García De Morales, J. Martínez-Sanz, M.D. Corbacho, M. Suárez, C. Cano, R. Ron, M.J. Cárdenas-Isasí, M. Vélez-Díaz-Pallarés, S. Moreno, M.J. Pérez-Eliás*

E0672 **Two-year comparative analysis of lipid profile changes between INSTI-based single tablet regimens in treatment-naïve people living with HIV: real-world evidence from South Korea** *S.Y. Lim* (Seoul, Korea, Republic of), B. Chin, M.K. Kim, Y. Kim, G. Kim, J. Bang*

E0673 **Long-acting antiretroviral therapy in PLWH with prior HBV exposure** *J. Mateo Gonzalez* (Valencia, Spain), J.I. Mateo-Gonzalez, M. Plaza-De-La-Torre, D. Martínez-Perez, J. Martínez-Andres, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, M. Garcia-Rodriguez, C. Ricart-Olmos, M. Garcia-Deltoro*

E0674 **Protease inhibitors in today's antiretroviral landscape: are we tracking resistance?** *J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Hernández-Cabezas, A. Valentín-Martín, M. Montero-Alonso, J.L. López-Hontangas*

E0675 **Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial** *L. Srikham* (Sakon Nakhon, Thailand), S. Sriphoosanaphan, O. Pucharoen*

E0676 **Impact of maternal dolutegravir on growth outcomes of HIV-exposed uninfected children: A prospective study** *E. Yoram* (Morongoro, Tanzania, United republic of), E. Luoga, S. Glanzman, F. Vanobberghen, M. Weisser, E. Dotto, G.J. Mollel, G. Sigalla, E. Nyenza, L. Moshi, L. Wilson, J. Okuma, D. Paris*

EF094 13:30 - 14:30 **Arena 3**

ePoster Flash Session

CLN DX PHEI

Speed, convenience and performance of virus diagnostic methods

Chair *Hans H. Hirsch (Basel, Switzerland)*

E0677 **Prospective evaluation of a rapid diagnostic test in a tertiary hospital and prospects for reinforced dengue surveillance in Catalonia (Northeastern Spain)** *L. Horvath* (Barcelona, Spain), L. Horvath Ruiz, J. Navero, M. Navarro, M. Pujada, A. Navarro, M. Garrido, B. Herreras, P. Rodriguez, N. Zancada, B. Escudero-Perez, M.J. Martinez*

E0678 **Sequence-Independent Single-Primer Amplification (SISPA) followed by Next-Generation Sequencing for Diagnosing Viral Respiratory Tract Infections** *P. Trindade* (Santa Maria, Brazil), B.C. Casarin, T.R. Y Castro, B.C. Piccoli, V.T. Santos, L.F. Tessele, A.V. Schwarzbold*

E0679 **Seasonal trends and co-infection dynamics of respiratory pathogens: insights from a yearlong study** *Z. Tsinaris* (Thessaloniki, Greece), A. Tychala, G. Meletis, A. Greco, T. Chatziantoniou, R. Dimitriadou, C. Chantzi, E. Georgiadou, G. Kagkalou, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou*

E0680 **Speed meets reliability in respiratory infections diagnosis with a new nucleic acid extraction workflow** *L. Pastor-Bernad* (San Mateo De Gállego, Spain), B. Santos Da Silveira, E. Lucia, M.C. Gil-Rodríguez, H. Alonoso, C. Giménez-Rota*

E0681 **Pathobiome characterization and role in disease**

ESCMID Global 2025 - Programme

		severity in children under 5-years with respiratory infection symptoms <i>L. Terranova* (Milan, Italy), L. Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna, M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchi, M. Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A. Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri</i>	
E0682		Viral viability markers of SARS-CoV-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR <i>C. Cuesta Chasco* (Barcelona, Spain), S. Alex, M. M^o Angeles, C.C. Genoveva, A. Francesco, R. Cristina, V. Anna, H. Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Mireia, G. Ignacio, B. Marta, G.V. Carolina</i>	
E0683		Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment <i>E. Vanhulle* (Bilthoven, Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. Brandenburg, K. Benschop</i>	
E0684		Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United States <i>A. Cuber* (Los Angeles, United States), S. Butler-Wu</i>	
E0685		Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma <i>F. Garcia* (Granada, Spain), A. Fuentes López, A. Rando Segura, R. Carracedo, A. Kessler, A. De Salazar González, S.Z. Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, A. Carrasco Durán, A. Aguilera, F. Garcia, M. Buti Ferret</i>	

KN130	13:30 – 14:30		Hall 1
		Keynote Lecture	

Infectious disease challenges in an ever-changing environment			
<i>Chairs</i>		<i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Annelies Zinkernagel (Zurich, Switzerland)</i>	

K0360	13:30	<i>Pamela Rendi Wagner (Stockholm, Sweden)</i>	
-------	-------	--	--

PM3	13:30 – 14:30		Hall 12
		Meet-the-Innovators	

Future prospects of electronic clinical decision support systems in stewardship programs			
---	--	--	--

L007	13:30	Opportunities for clinical decision support systems in infectious disease management <i>Nathan Peiffer-Smadja (Paris, France)</i>	
------	-------	--	--

L008	14:00	CDSS and AMS programs: the Lumed example <i>Valiquette Louis (Sherbrooke, Canada)</i>	
------	-------	--	--

SY132	13:30 – 14:30		Hall 13
		1-hour Symposium	

Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art			
<i>Chairs</i>		<i>Werner Ruppitsch (Vienna, Austria)</i> <i>Balaji Veeraraghavan (Vellore, India)</i>	

S0363	13:30	Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment <i>Thomas Schön (Kalmar, Sweden)</i>	
-------	-------	--	--

S0364	14:00	Antimicrobial resistance prediction using whole genome sequencing <i>Patricia Simner (Rochester, United States)</i>	
-------	-------	--	--

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee

OS092	13:30 – 14:30		Hall 14
		1-hour Case Session	

Mycobacterial mayhem			
<i>Chairs</i>		<i>Seif Al-Abri (Muscat, Oman)</i> <i>Linda Aulin (Leiden, Netherlands)</i>	

O0663		Limitations of the Xpert[®] MTB/RIF assay: A series of four clinical cases <i>A. Haas* (Salt Lake City, United States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C. Church, M. Narita, V. Escuyer, S. Shakir</i>	
-------	--	--	--

O0664		Pharmacokinetic analysis of blood and cerebrospinal fluid cotrimoxazole concentrations in a patient with tuberculous meningoencephalitis <i>W. Nie* (Beijing, China), N. Chu</i>	
-------	--	---	--

O0665		Is this the first case of Mycobacterium stephanolepidis infection in humans? <i>S. Pérez-Recio* (Barcelona, Spain), M.D. Grijota-Camino, A. Lérida, A. Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabé Fernández, F. Alcaide, M. Santin</i>	
-------	--	---	--

O0666		Diagnostic Aspects of a Bacillus Calmette-Guérin Infection Following Intravesical Treatment for Bladder Cancer <i>K.J. Kim* (Seoul, Korea, Republic of), J.H. Cha, S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho</i>	
-------	--	---	--

O0667		Mycobacterium abscessus: Is Shorter Antibiotic Therapy Combined with Surgery Sufficient? <i>M.J. Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M. Caixeiro, M. Alves, R. Macedo, P. Pacheco</i>	
-------	--	--	--

SY133	13:30 – 14:30		Hall 15
		1-hour Symposium	

Probiotics in infectious diseases: current state-of-play			
<i>Chairs</i>		<i>Nicolas Bénéch (Lyon, France)</i> <i>Silvia Corcione (Turin, Italy)</i>	

S0365	13:30	Probiotics in infectious diseases: the perfect complement to antimicrobial therapies? <i>Lena Biehl (Cologne, Germany)</i>	
-------	-------	---	--

S0366	14:00	The horizon of next generation probiotics for infectious diseases <i>Cormac Gahan (Cork, Ireland)</i>	
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAM)			

OS091	13:30 – 14:30		Hall 5
		1-hour Oral Session	

Genomic and molecular drivers of bacterial virulence and resistance			
<i>Chairs</i>		<i>Ecaterina Noroc (Chisinau, Moldova, Republic of)</i> <i>Guido Werner (Wernigerode, Germany)</i>	

O0658		Characterization of the virulence shaping and adaptability in the methicillin-resistant <i>Staphylococcus aureus</i> ST9 lineage <i>Y. Chen* (Hangzhou, China), L. Sun</i>	
-------	--	---	--

O0659		Elucidating molecular mechanisms of bacterial conjugation: towards an improved understanding of plasmid evolution and epidemiology <i>S. David* (Oxford, United Kingdom), C. Seddon, J. Wong, N. Ishimoto, S. He, J. Bradshaw, W.W. Low, D. Aanensen, G. Frankel, K. Beis</i>	
-------	--	--	--

O0660		Clinical carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP) strains carrying a mutH mutation are hypermutators that have heightened virulence and readily develop β-lactam/β-lactamase resistance <i>S. Cheng* (Pittsburgh, United States), C. Clancy, M.H. Nguyen, B. Hao, G. Liu</i>	
-------	--	---	--

O0661		Genomic insights into the new prophages of MDR <i>Pseudomonas aeruginosa</i>: an example of phage-host-phage interaction <i>A. Uskudar Guclu* (Ankara, Türkiye), S. Unlu</i>	
-------	--	---	--

ESCMID Global 2025 - Programme

O0662 **Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis***R. Mändar** (Tartu, Estonia), *E. Mutli, K. Koort, A. Salumets, T. Laisk*

EF099 **14:45 – 15:45** **Arena 1**
ePoster Flash Session

AMR IPC

Infection Prevention in Action: Innovations, Insights, and Global Intervention

Chair *Allison McGeer (Toronto, Canada)*

E0706 **A *Candida auris* cgMLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological Tracking***C. Harless** (Silver Spring, United States), *J. Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. Bennett, P. Mcgann, F. Lebreton*

E0707 **Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis Scenarios***A. Rearte** (Buenos Aires, Argentina), *F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi*

E0708 **Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023-2024 winter season***C. Savulescu** (Paris, France), *M. Rojas, K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Nardone*

E0709 **Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospital***N. Khanafer** (Lyon, France), *A. Regard, L. Beraud, R. Sintes-Tissot, Q. Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Chaboud*

E0710 **Contact precautions versus horizontal strategies to limit the spread of third-generation cephalosporin resistant gram-negative bacteria on intensive care units: Results of a country-wide, multicentered, non-randomized, before-after study on intensive care units***B. Schlosser** (Berlin, Germany), *S. Aghdassi, R. Leistner, E. Lemke, F. Schwab, C. Geffers*

E0711 **Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stay***V. Khillan** (New Delhi, India), *V.G. Nag P, P. Kale, A. Paul, A. Saran*

E0712 **Air and surface sampling around mpox Clade 1b in hospitals in the UKS***Gould** (Liverpool, United Kingdom), *B. Atkinson, B. Hack, T. Williams, J. Otter, Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W. Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. Dunning*

E0713 **Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024A***Baller** (Geneva, Switzerland), *N.R. Okum, G. Nsambi, K. Kabamba, Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton Hurwitz, M. Moon*

E0714 **The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization***M. Colaneri** (Milano, Italy), *P. Giordani, S. Lerta, A. Sangani, V.A. Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, R. Bruno*

EF100 **14:45 – 15:45** **Arena 2**
ePoster Flash Session

ANT

Cefiderocol: an efficient Trojan horse?

Chair *Anna Sramkova (Pilsen, Czech Republic)*

E0715 **Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution System***B. Li** (Beijing, China), *S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang*

E0716 **The hidden link between cefiderocol resistance and increased virulence in *Klebsiella pneumoniae*. Insights from a TraDIS-based investigation***E. Eger** (Greifswald, Germany), *L. Guardabassi, K. Schaufler, J.U. Müller, B. Jana, M. Schwabe, Y. Ma, M. Pirolo*

E0717 **Resistance profiles of Carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?***I. Baltas** (London, United Kingdom), *T. Patel, A.L. Soares*

E0718 **Impact of cefiderocol therapy on patient survival across different multi-drug resistant Gram-negative bacilli infections: insights from the SUSANA cohort.***N. Corti** (Monza, Italy), *M. Faltoni, L. Mezzadri, E. Ricci, M. Fois, A. De Vito, A. Bandera, P. Maggi, D. Bavaro, S. Rusconi, A. Mastroianni, M.A. Carleo, G. Cenderello, L. Bisi, G. Madeddu, P. Bonfanti*

E0719 **Decoding resistance: Investigating cefiderocol's battle against carbapenem-resistant *Acinetobacter baumannii****Y. T. Lee** (Taipei, Taiwan, China)

E0720 **Long-read sequencing reveals novel genetic factors in cefiderocol resistance in *Pseudomonas aeruginosa* ATCC 27853: A stepwise adaptive evolution study***M. Cardoso** (Groningen, Netherlands), *B.B. Xavier, B. Sinha, J. W. A. Rossen, A. Kumar Bari, T. T. Severs*

E0721 **Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales clinical isolates causing infection in hospitals in Europe and adjacent regions***R. Mendes** (North Liberty, United States), *A. Scullin, D. Beekman, Z. Kockler, J.M. Maher, H.S. Sader, M. Castanheira*

E0722 **Cefiderocol activity against planktonic and biofilm forms of β -lactamase-producing *Pseudomonas aeruginosa* from people with cystic fibrosis***G. Fabrizio** (Rome, Italy), *M. Truglio, I. Cavallo, F. Sivori, M. Francalancia, R. Riveros Cabral J, S. Petrolo, L. Pamparau, M. Comar, D. Compagnino, M. Trancassini, G. Antonelli, F. Ascenzioni, G. Cimino, F. Pimpinelli, E.G. Di Domenico*

E0723 **Activity of cefiderocol against clinical isolates of *Pseudomonas aeruginosa* collected from five European countries as part of SENTRY antimicrobial surveillance program 2020-2023***C. Longshaw** (London, United Kingdom), *J. Maher, R. Mendes, H. Yamashiro, Y. Yamano*

EF101 **14:45 – 15:45** **Arena 3**
ePoster Flash Session

VAX

Immunology of bacterial pathogens

E0724 **Serotype 38 *Streptococcus pneumoniae* emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands***K. Hajji** (Bilthoven, Netherlands), *I. Wróbel-Pawelczyk, J. Van Veldhuizen, K. Maruhn, W. Miellet, M. Rob, A. Steens, N. Van Sorge, K. Trzcińska, M. Van Der Linden, A. Skoczyska, L. Visser*

E0725 **Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116: a secondary analysis of five phase 3 studies***M. Esteves Jaramillo** (Rahway, United States), *J. Li, H. Platt, W. Hu, W. Xu, T. Chapman, K. Nolan, J. Hartzel, U. Buchwald*

E0726 **Baseline serotype-specific IgG responses to pneumococcal vaccines in type 2 diabetes: implications for vaccine strategy in vulnerable populations***S. Mettingal Ramakrishnan** (Bsk 2nd Stage, Bangalore, India), *V. Govindan, M.M. Akhila, N. Geetha, K.L. Ravikumar*

E0727 **Protection against invasive meningococcal disease and gonorrhoea, 5 years post introduction of a 4CMenB immunisation program in infants and adolescents in South Australia***H. Marshall** (Adelaide, Australia), *B. Wang, L. Giles, P. Andraweera, M. Mcmillan, S. Almond, R. Beazley, J. Mitchell, J.*

ESCMID Global 2025 - Programme

Sisnowski, C. Bell, L. Flood, J. Ward

E0728	Molecular epidemiology and correlates of protection among group B <i>Streptococcus</i> from carriage and disease: assessing vaccine coverage in Brazil T. <i>Pinto* (Rio De Janeiro, Brazil), L. Oliveira, N. Costa, E. Bressan, A. Rio Tinto, S. Fracalanza, L. Teixeira</i>
E0729	Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infants.R. <i>Namakula* (Bergen, Norway), V. Nankabirwa, S. Cose, O. Namugga, M.G. Netea, H. Steinsland, H. Sommerfelt, K. Hanevik</i>
E0730	Immune signature against <i>Klebsiella pneumoniae</i> proteins in a mother-baby cohort from Blantyre, Malawi. <i>Heinz* (Glasgow, United Kingdom), J. Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey</i>
E0731	A comprehensive computational mapping of B-cell epitopes in the <i>Klebsiella pneumoniae</i> porinome.S. <i>Prieto Martín Gil* (Madrid, Spain), S. Prieto Martín Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín Galiano</i>
E0732	Chronic infection induces a broadly neutralizing antibody response to Elastase B of <i>Pseudomonas aeruginosa</i>. <i>Albus* (Cologne, Germany), D. Kolling, K. Rox, D. Holzmann, K. Mundry, M. Sánchez Agut, C. Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Klein, J. Koehnke, J. Rybniker, A. Simonis</i>

KN137	14:45 - 15:45	Hall 1
	Keynote Lecture	

Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development

Chairs *Werner Ruppitsch (Vienna, Austria)*
Annelies Zinkernagel (Zurich, Switzerland)

K0376	14:45	<i>Juliane Bubeck Wardenburg (St. Louis, United States)</i>
-------	--------------	---

ME140	14:45 - 15:45	Hall 11
	Meet-the-Expert	

Bioinformatic tools from start to finish

M0381	14:45	<i>Vitor Borges (Lisbon, Portugal)</i>
M0382	14:57	<i>Clare Sloggett (Melbourne, Australia)</i>

ME141	14:45 - 15:45	Hall 13
	Meet-the-Expert	

AI use in antimicrobial stewardship

M0383	14:45	<i>Shruti Gohil (Irvine, United States)</i>
M0384	14:57	<i>Jose Ramon Pano-Pardo (Zaragoza, Spain)</i>

OS097	14:45 - 15:45	Hall 14
	1-hour Oral Session	

Update on zoonotic and enteric infections

Chairs *Steen Ethelberg*
Kavitha Saravu (Manipal, India)

O0696	A large-scale epidemiological study of <i>Campylobacter</i> employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK. <i>B. Lopes* (Middlesbrough,</i>
-------	---

O0697	Population dynamics and evolution of multidrug resistant clones of <i>Shigella sonnei</i> in Metropolitan France. <i>C. Silva Nodari* (Paris, France), I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill</i>
O0698	Shiga toxin-producing <i>Escherichia coli</i> O26 as an increasingly common cause of haemolytic uraemic syndrome in England: A fifteen-year analysis of national enhanced surveillance data. <i>L. Mcgeoch* (London, United Kingdom), O. Quinn, C. Sawyer, A. Douglas, C. Jenkins, S. Balasegaram</i>
O0699	Incidence, clinical presentation, and outcomes of Pasteurella infections: a population-based Danish study. <i>L.Ø. Larsen* (Aalborg, Denmark), H.L. Nielsen, K.K. Søgaard</i>
O0700	Natural history of latent brucellosis and efficacy evaluation of B-spot in active and latent cases: A 12-month prospective cohort study. <i>H. Wang* (Shanghai, China), G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang</i>

OS098	14:45 - 15:45	Hall 15
	1-hour Case Session	

Opportunistic infections in the Immunocompromised

Chair *Aleksandra Barac (Belgrade, Serbia)*

O0701	Dog scratch disease? A case of <i>Vibrio vulnificus</i> in a liver transplant patient. <i>E. Kim* (Galveston, United States), A. Covington</i>
-------	--

O0702	Mpox infection among solid organ transplant recipients: a single center experience at a U.S. Tertiary Care Facility. <i>J. Bini Viotti* (Miami, United States), J. Bini</i>
-------	---

O0703	Histoplasmosis in Hansen's Disease: Thalidomide for TNF-alpha Inhibition in ENL with a Risk of Opportunistic Infections. <i>K.K. Vaitheeswaran* (Delhi, India), M. Soneja, N. Bhari, R. M., G. K. V., S. Agarwal, R. Kumar, Y. Dharmashaktu</i>
-------	---

O0704	Nocardiosis in a kidney transplant recipient: pros & cons of tedizolid. <i>M. Pellegrino* (Modena, Italy), V. Todisco, S. Generoso, L. Benassi, E. Franceschini, F. Damiano, G. Donati, C. Mussini, A. Cervo</i>
-------	--

O0705	Mycobacterium genavense-Associated IRIS with Macrophage Activation Syndrome: A Case Report Highlighting Diagnostic Challenges. <i>M. Meri* (Verona, Italy), M. Morra, M.E. De Rui, E. Tacconelli, F. Soldani</i>
-------	--

SY139	14:45 - 15:45	Hall 16
	1-hour Symposium	

How to manage bacterial meningitis in low resource settings

Chair *Christina Obiero (Killifi, Kenya)*

S0379	14:45	Bacterial meningitis diagnosis and surveillance <i>Divya Deodhar (Muscat, Oman)</i>
-------	--------------	---

S0380	15:05	Clinical presentation and management of CNS Infections <i>Kartika Maharani (Jakarta, Indonesia)</i>
-------	--------------	---

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)

OS095	14:45 - 15:45	Hall 2
	1-hour Oral Session	

Community respiratory tract infections: latest trends and approaches

Chairs *Catia Cilloniz (Barcelona, Spain)*
Aurélien Dinh (Garches, France)

O0686	<i>Mycoplasma pneumoniae</i> increase in 2023/24
-------	---

ESCMID Global 2025 - Programme

00687	causes disease in adults in Europe. <i>B.M.M. Streng*</i> (Utrecht, Netherlands), <i>C. Prat Aymerich, L. Bont, P. Meyer Sauteur, M. Bonten, A. Van Rossum</i>	
00688	Serotype distribution of pneumococcal community-acquired pneumonia in hospitalized adults in Germany. <i>D. Karssen*</i> (Utrecht, Netherlands), <i>L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich</i>	
00689	Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis. <i>J. Wei*</i> (Oxford, United Kingdom), <i>K. Yuan, A. Luk, S. Walker, D. Eyre</i>	
00690	Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia. <i>F. Al-Zergani*</i> (Hvidovre, Denmark), <i>C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield</i>	
00690	Oropharyngeal carriage of gut-derived Enterobacteriales increases RTI risk in long-term aged care residents. <i>S. Miller*</i> (Adelaide, Australia), <i>F. Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers</i>	
SY138	14:45 - 15:45 1-hour Symposium	Hall 4
<p>Global clones and evolving resistance mechanisms towards newer beta-lactams: Where are we heading?</p> <p><i>Chairs</i> <i>Yesim Besli (Istanbul, Türkiye)</i> <i>Spyros Pournaras (Athens, Greece)</i></p>		
S0377	14:45 Carbapenemase-producing Enterobacteriales: the not so good, the bad and the ugly. <i>Arjana Tambic Andrasevic (Zagreb, Croatia)</i>	
S0378	15:15 The <i>P. aeruginosa</i> frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome <i>Katy Jeannot (Besançon, France)</i>	
Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)		
OS096	14:45 - 15:45 1-hour Oral Session	Hall 5
<p>Trends in antifungal resistance</p> <p><i>Chairs</i> <i>Alexandre Alanio (Paris, France)</i> <i>Ana Alastruey-Izquierdo (Madrid, Spain)</i></p>		
00691	Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies. <i>K. Schmidlin*</i> (Tempe, United States), <i>K. Geiler-Samerotte</i>	
00692	Role of the C2585G substitution in the <i>MRR1</i> gene in the development of azole resistance in <i>Candida parapsilosis sensu strictu</i> . <i>I. Franconi*</i> (Pisa, Italy), <i>P. Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, M. Falcone</i>	
00693	Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years. <i>J. Guinea*</i> (Madrid, Spain), <i>P. Escribano, G. Jesús, M. Machado, A. Burillo, P. Muñoz</i>	
00694	A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against <i>Candida auris</i> with EUCAST broth microdilution reference methodology. <i>J. Meletiadi*</i> (Haidari, Greece), <i>J. Guinea, S. Arikant</i>	

00695		<i>Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup</i>
SY144	16:15 - 17:15 1-hour Symposium	Hall 14
<p>Decoding <i>Candida auris</i> Resistance in Latin America: <i>Candida.app</i> vs. Pathogenwatch<i>J. Acosta España*</i> (Quiro, Ecuador), <i>P. Eduarda, J.D. Acosta-España, A. Herrera-Yela</i></p>		
<p>What's the role of infant and maternal immunisation for paediatric RSV prevention?</p> <p><i>Chairs</i> <i>Joanne M. Langley (Halifax, Canada)</i> <i>Peter Openshaw (London, United Kingdom)</i></p>		
S0391	16:15	Pros and cons of passive infant immunisation with mAb before their first RSV season. <i>Federico Martín-Torres (Santiago De Compostela, Spain)</i>
S0392	16:45	Pros and cons of maternal vaccination in preventing severe RSV infections in infants. <i>Anne Vergison (Luxembourg, Luxembourg)</i>
EF104	16:15 - 17:15 ePoster Flash Session	Arena 1
<p>Cutting-edge technologies to improve viral diagnostics</p> <p><i>Chair</i> <i>Patricia Alvarez (Rio De Janeiro, Brazil)</i></p>		
E0743		How straightforward is the switch from qPCR to dPCR in a routine lab setting for quantification of Varicella-zoster virus in CSF samples. <i>A. Baumhögger*</i> (Bochum, Germany), <i>T. Bähr, G. Geis, S. Gatermann</i>
E0744		A novel biosensor for the detection of RSV infection. <i>C. Zannella*</i> (Naples, Italy), <i>F. Passeggio, F. Napolitano, A. De Filippis, F. Arcadio, C. Marzano, I. Tavoletta, L. Zeni, M. Galdiero, G. Portella, N. Cennamo</i>
E0745		Insufficient sexual health bloods don't always need throwing away! <i>S. Hutchings*</i> (Bristol, United Kingdom), <i>R. Hopes, P. North, W. Stoate, M. Murphy, G. Beckley, J. Gabb</i>
E0746		A comparison of 4 HAV serology assays: the value of consensus results as a reference standard. <i>T. Chin*</i> (Ghent, Belgium), <i>E. Padalko</i>
E0747		Advancing herpesvirus diagnostics: clinical evaluation of a high-performance real-time PCR assay. <i>H. Alonso-Ezcurra*</i> (Zaragoza, Spain), <i>S. Lucea, C. Escolar, H. Alonso</i>
E0748		Evaluation of microbiological techniques for the diagnosis of West Nile Virus in the Virgen del Rocío hospital area (Sevilla, Spain). <i>M. Aznar Fernandez*</i> (Seville, Spain), <i>M. Aznar, C. Lozano, L. Merino, M.J. Pérez, J.L. Garcia, C. Cintora, J.A. Lepe</i>
E0749		Development of Non-Cross-Reactive Monoclonal Antibodies Against West Nile Virus and Usutu Virus Non-Structural Protein 1 to Improve Early Diagnosis. <i>M. Ceconi*</i> (Antwerp, Belgium), <i>K. Ariën, P. Delputte</i>
E0750		Enhancing Diagnostics and Global Standards through the QCMD Viral Metagenomics EQA. <i>G. Sutton*</i> (Glasgow, United Kingdom), <i>D. Montgomery, E. McCulloch, A. Ricketts</i>
E0751		Analysis of HIV-1 drug-resistance in newly diagnosed subjects using Next Generation Sequencing. <i>V. Micheli*</i> (Milan, Italy), <i>F. Bracchitta, L. Morelli, A. Cavallo, S. Giubileo, A. Tamoni, A. Lombardi, A. Dolci</i>
EF105	16:15 - 17:15 ePoster Flash Session	Arena 2
<p>New data in non-tuberculous mycobacterial disease</p> <p><i>Chair</i> <i>Lorenzo Guglielmetti (Paris, France)</i></p>		

ESCMID Global 2025 - Programme

E0752	Deciphering genotypic resistance to amikacin in <i>Mycobacterium abscessus</i> using whole genome sequencing and a specific pipeline (GenoMAB) C. Allam* (Paris, France), S. Agsous, P. Baylac, K. La, N. Godron, F. Mougari, Z. Awad, E. Cambau
E0753	<i>Pseudomonas aeruginosa</i> rapidly kills <i>Mycobacterium abscessus</i> in dual-species biofilms <i>in vitro</i> M. Mcdaniel* (Nijmegen, Netherlands), J. Scoffield, J. Van Ingen
E0754	Distribution of cotrimoxazole in different tissues of mice and human patients infected with <i>Mycobacterium abscessus</i> W. Nie* (Beijing, China), N. Chu
E0755	Exploration of clofazimine and bedaquiline activity against clinical strains of <i>Mycobacterium abscessus</i> to advance innovative therapeutic strategies C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, J.J. Aguilera-Correa, M.C. Muñoz-Egea
E0756	Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria S. Sarkar* (Parkville, Australia), K. Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Gonzalez, E. Stanley, S. Ranganathan
E0757	Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany N. Wetzstein* (Frankfurt, Germany), M. Diricks, D. Frank, I. Friesen, S. Niemann, T. Wichelhaus
E0758	Deciphering the Epidemiology of <i>Mycobacterium chimaera</i> . Genetic Lineages, Environmental Sources, and Infection Prevention Insights G. Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. Casadei, C. Scarparo
E0759	Evaluation of a novel media for susceptibility testing of <i>Mycobacterium avium-intracellulare</i> complex isolates T. Grams* (Salt Lake City, United States), S. Shakir
E0760	Emerging cases of <i>Mycobacterium chelonae</i> endocarditis associated with <i>BioIntegral</i> bioprostheses J. Kikhney* (Berlin, Germany), F. Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, A. Moter
EF106	16:15 – 17:15 ePoster Flash Session ANT CLN Arena 3
The ABC (allergy, bloodstream infections and clinical decision support) in AMS	
Chair	Céline Pulcini (Nancy, France)
E0761	Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study D. Wets* (Leuven, Belgium), R. Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Breyneert, T. Ieven, P. De Munter
E0762	Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trial. J. Sandoe* (Leeds, United Kingdom), S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P. Howard, D. Howdon, S. Mort, R. Mujica-Mota, A. Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, L.M. Yu, S. Pavitt
E0763	Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage X. Li* (Toronto, Canada), K. Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P. Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. Lovinsky
E0764	Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Staphylococcus aureus</i> (PRIMEKA): A Retrospective

E0765	Single-Center Cohort Study. F. Salvati* (Rome, Italy), F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo, R. Murri, C. Torti
E0766	The inappropriate use of antibiotics for blood culture contamination and colonisation by multidrug-resistant microorganisms: the role of counselling on antibiotic prescription R.R. Peña-Zalbidea* (Palma (balearic Islands), Spain), L. Martin, H. Vilchez, L. Periañez, E. Rojo, M. Peñaranda, M. Garcia, M. Riera, X. Mulet, A. Oliver, J. Murillas
E0767	Factors influencing meropenem prescription following the 2020 EUCAST « 1 » definition update : a multicentric observational study in Belgian hospitals L. Catteau* (Brussels, Belgium), L. Bonacini
E0768	Impact of an Antimicrobial Stewardship Mobile Application on Antimicrobial Prescribing, Length of Hospital Stay, and Cost Savings Z.O.E. Babiker* (Abu Dhabi, United Arab Emirates), L. Bukasa, A. Sadeq, J. Shamseddine, R. Ali
E0769	Evaluation of a model-based clinical decision support system for empirical antimicrobial therapy S.N. Søgaard* (Aabenraa, Denmark), L. Ward, M.L. Mogensen, C.B. Mogensen, H. Skjøl-Årtil
E0769	A rapid systematic review of criteria to facilitate prompt intravenous-to-oral antimicrobial switch in children and young people in England. R. Oettle* (London, United Kingdom), S. Patel, A. Demirjian, M. Mcleod, C. Jamieson, G. Damant, K. Hand, D. Ashiru-Oredope

EA 16:15 – 17:30 Hall 1

Awards

PRO
Excellence Award Lectures

A006	16:15	Towards pandemic prevention, moonshot or utopia? Marion Koopmans (Rotterdam, Netherlands)
A007	16:50	Can global warming bring new infectious diseases? Arturo Casadevall (Baltimore, United States)

SY143 16:15 – 17:15 Hall 11

VAX
1-hour Symposium

ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients

Chairs
Elisa Cordero Matia (Seville, Spain)
Zitta Barrella Harboe (Hillerød, Denmark)

S0389	16:15	Vaccination against respiratory pathogens Albert Vollaard (Bilthoven, Netherlands)
S0390	16:45	Other vaccines Olivier Epaulard (Grenoble, France)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGIHC), ESCMID Vaccine Study Group (EVASG)

EW146 16:15 – 18:15 Hall 13

Educational Session

How to detect, manage and communicate hospital outbreaks

Chairs
Margaret Ip (Shatin, Hong-Kong SAR, China)
Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)

W0395	16:15	How to detect hospital outbreaks David Fisman (Toronto, Canada)
W0396	16:35	How to confirm hospital outbreaks using genomics John W. A. Rossen (Groningen, Netherlands)
W0397	16:55	How to rapidly respond to an ongoing hospital outbreak Ermira Tartari (Msida, Malta)
W0398	17:15	How to communicate hospital outbreaks via scientific

ESCMID Global 2025 - Programme

publication *Ines Steffens (Solna, Sweden)*

ME145 16:15 – 17:15 Hall 15

CLN DX

Meet-the-Expert

Fungal meningitis: recognition and current status of management

M0393 16:15 *Olivier Lortholary (Paris, France)*

M0394 16:27 *Janis Blair (Phoenix, United States)*

JS2 16:15 – 17:15 Hall 16

PRO

Journal Session

Late-breaker research from the Lancet group: new interventions for familial and new infectious diseases

Chairs *Syeda Saleha Hassan (London, United Kingdom)*
Ursula Hofer (London, United Kingdom)

J011 16:15 TBA

J012 16:30 **The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America** *Jan Felix Drexler (Berlin, Germany)*

J013 16:45 TBA

J014 17:00 **Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three RSV seasons: a randomized trial** *Tba*

Co-organised with: The Lancet group

OS102 16:15 – 17:15 Hall 2

AMR DX

1-hour Oral Session

AI tools empowering AMR prediction in WGS and MALDI-TOF

Chairs *Oliver Nolte (Zürich, Switzerland)*
Patricia Simner (Rochester, United States)

O0733 **A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing data** *Y. Zhong* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope*

O0734 **Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for *Klebsiella pneumoniae* from Clinical NGS Data** *J. Xinmiao* (Beijing, China), X. Jia, J. Zhang, J. Chen, Q. Yang*

O0735 **AI-Powered Real-Time Plasmid Prediction Using Nanopore Sequencing** *E. Sauerborn* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban*

O0736 **MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence *K. pneumoniae*** *L. Dortet* (Le Kremlin-Bicêtre, France), L. Mancera Pascual, M.J. Arroyo*

O0737 **Predicting rifampicin resistance in *Mycobacterium tuberculosis complex* with a machine learning based MALDI-TOF MS approach** *Y.W. Sun* (Taichung, Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W. Lu, C.C. Chen, J. Yu*

LB005 16:15 – 17:15 Hall 3

1-hour Oral Session

Emerging pathogens in humans, animals and vectors

L0026 **Genome-wide association study identifies *ABCG1* as a susceptibility locus for tick-borne encephalitis** *P. Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek, N. Schweintzger, E. Hofer, B. Kohlmaier, V. Švendová,*

P. Bogovic, J. Zajkowska, L. Krbková, V. Štruncová, A. Mickiene, D. Kohlfürst, A. Sonnleitner, A. Fořtová, M. Berankova, M. Pychova, D. Zavadská, N. Sallah, A. Pichler, D. Sedláček, A. Chrdle, C. Haudum, B. Obermayer-Pietsch, P. Hoffmann, M. Nöthen, M.L. Tammesoo, A. Metspalu, P. Husa, K. Stiasny, A. Binder, A. Berghold, F. Strle, M. Hibberd, W. Zenz*

L0027 **First detection of tick-borne encephalitis virus in Belgian ticks, May 2024** *E. Portell-Buj* (Stockholm, Sweden), C. Philippe, S. Van Gucht, F. Dufrasne*

L0028 **Spread of a fusidic acid and methicillin-resistant *Staphylococcus aureus* clone causing impetigo in Europe** *A.R. Larsen* (Copenhagen, Denmark), A. Petersen, L. Roer, K. Vendrik, R. Zwiitink, D. Notermans, N. Yin, M. Perrin, K. Khonyongwa, A. Tristan, B. Youenou, F. Layer-Nicolaou, G. Werner, H. Enger, E.C.H. Eikrem, J. Darenberg, B. Mäkitalo, M. Paulsson, H. Fang, E. Tång Hallbäck, L. Lindholm, K. Moganeradj, B.J. Holzkecht, H.B. Eriksen, M. Hoppe, M.D. Bartels, J.A. Samaniego Castruita*

L0029 **Increase of PVL-positive livestock-associated MRSA in the Netherlands: a growing concern beyond livestock settings** *K. Vendrik* (Bilthoven, Netherlands), S. Witteveen, D.W. Notermans, S.C. De Greeff, C.C. Wielders, E. Van Duijkeren, A.S. Schoffelen, A.P. Hendrickx, R.D. Zwiitink*

L0030 **H5N1 human infection in the United Kingdom: a One-Health approach** *R. Puleston* (London, United Kingdom), N. Hamzaoui, S. Hayward, W. Proto, E. Booth, C. Beck, A. Lackenby, K. Spence, M. Beadsworth, N. Wong, M. Samuel, A. Singanayagam, K. Hoschler, N. Groves, D. Kumar, O. Olufon, W. Cook, N. Watkins, D. Ready, S. Makki, K. Marston, S. Collins, C. Arevalo, D. Blackman, L. Guinness, C. Chatt, M. MCGivern, A. Edwards, A. Banyard, R. Jorquera, K. Saville, R. Bence, S. Van Helvoort, E. Brown, L. Leighton McTeague, M. Chand, S. Rokadiya, S. Hopkins, H.I.M. Team, N. National Response Center Team*

SY142 16:15 – 18:15 Hall 4

DX TRN

2-hour Symposium

Precision genomics to improve infectious diseases management

Chair *Jacob Moran-Gilad (Beer Sheva, Israel)*

S0385 16:15 **Human genomics approaches to infection immunity** *Fergus Hamilton (Bristol, United Kingdom)*

S0386 16:45 **Applying bacterial GWAS to uncover new mechanisms of antibiotic resistance** *Marco Galardini (Hannover, Germany)*

S0387 17:15 **Evolution in action: large-scale within-host evolution analyses of persistent bacterial infections** *Stefano Giulieri (Melbourne, Australia)*

S0388 17:45 **Machine learning in bacterial genomics and metagenomics** *Francesco Asnicar (Trento, Italy)*

OS103 16:15 – 17:15 Hall 5

AMR TRN

1-hour Oral Session

Polymicrobial interactions and competition

Chairs *Alessandra Bragonzi (Milano, Italy)*
Kimberly Kline (Genève, Switzerland)

O0738 **The *Klebsiella pneumoniae* type VI secretion system effector Tie4 facilitates adaptation survival by damaging the cell membrane of competing bacteria** *W. Li* (Shanghai, China), J. Zhang*

O0739 ***Candida albicans* promotes TSST-1 production in *Staphylococcus aureus* by depleting glucose and lifting carbon catabolite repression** *M. Carriou* (Lyon, France), C. Badiou, A. Soulard, K. Chikh, O. Vitalis, A. Frugier, K. Dufresne, G. Lina*

O0740 **Understanding polymicrobial biofilm dynamics: focus on *Pseudomonas aeruginosa* and its molecular**

ESCMID Global 2025 - Programme

	interactions <i>S. Kansal*</i> (Chandigarh, India), <i>U. Dutta, A. Angrup, P. Ray</i>				<i>Weksler, M. Correia, W. Golebiovski</i>
00741	Intra- and interspecific antagonism inhibits growth of <i>Staphylococcus aureus</i> in human nasal microbial communities. <i>L. Brüllsauer*</i> (Zurich, Switzerland), <i>M. Boumasmoud, S. Brugger, A.R. Hall</i>			EF111	17:30 – 18:30 Arena 2 ePoster Flash Session
00742	Combination therapy against drug resistance biomimetic dual-species biofilm model of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i>. <i>P. Mojarrad*</i> (Helsinki, Finland), <i>P. Tammela, T. Laaksonen, Z. Gounani</i>				
EF110	17:30 – 18:30 Arena 1 ePoster Flash Session				
	Advancing diagnostics and treatment of endocarditis				
	<i>Chair</i> <i>Benoît Guery</i> (Lausanne, Switzerland)				
E0785	18F-FDG-PET/CT improves source control of extra-cardiac complications in infective endocarditis. <i>J.M. Prins*</i> (Amsterdam, Netherlands), <i>S. Douiyeb, W. Van Gameren, D. Buis, T. Van Der Vaart, M. Boekholdt, J. Selder, D. Robbers-Visser, H. Verberne, H. Van Werkhoven, K. Sigaloff</i>			E0794	Neurosyphilis and Mpox co-infection mimic HIV encephalitis. <i>L. Mejdoubi*</i> (Vienna, Austria), <i>A. Nader, L. Mautner, A. Bahrami, F. Hofer</i>
E0786	Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materials. <i>M. Papadimitriou Olivgeris*</i> (Sion, Switzerland), <i>M. Papadimitriou-Olivgeris, B. Ledergerber, N. Fourné, V. Zimmermann, N. Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, O. Dzemali, J. Epprecht, B. Guery, B. Hasse</i>			E0796	An unusual cause of transverse myelitis. <i>J. Koleri*</i> (Doha, Qatar), <i>M. Samawi, M. Maslamani</i>
E0787	In vivo Dalbavancin efficacy against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and high-level aminoglycoside resistant (HLAR) <i>Enterococcus faecalis</i> (EFAE) experimental endocarditis model. <i>C. Garcia De La Maria*</i> (Barcelona, Spain), <i>C. Garcia De La Maria, M.A. Cañas, M. Brunet, J. Garcia-González, G. Cuervo, M. Espasa, M. Hernandez-Meneses, C. Falces, A. Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. Llopis, A. Moreno, J.M. Miro</i>			E0797	It might be syphilis: a case report and systematic review on syphilitic osteomyelitis. <i>C. Inácio Dos Santos*</i> (Alcantara, Portugal), <i>C. Inácio Santos, A. Torcato Cartaxo, I. Sousa Miranda, S. Gomes Rocha, M. Teixeira Almeida, J. Vaz Alves, K. Kmansinho</i>
E0788	Identification and validation of clinical phenotypes in <i>Staphylococcus aureus</i> blood stream infection and their association with mortality (FEN-AUREUS study). <i>J. Rodriguez-Baño*</i> (Seville, Spain), <i>B. Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M. Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-Santos, Á. Cano, R. Palacios, S. López-Cárdenas, M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E. Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez, L. Romero-Calderón, A. Alemán-Rodríguez, E. Recacha, J. Torre-Cisneros, N. Merchante, Á. Pascual, L.E. López-Cortés</i>			E0798	Ocular Syphilis, an uncommon presentation form of syphilis: two cases. <i>R. Kardashi*</i> (Dresden, Germany), <i>A. Frenz, K. De With</i>
E0789	Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomes. <i>M. Singh*</i> (London, United Kingdom), <i>C. Watkins, H. Bristowe, M. Gunning, J. Galloway, R. Dworakowski, M. Arias</i>			E0799	Case report of a severe skin infection in a young man on PrEP and DoxyPEP. <i>M. Zlámala*</i> (Prague, Czech Republic), <i>Z. Bartovská, B. Lacmanová, M. Holub</i>
E0790	Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohort. <i>C. Meyer-Schwickerath*</i> (Cologne, Germany), <i>K. Schmidt-Hellerau, J. Camp, K. Last, I. Joost, S. Rieg, N. Jung</i>			E0800	Serowaffling in PrEP Users: The Difficulty of HIV Diagnosis – A Case Report. <i>P. Pillado Alonso*</i> (Badalona, Spain), <i>G. Fernández Rivas, A. Rivero Calaf, Á. Hernández-Rodríguez, R. Peña, J. Prado, J. Martínez-Picado</i>
E0791	The optimal management of <i>Enterococcus faecium</i> catheter-related bloodstream infections: a gap to bridge. <i>I. Rancan*</i> (Florence, Italy), <i>M. Rinaldi, F. Malerba, B. Profitti, L. Ancillotti, M. Tumbarello, P. Viale, M. Giannella</i>			E0801	Severe disseminated mpox in a patient with advanced HIV: A case report. <i>M.A. Quadros Flores*</i> (Lisbon, Portugal), <i>R. Diogo, F. Gonçalves, T. Marques, S. Paulo, F. Cota Medeiros, D. Mendes Pedro</i>
E0792	Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant <i>Enterococcus faecalis</i>. <i>Funk*</i> (Brooklyn, United States), <i>I. Khan, J. Li, J. Cusumano</i>			E0802	Sensorimotor polyneuropathy in a patient affected by HIV-1: an atypical presentation of neurosyphilis associated to anti-SOX-1 antibodies. <i>A. Lippi*</i> (Siena, Italy), <i>L. Ancillotti, M. Fabbiani, L. Migliorini, S. Bartalini, F. Ginanneschi, M. Tumbarello, F. Pippi, C. Puttini, F. Montagnani</i>
E0793	Risk factors for in-hospital mortality in 500 cases of infective endocarditis. <i>C. Lamas*</i> (Rio De Janeiro, Brazil), <i>G. Pompeo, T. De Almeida, M. De Carvalho, N. Feijóo, R. Garrido, G. Barbosa, B. Zappa, C.</i>			EF112	17:30 – 18:30 Arena 3 ePoster Flash Session
					Clinical considerations in resistant organisms
					<i>Chair</i> <i>Divya Deodhar</i> (Muscat, Oman)
				E0803	Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicenter clinical experience. <i>F. Serapide*</i> (Catanzaro, Italy), <i>R. Serraino, L. Spadafora, M. Bernardi, G. Brucci, G. Cattarico, S. Corcione, I. De Benedetto, M. Del Monte, A. Limongelli, D.R. Giacobbe, E. Graziano, M. Meschiari, S. Mornese Pinna, M. Peghin, G. Tiseo, A. Vena, F. Romeo, G. Sarto, M. Bassetti, G. Biondi-Zoccai, F.G. De Rosa, M. Falcone, P.A. Grossi, C. Mussini, A. Russo</i>
				E0804	Clinical outcomes of MSSA bacteremia exhibiting the ceftazolin inoculum effect and development of a novel diagnostic method. <i>S. Yoshizawa*</i> (Ota-Ku, Japan), <i>T. Sato, K. Komori, K. Yamada, T. Yamaguchi, K. Tateda</i>
				E0805	Third- and fourth-generation cephalosporins for the treatment of infections due to OXA48 carbapenemase-producing <i>Enterobacterales</i>. <i>A. Blanco Arévalo*</i> (Barcelona / Singapore, Spain), <i>A. Blanco-Arevalo, E. Sastre-Escola, J. Camara Mas, F. Tubau Quintano, R. Costa, A. Padullés, E. Shaw, C. Gudiol, M. Puig-Asensio</i>
				E0806	Are meropenem or imipenem-clastatin effective therapies for patients with invasive ertapenem-resistant infections? <i>A. Peters*</i> (Santiago, Chile), <i>S. Fiawoo, L. Diaz, J.R. Martínez, M. Spencer-Sandino, L. Rivas, M.P. Riquelme, P. Rojas, L. Rojas, M.L.</i>

ESCMID Global 2025 - Programme

Rioseco, J. Moreno, R. Araos, P. Garcia, P.D. Tamma, J.M. Munita

E0807	Oral Fosfomycin after Carbapenems as de-escalating therapy in Complicated Urinary Tract Infection: A randomized controlled trial. <i>K. Angkanavisant* (Bangkok, Thailand), B. Sakboonyarat, C. Ungthammakun</i>	
E0808	Oral switch vs. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacteriales and <i>Pseudomonas aeruginosa</i> infections on hospital discharge: the next frontier for oral switch? <i>C. Arena* (Detroit, United States), A. Abed, R. Kenney, G. Suleyman, A. Shallal, S. Davis, M. Veve</i>	
E0809	Metallo-β-lactamase colonization and subsequent risk of infection: a retrospective study. <i>C. Lee Luna Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, S. Castelbuono, G. Di Martino, F. Cardinale, F. Monaco, A. Cona, A. Mularoni</i>	
E0810	Polymyxin including therapy versus colistin including therapy in the therapy of carbapenem-resistant Gram-negative infections: A retrospective matched cohort study. <i>M. Mert Vahabi* (Van, Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyoğlu, G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkar, M. Çeylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Vatanserver, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi</i>	
E0811	Prognostic factors and role of clinical management in carbapenem-resistant <i>Acinetobacter baumannii</i> bacteraemia: results from a prospective, international, multicentre cohort (EURECA). <i>F. Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, S. Benea, D. Tomescu, A. Meda Vasiesiu, L. Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H. Goosens, M.J.M. Bonten, J. Rodriguez-Baño</i>	

SY147	17:30 - 18:30	Hall 11
	1-hour Symposium	

Avian influenza in mammals: jumps under the radar		
Chairs	<i>Patricia Antunes (Porto, Portugal)</i> <i>Ana Vale (Dublin, Ireland)</i>	

S0399	17:30	Threat of highly pathogenic avian influenza to non-traditional hosts, including humans <i>Thijs Kuiken (Rotterdam, Netherlands)</i>
S0400	18:00	Recent changes in the epidemiology of avian influenza in relation to human health risks <i>Ron Fouchier (Rotterdam, Netherlands)</i>

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)

SY148	17:30 - 18:30	Hall 15
	1-hour Symposium	

Echinococcosis: neglected but expanding		
Chairs	<i>Daniel Grupel (Jerusalem, Israel)</i> <i>Francesca Tamarozzi (Negrar-Verona, Italy)</i>	

S0401	17:30	Expansion and diversity of cystic echinococcosis <i>Pedro Legua (Lima, Peru)</i>
S0402	18:00	Management of echinococcosis: evidence, eminence and new developments <i>Beate Grüner (Ulm, Germany)</i>

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft

für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

OS109	17:30 - 18:30	Hall 16
	1-hour Oral Session	

Training CM/ID - a global view		
Chairs	<i>Mihai Mares (Iasi, Romania)</i> <i>Priya Nori (New York, United States)</i>	

O0780	Specialist training in infectious diseases in Europe. <i>J. Salmanton-Garcia* (Cologne, Germany), J. Salmanton-Garcia, A. Guerra Maio, J.P. Stahl, E. De Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró, A. Verbon, O.A. Cornely, N. Beeching</i>	
-------	---	--

O0781	Infectious Diseases Residency Training over the World. <i>P. Irkoren* (Zeytinburnu/Istanbul, Türkiye), P. Irkoren, C. Cimen, S. Keske, Ö. Ergönül</i>	
-------	---	--

O0782	Five years of experience with the virtual International Postgraduate Diploma in Infection Prevention and Control from the Infection Control Africa Network. <i>A. Tostmann* (Nijmegen, Netherlands), E. Schoeman, B. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman, C. Azzouz, S. Mehtar</i>	
-------	---	--

O0783	Combatting challenges in laboratory capacity through an innovative, longitudinal Gram stain training programme for blood culture specimens in Zimbabwe. <i>T. Mwaturura* (Harare, Zimbabwe), D. Hettle, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer</i>	
-------	---	--

O0784	Benefit of the implementation of Entrustable Professional Activities (EPA) as an assessment tool in the Laboratory of clinical bacteriology: a study focused on the improvement of residents' skills and feelings. <i>H. Pailhories* (Angers, France), H. Pailhories, C. Zins, R. Chenouard, M. Kempf, M. Eveillard</i>	
-------	---	--

ME149	17:30 - 18:30	Hall 2
	Meet-the-Expert	

How to perform molecular surveillance of multidrug resistant bacteria		
--	--	--

M0403	17:30	<i>Martina Lengerova (Brno, Czech Republic)</i>
M0404	17:42	<i>Henrik Hasman (Copenhagen, Denmark)</i>

OS107	17:30 - 18:30	Hall 3
	1-hour Oral Session	

Novel vaccines in clinical development		
Chair	<i>Hanna M. Nohynek (Helsinki, Finland)</i>	

O0770	Safety and immunogenicity of a seasonal booster dose of the 6-valent, OspA-based Lyme borreliosis vaccine candidate VLA15 in a healthy population aged 5-65 years. <i>M. Messier* (Vienna, France), L. Wagner, R. Hochreiter, J. Larcher-Senn, E. Lamberth, R. Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach</i>	
-------	--	--

O0771	Safety and immunogenicity of mRNA mpoX vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial. <i>H. Hiruy* (Cambridge, United States), R. Lazarus, K. Mcafferty, K. Cohen, R. Dhar, T. Rizk, A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav</i>	
-------	--	--

O0772	Development of a Rapid-Acting Oral Cholera Vaccine: Phase I Clinical Trial. <i>A. Hannaford* (Boston, United States), D. Leitner, M. Waldor, L. Baden, M. Desjardins, M. Suzuki, L. Carr, D. Slater, H. Levine, H. Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B. Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S. Walsh</i>	
-------	--	--

O0773	Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years. <i>L. Oostvogels* (Frederiksberg, Denmark), A.</i>	
-------	---	--

ESCMID Global 2025 - Programme

Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B. Johansson-Lindbom, G. Kitson, G. Waerlop, I. Leroux-Roels

00774 **Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme***L. Tindale** (Toronto, Canada), *J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell*

OS108 **17:30 - 18:30** **Hall 5**

1-hour Oral Session

CLN IPC

Novel approaches to preventing device-related infections

Chairs *Natividad Benito (Barcelona, Spain)*
Preeti Malani (Ann Arbor, United States)

00775 **Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults.***M. Sanz De Mena** (Barcelona, Spain), *I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada*

00776 **Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial***AntiRedMen.S. Scheithauer** (Goettingen, Germany), *O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr*

00777 **Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis***A. Mahajan** (Melbourne, Australia), *C. Robson*

00778 **A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients***J. Guerrero** (Scarborough, Canada), *A. Garga, S. Paramalingam, R. Lovinsky, F. Go*

00779 **Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89'709 patients***N. Imhasly** (Lucerne, Switzerland), *A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein*

Tuesday, 15 April 2025

SY152 **08:30 - 10:30** **Hall 12**

2-hour Symposium

PHEI VAX

Out of the spotlight or out of reach? Vaccination of hard-to-reach groups

Chairs *Olivier Epaulard (Grenoble, France)*
Justyna Kowalska (Warsaw, Poland)

S0413 **08:30** **Ukrainian war refugees and vaccination attitudes: experience from Poland***Maria Ganczak (Zielona Gora, Poland)*

S0414 **09:00** **Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama***Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

S0415 **09:30** **Are penitentiary systems ready for introducing vaccination programmes?***Lara Tavoschi (Pisa, Italy)*

S0416 **10:00** **HPV and other essential vaccinations for sex workers***Debora Konopnicki (Brussels, Belgium)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SY153 **08:30 - 10:30** **Hall 13**

2-hour Symposium

CLN

Breaking new ground in febrile neutropenia management

Chairs

Murat Akova (Ankara, Türkiye)
Stefan Schwartz (Berlin, Germany)

S0417 **08:30** **Do we need to redefine the concept of febrile neutropenia in the era of immunotherapy?***Manuela Aguilar-Guisado (Seville, Spain)*

S0418 **09:00** **Should some patients be empirically treated with combination therapy?***Dina Averbuch (Jerusalem, Israel)*

S0419 **09:30** **Role of new antibiotics in febrile neutropenia***Malgorzata Mikulska (Genoa, Italy)*

S0420 **10:00** **Can treatment strategies be personalised using AI or new diagnostic tools?***Carolina Garcia Vidal (Barcelona, Spain)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Conference on Infections in Leukemia (ECL)

EW156 **08:30 - 10:30** **Hall 5**

Educational Session

PRO

The rules of the game: how to tackle the peer-review and publication process

Chairs *Christian Kraef (Copenhagen, Denmark)*
Oana Sandulescu (Bucharest, Romania)

W0429 **08:30** **Communicating with journals, editors and reviewers***Angela Huttner (Geneva, Switzerland)*

W0430 **08:50** **The Wild West of predatory journals***Ursula Hofer (London, United Kingdom)*

W0431 **09:10** **Communicating your publications on social media***Neil Stone (London, United Kingdom)*

W0432 **09:30** **Re-imagining peer review***Amelia Joseph (Nottingham, United Kingdom)*

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, CMI Communications Board of Editors, ESCMID Parity Commission, CMI Board of Editors

EF114 **08:30 - 09:30** **Arena 1**

ePoster Flash Session

DX

Innovations and insights in diagnosing parasitic infections

Chair *Pikka Jokelainen (Copenhagen, Denmark)*

E0822 **Evaluation of a multiplex beads assay for the simultaneous detection of serum antibodies in neurocysticercosis patients.***A. Lopez Alva** (Lima, Peru), *P.D.S. Nakazaki Aza, L.M. Toribio Salazar, H.H. Garcia Lescano*

E0823 **Development and evaluation of real-time loop mediated isothermal amplification assay for rapid detection of hookworm (Ancylostoma duodenale) in human fecal samples***M. Thakur** (Chandigarh, India), *S. Khurana, A. Mewara, L. Pvm*

E0824 **Exploring Genotypic Prevalence and Transmission of Cryptosporidium and Giardia in Immunocompromised Patients: A Dual Approach with Modern Molecular Methods: MLST & nested real-time HRMP.***Rani** (Chandigarh, India), *P. Datta, S.L. Bhasin, P. Malhotra, S.S. Rana, R. Sehgal*

E0825 **Prevalence and diagnostic accuracy of different diagnostic tests for Chagas disease in the Paraguayan Chaco***S. Ardiles Ruesjas** (Saarbruecken, Germany), *S. Ardiles-Ruesjas, V. Lesmo, V. González-Romero, Z. Cubilla, L. Chena, C. Huber, M.J. Rivas, P. Saldaña, A. Carrascosa, S. Méndez, S. Sanz, S.L. Becker, J. Alonso-Padilla, I. Losada*

E0826 **Development and validation of an artificial Intelligence model for detection of gastrointestinal parasites from concentrated wet-mount stool examinations***M.R. Couturier** (Salt Lake City, Ut, United States), *B. Mathison, K.A. Knight, J.R. Potts, F. Markow, A.E. Wood, K.W. Dixon, J.F. Walker, D.L.*

ESCMID Global 2025 - Programme

Bess, W. Hymas

E0827 **Evaluation of KU-F40 automated microscope for diagnosis of intestinal parasitic infections: will AI rescue old-time microscopy?** A. Aupaix* (Hornu, Belgium), L. Filippin, I. Mansoor, M. Chemais, D. Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Deckers, V. Verbelen, J. Brauner

E0828 **Improving vector surveillance: evaluating a real-time PCR assay for *Leishmania* DNA detection in sandflies** H. Alonso-Ezcurra* (Zaragoza, Spain), M.P. Peris, I. Ruiz-Arondo, J.A. Castillo, D. Martínez-Durán, S. Delacour, I. Ruiz-Zarzuola, I. De Blas, C. Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H. Alonso

E0829 **Assessment of a new immunochromatographic assay for serological diagnosis of amoebic liver abscess** R. Fleury* (Besançon, France), M.P. Brenier-Pinchart, P. Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A. Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont, A. Moreno-Sabater, F. Grenouillet

E0830 **Human piroplasmiasis: diagnostic lessons from a national parasitology reference laboratory in South Africa** C. Sriruttan-Nel* (Johannesburg, South Africa), J. Frean

EF115 **08:30 - 09:30** **Arena 3**

DX **PHEI**

ePoster Flash Session

New genomic methods in clinical microbiology

Chair *Natacha Couto (Oxford, United Kingdom)*

E0831 **Prediction of antimicrobial minimum inhibitory concentration from *Escherichia coli* whole genome sequence data using machine learning** A. Gerada* (Liverpool, United Kingdom), N. Harper, Y. Zhong, A. Howard, P.L. Green, W. Hope

E0832 **Dynamically Optimized Reference Adaptive Sampling (DORAS) to streamline bacterial Multi-Locus Sequence Typing** A. Ramette* (Bern, Switzerland), L. Borcard, M.A. Terrazos Miani, S. Gempeler, S. Neuenschwander

E0833 **Prediction of antibiotic resistance in *Pseudomonas aeruginosa*, *Escherichia coli* and *Klebsiella pneumoniae* from genomic data using machine learning and deep learning approaches** E. Denakpo* (Gif-Sur-Yvette, France), N. Dias, F. Jay, B. Iorga

E0834 **Machine learning pipeline accelerates identification of diagnostic targets for *Neisseria gonorrhoeae*** A. Verich* (Sydney, Australia), T. Applegate, D. Bauer, P. Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany

E0835 **Reliable bacterial genomic genotyping from Oxford Nanopore Technologies data – the ONT cgMLST Polisher** N. Scherff* (Muenster, Germany), J. Rothgänger, D. Harmsen

E0836 **Developing a core genome MLST (cgMLST) for *Mycoplasma pneumoniae*** C. Dixon* (Cardiff, United Kingdom), R. Mamede, M. Ramirez, H. Milton, P.M. Meyer Sauter, G. Greub, N. Couto, M.L. Beeton

E0837 **Voyager: real-time taxonomic characterization of long-read mixed-species sequencing samples in sorted motif distance space** S. Branders* (Hamar, Norway), M. Grabherr, R. Ahmad

E0838 **VCP: a signature protein-based tool for accurate and rapid profiling of human gut virome** J. Li* (Shenzhen, China), F. Yang, L. Xiong, X. Feng, H. Zhong

E0839 **Genomic Data-Driven Machine Learning for Predicting Antimicrobial Resistance in ESCAPEE Pathogens** A. Skoulakis* (Lamia, Greece), K. Daniilidis, S. Digenis, A. Hatzigeorgiou

CGR **08:30 - 10:30** **Hall 1**

CLN

Special Session

Clinical Grand Round

Experts *Nina Khanna (Basel, Switzerland)*

Dimitrios P. Kontoyiannis (Houston, Tx, United States)
Lior Neshet (Beersheba, Israel)
David L. Paterson (Singapore, Singapore)
Priscilla Rupali (Vellore, India)
Monica Slavin (Melbourne, Australia)

CGR01 **Case 1K. Malur Kumaraswamy* (Mumbai, Maharashtra, India), K. Malur, U. Agrawal, N. Shah, A. Sunavala, S. Basu, C. Rodrigues**

CGR02 **Case 2C. Wong* (Victoria, Australia), M. Tang, C. Aboltins, L. Gardner, Y. Hersusianto**

CGR03 **Case 3F. Ferreira* (Porto, Portugal), F. Pinto Ferreira, F. Faria, D. Nogueira, M. Pinto Alves, S. Almeida, C. Miranda, I. Furtado, A. Ludgero Vasconcelos**

CGR04 **Case 4J.A. Lee* (Taipei, Taiwan, China), C.T. Yuan, Y.T. Huang, C.Y. Huang, Y.H. Wang, M. Tseng**

CGR05 **Case 5L. Bertolino* (Napoli, Italy), R. Gallo, A.M.C. Peluso, F. Patauner, O. Infante, F. Luciano, A. Vulcano, L. Panico, E. Durante Mangoni**

CGR06 **Case 6Armani Hawes (Baltimore, United States)**

CGR07 **Case 7Sima Sharara (Baltimore, United States)**

Co-organised with: Infectious Diseases Society of America (IDSA)

OS113 **08:30 - 10:30** **Hall 11**

AMR **ANT** **TRN**

2-hour Oral Session

Knockin' on Science's Door: New Antimicrobial Solutions

Chairs *Sandrine Marchand (Poitiers, France)*
Ursula Theuretzbacher (Vienna, Austria)

O0812 **Chimerbactin: a hybrid antibiotic for persistent Gram-positive infections that overcomes resistance development** R. Lee* (Memphis, United States), Y. Zhao, A. Arya, M. Lafleur, R. Conlin, G. Phelps, C. Dunn, E. Griffith, J. Portelinha, N. Chumbler, V. Loudon, I. Lister, S. Zia, K. Urish, K. Lewis

O0813 **A Novel Klebicin Cocktail to Treat Lung Infection Caused by *Klebsiella pneumoniae*** V.D. Paul* (Bangalore, India), A. Ambady, U. Chopra

O0814 **Thiophene derivatives: A promising solution against MDR Gram-negative bacilli** Y. Smani* (Seville, Spain), I. Molina Panadero, Á. Rey Hidalgo, M. Morales-Tenorio, A. García-Rubia, T. Samernate, P. Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón, C. Gil

O0815 **Molecular insight into non-lytic polyproline peptide disruption of *Klebsiella pneumoniae* biofilms** R. Fleeman* (Orlando, United States), R. Beckman Iv, B. Victoria, L. Suits, P. Eswara

O0816 **Reverting cefotaxime resistance in CTX-M-15-producing *Escherichia coli* using Targeted-Antibacterial-Plasmids (TAPs): a CRISPR-Cas9 approach** N. Roson Calero* (Barcelona, Spain), N. Roson-Calero, E. Derollez, P. Rouze, A. Dedieu-Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P. Bogaerts, C. Lesterlin

O0817 **Structural and functional characterization of LysSM5: An innovative endolysin from Salmonella Phage vB_SenA_SM5K** K. Sharma* (Chandigarh, India), H. Kaur, N. Chaudhary, S. Prajapati, B. Mohan, N. Taneja

O0818 **Rational step-by-step design of a two-phage cocktail against a contemporary *A. baumannii* strain recovered from a burned patient at CHUV** G. Resch* (Lausanne, Switzerland), H. De Villiers De La Noue, G. Golliard, X. Vuattoux

O0819 **A novel antibiotic class targeting the enolase of *Acinetobacter baumannii*** I. Molina Panadero* (Seville, Spain), A. Moreno Rodríguez, Á. Rey Hidalgo, L. Tomás Gallardo, M. De La Cruz, P. Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic, O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani

O0820 **Reviving antibiotic potency: Pharmacological Assessment of JS238 a newly designed potentiator against *P. aeruginosa*** P. Rasouli* (Brussels, Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke

ESCMID Global 2025 - Programme

00821 **Advancements in combating tularemia: Novel therapeutic strategies targeting *Francisella tularensis*** *S. Guillier** (Brétigny-Sur-Orge, France), *M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde, C. Demeure, J. Pizarro Cerda, G. Guichard, G. Compain, D. Burnouf, O. Gorgé, J. Wagner*

Chairs *Lindsey Ann Edwards (London, United Kingdom)*
Ed J. Kuijper (Leiden, Netherlands)

SY154 **08:30 - 10:30** **Hall 14**
2-hour Symposium

S0405 **08:30** **How can we recognise and deal with adverse events of Faecal Microbiota Transplantation?** *Serena Porcari (Roma, Italy)*

S0406 **09:00** **What to check? – An attempt at evidence-based donor screening** *Elisabeth Terveer (Leiden, Netherlands)*

S0407 **09:30** **What are the right bugs – Developing LBPs out of FMTs** *Lena Biehl (Cologne, Germany)*

S0408 **10:00** **What's up next? – Hot LBP candidates** *Ilan Youngster (Beer Yaakov, Israel)*

Using mathematical and epidemiological models to identify the drivers of AMR

Chairs *Marc J.M. Bonten (Utrecht, Netherlands)*
Sarah Tschudin Sutter (Basel, Switzerland)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), The European Faecal Microbiota Transplantation Network of academics (EurFMT), European Helicobacter & Microbiota Study Group (EHMSG)

S0421 **08:30** **Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution?** *Roger Kouyos (Zürich, Switzerland)*

S0422 **09:00** **Inferring the determinants of AMR dynamics across bacterial pathogens** *Lulla Opatowski (Paris, France)*

S0423 **09:30** **Modelling the evolution of resistance** *Erida Gjini (Lisbon, Portugal)*

S0424 **10:00** **Assessing the associations of microbiome and socio-demographic dynamics on AMR** *Katariina Pärnänen (Helsinki, Finland)*

SY151 **08:30 - 10:30** **Hall 4**
2-hour Symposium

News in endocarditis care

Chairs *Michele Bartoletti (Milan, Italy)*
Pilar Retamar Gentil (Seville, Spain)

EW157 **08:30 - 10:30** **Hall 15**
Educational Session

Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases

Chairs *Ana Alastruey-Izquierdo (Madrid, Spain)*
Rita Oladele (Lagos, Nigeria)

S0409 **08:30** **Endocarditis guidelines: what is new?** *Siegbert Rieg (Freiburg, Germany)*

S0410 **09:00** **Oral therapy and outpatient care** *Laura Escolà-Vergé (Barcelona, Spain)*

S0411 **09:30** **PK/PD aspects of endocarditis antibiotic therapy** *Fekade Bruck Sime (Brisbane, Australia)*

S0412 **10:00** **The Endocarditis Team: there is no way to work alone** *Barbara Hasse (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares (SEICAV)

W0433 **08:30** **Advances and gaps in the diagnosis and treatment of histoplasmosis** *Diego Rodrigues Falci (Porto Alegre, Brazil)*

W0434 **08:50** **Paracoccidioidomycosis: an update on diagnostic challenges** *Beatriz L. Gomez (Bogota, Colombia)*

W0435 **09:10** **What is new in Talaromyces** *Brown Lottie (London, United Kingdom)*

W0436 **09:30** **Mycetoma: treatment challenges of a unique neglected tropical disease** *Borna Nyaoke-Anoke (Nairobi, Kenya)*

EF116 **09:30 - 10:30** **Arena 2**
ePoster Flash Session

Sepsis revolutions: from machines to molecules

EW155 **08:30 - 10:30** **Hall 2**
Educational Session

An update on arboviral disease challenges

Chairs *Misa Korva (Ljubljana, Slovenia)*
Anna Papa-Konidari (Thessaloniki, Greece)

E0840 **Machine learning enabled prediction of blood stream infection in emergency department attendees.** *C. Rosato* (Liverpool, United Kingdom), S. Aston, A. Velluva, A. Howard, W. Hope*

E0841 **Utilizing Automation to Streamline the Blood Culture Process: Enhancing Efficiency and Patient Outcomes.** *J. Qin* (Shanghai, China), M. Li, Z. Shen*

E0842 **Implementation of a bundle for Gram-negative bloodstream infection: impact on mortality and MDT/DTT carriage.** *C. Bonazzetti* (Bologna, Italy), A. Grechi, D. Gibertoni, L. Mangione, F. Todisco, N. Carocchia, M. Rinaldi, R. Pascale, B. Tazza, A. Toschi, A. Amicucci, C. Campoli, Z. Pasquini, F. Calo', P. Viale, M. Giannella*

E0843 **A matter of time: impact of time to first follow-up blood cultures in patients with candidemia and *Staphylococcus aureus* bacteremia from a retrospective cohort.** *P. Valsecchi* (Pavia, Italy), E. Bono, A. Valeretto, S. Resulli, M. Corbella, P. Cambieri, E. Seminari, R. Bruno*

E0844 **Characteristics of infections and outcomes in patients with left ventricular assist devices.** *N. Sari* (Ankara, Türkiye), E. Ateş, Ç. Sarikaş, Ö. Kurt Azap, Ç. Erol, A. Sezgin*

E0845 **Nb₂(Sn_{0.7}Cu_{0.3})C MAX phase for anti-infection therapy via hyperthermia-mediated bacterial metabolic interference.** *M. Yang* (Chengdu, China)*

E0846 **Age-Dependent Plasma Lipidomic Alterations and**

W0425 **08:30** **The global epidemiology of arboviral diseases** *Chantal B.E.M. Reusken (Bilthoven, Netherlands)*

W0426 **08:50** **Arboviral diseases transmitted by mosquitoes** *Luisa Barzon (Padua, Italy)*

W0427 **09:10** **Arboviral diseases transmitted by ticks** *Joanna Maria Zajkowska (Białystok, Poland)*

W0428 **09:30** **Arboviral diseases transmitted by sandflies** *Rémi Charrel (Marseille, France)*

Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists

SY150 **08:30 - 10:30** **Hall 3**
2-hour Symposium

Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges

ESCMID Global 2025 - Programme

	Immune Correlations in Sepsis: Insights into Disease Severity and Biomarker Potential <i>Y. Sun*</i> (Shanghai, China), <i>K. Lin, L. Wang, J. Ai, J. Zhao, X. Cheng, Y. Wan, P. Cui, S. Wang, J. Wu, J. Jin</i>
E0847	Aberrant integrin activation causes transmigration defects in S100A9^{-/-} neutrophils during sepsis <i>S. Müller*</i> (Münster, Germany), <i>N. Ludwig, J. Rossaint, T. Vogl</i>
E0848	Efficacy of dimercaptosuccinic acid in combination with imipenem in a murine model of experimental sepsis due to metallo-β-lactamase-producing <i>Pseudomonas aeruginosa</i> <i>S. Herrera-Espejo*</i> (Seville, Spain), <i>M. Bouvier, J. Findlay, L. Ceballos-Romero, J. Pachón, J.M. Cisneros, M.E. Pachón-Ibáñez, P. Nordmann</i>

EF117	09:30 – 10:30	Arena 4
	ePoster Flash Session	

C. diff challenges: insights into treatment, monitoring, and infection prevention	
Chair	<i>Kerrie Davies (Leeds, United Kingdom)</i>

E0849	Epidemiology, risk factors, and outcomes of nosocomial <i>Clostridioides difficile</i> infections: a cohort study in a tertiary hospital <i>L. Ruiz Salazar*</i> (Madrid, Spain), <i>T. Mata Forte</i>
E0850	Long-read or short-read sequencing in <i>Clostridioides difficile</i> infection surveillance? <i>M. Brajerová*</i> (Prague, Czech Republic), <i>M. Brajerova, P. Kinross, P. Drevinek, M. Krutova</i>
E0851	"Beyond C. difficile Colitis": Exploring the Role of Fidaxomicin in preventing concomitant and secondary bloodstream infections in patients with <i>Clostridioides difficile</i> colitis <i>D.F. Bavaro*</i> (Milan, Italy), <i>D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D. Mondatore, F. Medioli, M. Casana, A. Belati, L. Bussini, V. Cento, R. Epis, M. Bartoletti</i>
E0853	Comparison of bezlotoxumab versus no-bezlotoxumab on recurrence in high-risk patients with <i>Clostridioides difficile</i> infection <i>C. Arena*</i> (Detroit, United States), <i>A. Abed, R. Kenney, A. Shalal, S. Davis, M. Veve</i>
E0854	Exploring bacterial contributors to <i>C. difficile</i> colonization resistance: comparative effects of vancomycin and fidaxomicin in humanised mice <i>E. Montenegro-Borbolla*</i> (Lausanne, Switzerland), <i>L. Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery</i>
E0855	An optimised vancomycin dosing regimen is effective against <i>C. difficile</i>, reduces gut microbiota impact and prevents recurrent <i>C. difficile</i> infection in a human in vitro gut model <i>J. Freeman*</i> (Leeds, United Kingdom), <i>C. Normington, E. Clark, K. Bentley, J. Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. Wilcox, K. Davies</i>
E0856	Cost and resource utilization of fidaxomicin in risk patients with recurrent or refractory <i>Clostridioides difficile</i> infection <i>M. Engelhard*</i> (Cologne, Germany), <i>I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff</i>
E0857	Impact of a cohorting intervention on the incidence of hospital-acquired <i>Clostridioides difficile</i> infection (CDI): an interrupted time series analysis <i>C.D. Moschopoulos*</i> (Athens, Greece), <i>M. Tsakona, S. Grigoropoulou, P. Kazakou, M. Kostoula, I. Kliani, C. Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, D. Kavatha</i>

ME165	11:00 – 12:00	Hall 12
	Meet-the-Expert	

How to use citizen science for public health	
---	--

M0450	11:00	<i>Anna Noel-Storr (Leamington Spa, United Kingdom)</i>
M0451	11:12	<i>Jani Sormunen (Turku, Finland)</i>

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

SY164	11:00 – 12:00	Hall 15
	1-hour Symposium	

dsDNA virus infections in immunocompromised patients	
Chair	<i>Michelle Yong (Melbourne, Australia)</i>

S0448	11:00	Challenges of diagnosis: do we need to treat all patients with detectable dsDNA virus PCR? <i>Hans H. Hirsch (Basel, Switzerland)</i>
S0449	11:30	The role of CRISPR-Cas9-edited antiviral T cells against dsDNA virus infections <i>Tba</i>

FO167	11:00 – 12:00	Arena 1
	Open Forum	

Vaccine rollout in low resource settings	
Chair	<i>Asma Nasim (Karachi, Pakistan)</i>

F0454	11:00	Typhoid vaccine roll out <i>Nginache Nampota (Baltimore, United States)</i>
-------	-------	--

F0455	11:10	Introduction of malaria vaccines to countries in sub-Saharan Africa: acceptance and barriers <i>Bernhards Ogotu Ragama (Nairobi, Kenya)</i>
-------	-------	--

F0456	11:20	The story of COVID-19 vaccines in LMIC <i>Paul Adepoju (Perton, United Kingdom)</i>
-------	-------	--

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

EF123	11:00 – 12:00	Arena 2
	ePoster Flash Session	

Advancing antimicrobials: trials and therapies for resistant infections	
--	--

E0883	Evaluation of CRS3123 compared to vancomycin for the treatment of <i>Clostridioides difficile</i> infection (CDI) <i>J. Bruss*</i> (Pagosa Springs Co, United States), <i>M.A. Degroote, L. Boccumini, W. Ribble, J. Day, C. Mason, X. Sun, J. Freeman, N. Seema, N. Janjic, T. Jarvis, U. Ochsner, M. Wilcox, T. Louie</i>
-------	--

E0884	Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in paediatric patients with gram-negative bacterial infection <i>J. Bradley*</i> (San Diego, United States), <i>C.T. Norice, E. Roilides, A. Shevelev, B. Jurkiewicz, J.A. Piedrahita, S. Koseoglu, I. Masih, P. Nair, K. Young, D.W. Hilbert, G.T. Nieddu, J.A. Huntington, C.J. Bruno</i>
-------	---

E0885	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Intravenous Ertapenem (ERT) with Zidebactam (ZID) in Combination (WCK 6777) in Healthy Adult Subjects <i>T. Lodise*</i> (Albany, United States), <i>R. Chavan, A. Patel, R. Yeole, S. Bhagwat, M. Patel, G. Saviolakis, K. Gu, V. Ghazaryan, M. Kankam, A. Jaunarajs, E. Hammett, H. Howell, R.A. Bonomo</i>
-------	---

E0886	Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICU patients with KPC-producing <i>K. pneumoniae</i> infections – Results from a retrospective multicentre study <i>A. Marino*</i> (Catania, Italy), <i>A.E. Maraolo, M. Mazzitelli, A. Oliva, N. Geremia, A. De Vito, C. Gullotta, V. Scaglione, E. Vania, S. Lo Menzo, P. Navalesi, L. Volpicelli, A. Fiori, P. Prestifilippo, A. Cattelan, C.M. Mastroianni, G. Madeddu, B. Cacopardo, G. Nunnari</i>
-------	---

E0887	Phase 3 study of oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese
-------	---

ESCMID Global 2025 - Programme

		female participants (EAGLE-J) <i>Y. Kayama* (Tokyo, Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Mozzicato, S. Ura</i>
E0888		Efficacy of High Dose Tigecycline-Containing Regimens for the Combination Treatment of Carbapenem Resistance <i>Enterobacteriales</i> Bacteremia: a propensity score-matched study <i>V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, P. Wanloptaree</i>
E0889		Efficacy of Ceftolozane/Tazobactam vs. Ceftazidime/Avibactam in the Treatment of Nosocomial Pneumonia Caused by <i>Pseudomonas aeruginosa</i>: a multicenter retrospective study from the SUSANA cohort <i>A. Bitti* (Sassari, Italy), A. De Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Socio, P. Morelli, P. Bonfanti, G. Madeddu</i>
E0890		Experience of dalbavancin use for unlicensed indications in a UK tertiary infectious diseases setting <i>C. Darlow* (Liverpool, United Kingdom), J. Parsons, D. Lucy, N. Wong</i>
E0891		Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare-associated and hospital-acquired gram-negative bacterial bloodstream infections (BSI) : Hierarchical composite endpoint analysis with DOOR and generalised pairwise comparisons <i>M. Hardy* (Maroochydore, Australia), D.L. Paterson, M. Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris</i>
EF124	11:00 - 12:00	Arena 3
	ePoster Flash Session	
	DX	
	Thinking outside the box in urinary tract infection	
	Chair	Özlem Kurt Azap (Ankara, Türkiye)
E0892		Targeted NGS: a promising approach for pathogen detection of urinary tract infection <i>W. Gao* (Beijing, China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang</i>
E0893		Turnaround time of just four hours from sample collection to informed decision-making for complicated urinary tract infections in a urology ward, using culture-independent metagenomics <i>A.B. Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. Asadi, T.E.B. Johansen, C. Imrızalioglu, T. Hain, F. Wagenlehner, R. Ahmad</i>
E0894		Identification of Microorganism Types in Urinary Tract Infections Using Machine Learning and Flow Cytometry <i>E. Flores* (Alicante, Spain), I. Gutierrez, R. Torreblanca, A. Blasco, R. Carbonell, M. Lopez-Garrigós</i>
E0895		A New Approach In Diagnosis Of Urinary Tract Infections <i>B. Dinc* (Ankara, Türkiye), F. Kırca, S. Kazıcı, Ö. Uslu, N. Çöplü</i>
E0896		Diagnosis of urinary tract infections: from machine learning to clinical practice <i>E. Flores* (Alicante, Spain), R. Torreblanca, I. Gutierrez, R. Carbonell, L.G. Maite, A. Blasco</i>
E0897		Strategic testing optimisation practices for urinary tract infections (STOP-UTI): findings from LMIC hospital setting <i>S. Sarika* (Tamil Nadu, India), B. Rithik Dharan</i>
E0898		Rapid culture-independent mass spectrometry based proteomics methods for improving urinary tract infection diagnostics <i>S. El-Ali* (Gothenburg, Sweden), L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. Moore</i>
E0899		Unraveling the complexity: <i>Corynebacterium</i> diversity and antimicrobial resistance hub in the

		urinary tract ecosystem <i>E. Cappelli* (Porto, Portugal), A. Morais, T. Ribeiro, L. Peixe</i>
E0900		Active surveillance in the diagnosis of sexually transmitted infections: performing PCR in negative urine cultures <i>A. Castellano Verdasco* (Lleida, Spain), E. Sánchez Bascos, E. López González, A. Blanquero-Porras, M. Riesgo Magaña, A. Bernet Sánchez, S. Mormeneo Bayo, I. Prats Sánchez, A. Bellés-Bellés, M. García González</i>
EF125	11:00 - 12:00	Arena 4
	ePoster Flash Session	
	CLN TRN	
	Bugs breaking the blood-brain barrier	
	Chair	Markus Zeitlinger (Vienna, Austria)
E0901		Pharmacologic depletion of meningeal macrophages worsens disease in a mouse model of meningitis <i>U. Koedel* (Munich, Germany), S. Dyckhoff-Shen, I. Masouris, H.W. Pfister, M. Klein</i>
E0902		<i>Pgm1</i> modulates the inflammatory response of macrophages in experimental pneumococcal meningitis <i>D. Bakker* (Amsterdam, Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van De Beek</i>
E0903		Heparin-binding protein in cerebrospinal fluid as a biomarker for bacterial meningitis: a study of diagnostic accuracy <i>S. Olie* (Amsterdam, Netherlands), S.L. Staal, A.C. Da Cruz Campos, J. Bodilsen, H. Nielsen, D. Van De Beek, M.C. Brouwer</i>
E0904		Efficacy Analysis of Intraventricular/Intrathecal Polymyxin B sulphate Injections in the Treatment of Post-neurosurgical CNS Infections in Neurocritical III Patients: a prospective observational study <i>L. Yang* (Shanghai, China), J. Song, M. Wang, H. Yuan, Q. Yuan, Z. Du, G. Wu, J. Hu, W. Chen</i>
E0905		Ventriculitis characteristics and outcomes (VELCRO): an international retrospective cohort study <i>D. Luque Paz* (Rennes, France), B. Díaz Pollán, M. Boyer-Besseyre, F. Djanikian, A.L. Munier, F. Cunha, L. Escout, G. Martin-Blondel, B. Sarton, P. Jaquet, F. Arrivé, R. Wolf, V. Legros, M. Willig, O.R. Sipahi, L. Flurin, A. Bianchi, B. Balança, J. Puel, R. Lino, B. Soyer, T. Leveque, A. Salomon, A. Serris, R. Larcher, F. Bruneel, N. Mongardon, A. Mazeraud, M. Wolff, R. Sonneville, F. Valour, P. Tattevin</i>
E0906		Clinical Features and Outcomes of <i>Staphylococcus aureus</i> Brain Abscess <i>E. Eriksen* (Aalborg, Denmark), M. Bijlsma, S. Olie, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, M. Brouwer, J. Bodilsen</i>
E0907		Epidemiology of Adult Intracranial Bacterial Abscess in the Republic of Ireland (2010-2021) <i>S. Kilgarrieff* (Cork, Ireland), E. Glynn, D. Murray, C. Lim, C. Hickey, S. O'Donnell, B. Dinesh, C. O'Connor, A. Doherty</i>
E0908		Corticospinal tract involvement in Neuromyeloidosis: A Retrospective cohort Study from South India and a Systematic Review of Literature <i>P.K. Tirlangi* (Manipal, India), N. Gupta, V. Muralidhar, C. Mukhopadhyay</i>
E0909		A multicenter prospective study to develop and validate clinical prediction models for diagnosis of scrub typhus and treatment with doxycycline in children with acute encephalitis syndrome in southern India <i>T. Damodar* (Bangalore, India), L. Turtle, R. Kolamunnage-Dona, M. Jose, U. Kinhal, B. Singh, A. L. S. Marate, N. Prabhu, L. A V, F.S. D'souza, S.V. Sajjan, K. Malleth, R.S. Mani, T. Solomon, V.K. Gowda, R. Vasanthapuram, R. Yadav</i>
KN158	11:00 - 12:00	Hall 1
	Keynote Lecture	
	TRN	
	What genomics brought to the knowledge of tuberculosis, leprosy and buruli ulcer	
	Chairs	Emmanuelle Cambau (Paris, France) Kathryn Holt (London, United Kingdom)

ESCMID Global 2025 - Programme

K0437 11:00 *Stewart T. Cole (Paris, France)*

SY162 11:00 – 12:00 Hall 11

1-hour Symposium

AMR

Antimicrobial stewardship across the lifespan from paediatrics to geriatrics

Chairs *Lucy Catteau (Bruxelles, Belgium)*
Priya Nori (New York, United States)

S0444 11:00 **Antimicrobial Stewardship in paediatrics across different settings** *Taylor Morrisette (Charleston, United States)*

S0445 11:30 **Stewardship in geriatrics: an exceedingly important target** *Dafna Yahav (Ramat-Gan, Israel)*

ME166 11:00 – 12:00 Hall 13

Meet-the-Expert

DX

Implementing AI in microbiological diagnostics: practical steps and quality control

M0452 11:00 *Oliver Nolte (Zürich, Switzerland)*

M0453 11:12 *Jennifer Dien Bard (Los Angeles, United States)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)

SY163 11:00 – 12:00 Hall 14

1-hour Symposium

AMR

People-centred approach to strengthening the AMR response at primary care

Chairs *Benedikt Huttner (Geneva, Switzerland)*
Mirfin Mpundu (Lusaka, Zambia)

S0446 11:00 **Implementation of WHO's people-centred interventions** *Nienke Van De sanDe Bruinsma (Geneva, Switzerland)*

S0447 11:30 **Opportunities for strengthening AMR interventions in primary healthcare** *Sholpan Kaliyeva (Karaganda City, Kazakhstan)*

Co-organised with: World Health Organisation (WHO)

OS122 11:00 – 12:00 Hall 16

1-hour Oral Session

PRO

Serious games - a serious business

Chairs *Christian Kraef (Copenhagen, Denmark)*
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)

O0878 **The development process, impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherlands.** *A. Tostmann* (Nijmegen, Netherlands), O. Coenen-Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers*

O0879 **Impact of Professional Background on Performance in ToREIMC: A Gamified Medical Knowledge Platform.** *A. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García*

O0880 **Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter study.** *T. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho-Nevers, A. Gagneux-Brunon*

O0881 **'The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge game.** *C. Uhomoihi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra*

O0882 **Improvement of learners' confidence in antibiotic management by an interdisciplinary annual multi-centred webinar.** *A. Friedrichs* (Kiel, Germany), E. Kramme, T. Koch, J. Jochum, A. Van Der Linde, H. Gerth, F. Jahn, A. Neubert*

SY159 11:00 – 12:00 Hall 2

1-hour Symposium

CLN TRN

Beat the cancer by beating the infections

Chairs *Daniela Maric (Novi Sad, Serbia)*
Mojca Maticic (Ljubljana, Slovenia)

S0438 11:00 **Prevention of infection-associated cancer: learning from each other** *Catharina Alberts (Amsterdam, Netherlands)*

S0439 11:30 **Test and treat early to prevent cancer: hepatitis B and hepatitis C** *Francesco Negro (Geneva, Switzerland)*

SY160 11:00 – 12:00 Hall 4

1-hour Symposium

CLN IPC

Personalised patient management and infection prevention: Current evidence and future perspectives

Chairs *Agnes Hajdu (Budapest, Hungary)*
Iris K. Minichmayr (Vienna, Austria)

S0440 11:00 **The dosing perspective: towards individualised treatment strategies** *Thomas Tängdén (Uppsala, Sweden)*

S0441 11:30 **The infection control perspective: advancing patient-centred approaches** *Alessia Savoldi (Verona, Italy)*

SY161 11:00 – 12:00 Hall 5

1-hour Symposium

CLN

Emerging fungal diseases in children: Global challenges and approach to management

Chairs *Andreas H. Groll (Münster, Germany)*
Adilia Warris (Exeter, United Kingdom)

S0442 11:00 **Emerging fungal infections in immunocompromised and geographically exposed children** *Laura Ferreras-Antolin (London, United Kingdom)*

S0443 11:30 **Best available treatments and options for children in resource-limited settings** *Fabianne Carlesse (Sp, Brazil)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-Speaking Mycological Society (DMyKG)

OS118 11:00 – 12:00 Hall 6

1-hour Oral Session

AMR ANT

Plasmids as a powerful tool of antibiotic resistance spread

Chair *Monika Dolejska (Pilsen, Czech Republic)*

O0858 **Co-anchorage of antibiotic resistance genes and mobile genetic elements on bacterial plasmids boosts horizontal gene transfer across sewage interfaces.** *M. Shafiq* (Shantou, China)*

O0859 **The emergence of *tet(X4)* and *mcr* co-harbored on the same plasmid and its clinical significance.** *N. Rakhi* (Oxford, United Kingdom), A. Lankapalli, T. Lanyon-Hogg, P. Niurusup, K. Thomson, K. Sands, T.*

ESCMID Global 2025 - Programme

		<i>Walsh</i>
00860	The plasmidome of a global collection of convergent <i>K. pneumoniae</i> and its impact on virulence. <i>F. Lebreton*</i> (Silver Spring, United States), <i>M. Martin, A.P. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B. Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann</i>	
00861	Factors that affect plasmid transfer in multispecies biofilms. <i>H.Y. Liu*</i> (Norwich, United Kingdom), <i>M. Yasir, E. Trampari, G. Langridge, M. Webber</i>	
00862	Identification of the <i>czc</i> metal efflux operon on a new plasmid type in a <i>Pseudomonas aeruginosa</i> clinical isolate belonging to ST357 O11A. <i>Valcek*</i> (Brussels, Belgium), <i>D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst</i>	

OS119	11:00 – 12:00	Hall 7
	1-hour Case Session	

CLN

Looking inside endovascular infections

<i>Chairs</i>	<i>Claus Moser</i> (Copenhagen, Denmark) <i>Matthaios Papadimitriou Olivgeris</i> (Sion, Switzerland)
---------------	--

00863	A Case of Persistent <i>Legionella micdadei</i> Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges. <i>V. Zwart*</i> (Breda, Netherlands), <i>E. Kayabasi, H. De Groot, R. Bentvelsen</i>
-------	--

00864	Management and Prognosis of Vascular Endograft Infections: Case Series. <i>N. Scarpulla*</i> (Napoli, Italy), <i>F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni</i>
-------	--

00865	Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis. <i>I. Cafarella*</i> (Naples, Italy), <i>R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante-Mangoni</i>
-------	---

00866	Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by <i>Enterococcus</i> spp.: Experience from Seven Cases in a Referral Center. <i>F. Frondizi*</i> (Rome, Italy), <i>G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti</i>
-------	---

00867	Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital. <i>G. Oliva*</i> (Rome, Italy), <i>F. Giovannenze, G.M. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. Scoppettuolo, C. Torti</i>
-------	--

OS120	11:00 – 12:00	Hall 8
	1-hour Oral Session	

AMR TRN

Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial Virulence

<i>Chair</i>	<i>Simon Foster</i> (Sheffield, United Kingdom)
--------------	---

00868	Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid <i>pVirh1</i> in hypervirulent Carbapenem-resistant <i>Klebsiella pneumoniae</i>. <i>Y. Zhang*</i> (Shanghai, China), <i>W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang</i>
-------	---

00869	Presence and role of hypervirulence-associated markers in <i>Klebsiella pneumoniae</i> groups based on LD50 value in mouse septic model. <i>A. Avdeeva*</i> (Saint-Petersburg, Russian Federation), <i>D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, V. Ageevets, S. Sidorenko</i>
-------	--

00870	Meta-transcriptomic insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis. <i>T. Vashist*</i> (Chandigarh, India), <i>N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora</i>
-------	--

00871	Unveiling the hidden virulence of <i>Acinetobacter baumannii</i>: how the lipooligosaccharide core modulates immune responses and enhances interferon-γ production. <i>Y.T. Lee*</i> (Taipei, Taiwan, China), <i>Y.C. Wang</i>
-------	--

00872	Platelets drive neutrophil-mediated neuroinflammation in tuberculous meningitis. <i>K. Skolimowska*</i> (London, United Kingdom), <i>R. Wilkinson, J.S. Friedland, D. Kirwan, T. Reid, D. De Swardt, D.L.W. Chong, J. Kutschenreuter, M. Saeed, A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P. Renner, M. Panchoo, C. Stek, R. Johnson, M. Maxebengula</i>
-------	---

OS121	11:00 – 12:00	Hall 9
	1-hour Oral Session	

AMR IPC

Shaping the future of IPC - digitalisation of surveillance

<i>Chairs</i>	<i>Diamantis Plachouras</i> (Solna, Sweden) <i>Maaik S.M. Van Mourik</i> (Utrecht, Netherlands)
---------------	--

00873	PRAISE hospital-onset bacteraemia and fungaemia algorithm as novel automated surveillance indicator: results from four European university hospitals. <i>S. Van Der Werff*</i> (Stockholm, Sweden), <i>S.J.S. Aghdassi, M. Behnke, M.S.M. Van Mourik, G. Catho, M. Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D. Dinis Teixeira, D. Sjöholm, P. Nauclel</i>
-------	--

00874	Transforming hospital-onset bacteremia and fungemia data to the OMOP common data model. <i>H. Düsseldorf*</i> (Vienna, Austria), <i>G. Duftschmid, E. Presterl</i>
-------	--

00875	Prospective evaluation of a machine learning-based real-time multidrug-resistant organism prediction system. <i>V. Vaskasin*</i> (Bangkok, Thailand), <i>W. Nasomsong, A. Holmes, R.L. Peach, K. Bhangnanda, A. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee, J. Price, B. Mauricio, T.M. Rawson</i>
-------	--

00876	Dutch Electronic Health Records in primary care: the Nivel general practitioners database. <i>F.F. Stelma*</i> (Utrecht, Netherlands), <i>J. Van Summeren, M. Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S. Van Beusekom</i>
-------	--

00877	Local signs at catheter insertion sites: Insights from the multicenter DeepCath cohort study with 4,256 pictures. <i>N. Buetti*</i> (Geneva, Switzerland), <i>S. Ruckly, A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar, J.F. Timsit</i>
-------	---

EF131	13:30 – 14:30	Arena 1
	ePoster Flash Session	

AMR

The current landscape of carbapenem resistance: from genotype to phenotype and virulence determinants

<i>Chair</i>	<i>Amy Mathers</i> (Charlottesville, United States)
--------------	---

E0940	Molecular Insights into the Growing Threat Carbapenem-Resistant Hypervirulent <i>Klebsiella pneumoniae</i> and the Rising Challenge of Ceftazidime-Avibactam Resistance. <i>C. Vatansever*</i> (Istanbul, Türkiye), <i>A. Akpınar, J. Boral, S. Belge, N. Kardan, B. Tanyolaç, G. Shahrokhi, G. Ekinci, E. Ural, B. İşler, Ö. Ergönül, F. Can</i>
-------	---

E0941	Global large-scale genomic snapshot on the diversity of carbapenem-resistant and hypervirulent <i>Klebsiella pneumoniae</i> strains. <i>R. Elias*</i> (Lisboa, Portugal), <i>T. Clark, I. Portugal, J. Perdigo</i>
-------	--

E0942	Carbapenem-resistant <i>Enterobacter cloacae</i> complex: genetic determinants of resistance and molecular epidemiology. <i>D. Pinheiro De Sousa Santos*</i> (Lisbon, Portugal), <i>D. Santos, A. Bruschy-Fonseca, E. Gonçalves, D. Ranhel, C. Conceição, A. Pedrosa, A.C. Silva, A. Duarte, L. Méndez, C. Toscano, J. Melo-Cristino, C. Caneiras</i>
-------	---

E0943	Molecular epidemiology of carbapenemase-
-------	---

producing *Escherichia coli* in Hungary. *A. Hanczvíkkel** (Budapest, Hungary), *D. Göbhardter, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Buzgó, L. Holub, K. Papp, K. Kristóf, L. Majoros, K. Kamotsay, M. Käfer, G. Jakab, Á. Sonnevend, Á. Tóth*

Corredor Nassar, A.P. Rodriguez Zulueta

E0944 **Genomic multicentre surveillance of VIM-producing *Enterobacterales* shows spread driven by bacterial clones and plasmids in Germany from 2015 to 2021A.** *Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Müller, A. Hamprecht, S. Peter*

E0945 **Three distinct routes of virulence-resistance convergence in ST-395 *K. pneumoniae* from Eastern Europe over the last decade.** *A. Sapre* (Silver Spring, United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton*

E0946 **Carbapenemases in Germany in 2024: Report of the German National Reference Centre for Multidrug-resistant Gram-negative Bacteria.** *N. Pfennigwerth* (Bochum, Germany), S. Möller, J. Einfeld, F. Pankok, A. Anders, S. Gatermann*

E0947 **Unravelling divergent genomic modes of transmission of Carbapenemase-Producing Organisms in a single hospital in Singapore between 2019 and 2022.** *V. Koh* (Singapore, Singapore), Z.Q. Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakk, P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, S. Vasoo, K. Marimuthu, O.T. Ng*

E0948 **2011-2017 vs 2018-2024: comparison of carbapenem non-susceptibility trends among bloodstream *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates from Greek hospitals: data from the Electronic System for the AMR surveillance-WHONET-Greece.** *M. Polemis* (Vari, Greece), A. Vatopoulos, K. Tryfinopoulou*

EF133 **13:30 – 14:30** **Arena 3**

CLN PHEI VAX

ePoster Flash Session

Viral Infections in special populations

E0958 **ORCHESTRA Delphi Consensus: Therapeutic and Diagnostic Management of SARS-CoV-2 Infection in Rheumatological Patients.** *M.G. Caponcello* (Seville, Spain), P. Olivares Navarro, J. Rodríguez Baño, Z.R. Palacios Baena, C. Bonazzetti, C. Campoli, A. Savoldi, E. Gentilotti, G. Marchetti, S. Lo Caputo, L. Otero-Varela, I. Castrejón, E. Tacconelli*

E0959 **Immunogenicity, reactogenicity and safety of booster vaccinations with BNT162b2 or full-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report.** *J. Stemler* (Cologne, Germany), L. Yeghiazaryan, C. Stephan, R. Cox, K. Greve-Isdahl Mohn, A.J. Carcas-Sansuan, E. Romero Rodriguez, J. Moltó, I. Vergara Mitxelorena, T. Welte, B. Zablockienė, M. Akova, U. Bethe, S. Grimm, J. Salmanton-García, J. Jakobs, L. Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J. Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhann, R. Sprute, J. Frías-Iniesta, R. Negí, C. Gaillard, G. Saini, A. García León, P.W.G. Mallon, C. Lammens, A. Hotterbeekx, L. Katherine, S. Malhotra-Kumar, H. Goossens, S. Kumar-Singh, F. König, M. Posch, P. Koehler, O.A. Cornely*

E0960 **Effectiveness of adjuvanted recombinant zoster vaccine in adults aged ≥50 years in the United States.** *L. Qian* (Pasadena, United States), L.S. Sy, B.K. Ackerson, E. Rayens, J. Wu, Y. Luo, Y. Cheng, J.H. Ku, L.I. Vega Daily, H.S. Takhar, J. Song, R.A. Cohen, H. Yun, D. Oraichi, H. Seifert, H.F. Tseng*

E0961 **Differential SARS-CoV-2 RNAemia features and humoral immune response analysis of acute COVID-19 in solid organ transplant recipients and patients with hematological malignancies.** *A. Ruiz-Molina* (Seville, Spain), J. Martín-Escolano, C. Infante-Domínguez, Z.R. Palacios-Baena, I. Tallón-Ruiz, F. Martín-Domínguez, G. Bernal-Blanco, B. Villacorta-Linaza, G. Suárez-Artacho, C. Cepeda-Franco, D. Rangel-Sousa, C. Rodríguez-Urbistondo, B. Gutiérrez-Gutiérrez, M. Carretero-Ledesma, N. Maldonado, S. Salto-Alejandre, B. Gallego, L. Merino, J. Rodríguez-Baño, J.M. Cisneros, J.A. Pérez-Simón, E. Cordero, J. Pachón, M. Aguilar-Guisado, R. Álvarez-Marín, J. Sánchez-Céspedes*

E0962 **Prevalence of and risk factors for persisting COVID-19 in patients with B-cell malignancies.** *A. Toschi* (Bologna, Italy), Z. Pasquini, A. Amicucci, N. Caroccia, M. Di Chiara, F. Simone, B. Casadei, C. Pellegrini, A. D'abramo, P. De Marco, L. Bussini, M. Ciccone, A. Visentin, G. Caponcello, M. Bartoletti, E. Nicastri, M. Krampera, P.L. Zinzani, J. Rodríguez Baño, E. Tacconelli, M. Giannella*

E0963 **Clinical characteristics and predictors of severe outcome among older adults hospitalized with respiratory syncytial virus (RSV) infection – a retrospective study from Israel.** *M. Jurkowicz* (Tel Aviv, Israel), I. Margalit, I. Harris, D. Mazar, A. Teper, I. Rojzman, S. Uppal, C. Liang, E. Begier, I. Ganiel, M. Mandelboim, D. Yahav*

E0964 **RSV and bronchiolitis associated primary care and emergency department visit rates in children under 5 years: Estimates for Europe and other high-income countries.** *F.F. Stelma* (Utrecht, Netherlands), S. Heemskerk, L. Van Heuvel, P. Spreeuwenberg, L. Bont, J. Van Summeren*

E0965 **Higher incidence of post-transplant EBV infection in pediatric liver transplant recipients compared to pediatric kidney transplants: a retrospective analysis from a tertiary pediatric transplant center.** *S. Mercadante* (Rome, Italy), L. Romani, A. Pietrobattista, I. Guzzo, R. Labbadia, A. Cappoli, A. Mosca, L. Lancellata, M. De Luca*

E0966 **Insights from a single center's experience in hepatitis C treatment across four prisons in**

EF132 **13:30 – 14:30** **Arena 2**

CLN

ePoster Flash Session

Difficult-to-treat cases in the immunocompromised

Chair *Nicolas Mueller (Zurich, Switzerland)*

E0949 **A case of IRIS nocardiosis.** *S.K. Dlamini* (Cape Town, South Africa), P. Namale, P. Arnab*

E0951 **Concurrent invasive disseminated Nocardia farcinica and Candida infections in a patient undergoing long-term glucocorticoid therapy for autoimmune thrombocytopenia: A case report.** *N. Zhang* (Bengbu, China)*

E0952 **Subcutaneous paeohyphomycosis due to *Alternaria infectoria* in an immunosuppressed renal transplant recipient: successful multidisciplinary management.** *E. Vetsiou* (London, United Kingdom), E. Rudd, S. Rai, K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli, M. Arias*

E0953 **Lung nodules in a patient with breast cancer history... Not everything is cancer.** *E. Muñoa Hernández* (Chiapas, Mexico), E. Muñoa*

E0954 **Treatment of fulminant *Clostridioides difficile* infection using bacteria-free stool supernatant in adult hematological patients during chemotherapy-induced aplasia.** *B.G. Szabo* (Budapest, Hungary), D. Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko*

E0955 **Eradication of multidrug resistant *Pseudomonas aeruginosa* pneumonia in acute lymphoblastic leukemia patient with broad host-range phage.** *P. Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. Ferrés, A. Galiana, F. Grill, G. Iraola*

E0956 **An Emerging fungal pathogen in immunocompromised hosts: A rare case of subcutaneous abscess caused by *Chondrostereum purpureum*.** *P. Kitjacharoenchai* (Bangkok, Thailand), A. Thammahong, J. Vanichanan*

E0957 **Unveiling a Rare Simultaneous Central Nervous System infection in an Immunocompromised Patient from Mexico.** *E. Siembra Iracheta* (Tlalpan, Mexico), A. Magallanes Lopez, J.P. Venzor Castellanos, M.J.*

ESCMID Global 2025 - Programme

Slovakia. *Hockickova** (Slovakia, Slovakia), *I. Hockicková, J. Hockicko, M. Novotný, Z. Paraličová, P. Kristian*

EF134 13:30 – 14:30 Arena 4

ePoster Flash Session

AMR DX IPC

Infection Controller's Daily

Chair *Cansu Cimen (Oldenburg, Germany)*

E0967 Mortality and length of stay associated with antimicrobial-susceptible and resistant hospital-onset bloodstream infections at a tertiary referral hospital in Melbourne, Australia. *A. Stewardson** (Melbourne, Victoria, Australia), *S.J. Curtis, S.L. Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, A.C. Cheng, D.W. Spelman, A.Y. Peleg*

E0968 MRSA on the rise in neonatal care departments. *E. Herkes** (Amsterdam, Netherlands), *A. Schoffelen, R. Zwiittink, J. Kluytmans, D. Notermans*

E0969 Risk factors for OXA-carbapenemase-producing *Enterobacteriaceae* acquisition in Israel: a retrospective case control study. *M. Amar** (Haifa, Israel), *R. Najjar-Debbiny, G. Weber, R. Yasin, A. Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked-Mishan, O. Barnett-Griness*

E0970 Experience providing a rapid, reactive nanopore isolate sequencing service for bacterial outbreak investigation for hospitals in London, UK. *Raharison** (France), *A. Alcolea-Medina, L.B. Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V. Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. Goldenberg, J. Edgeworth, J. Otter*

E0971 Duration of colonization and time to de-isolation in patients with extended-spectrum beta-lactamase producing non-*Escherichia coli* Enterobacteriales. *J. Männer** (St. Gallen, Switzerland), *V. Steinacher, T. Dörr, M. Schlegel, P. Kohler*

E0972 A tale of three cities: The comparative longitudinal epidemiology of vancomycin-resistant *Enterococcus faecium* from bloodstream infections at three tertiary care hospitals in Bavaria, Germany. *A. Rath** (Regensburg, Germany), *B. Neumann, V. Rauschenberger, B. Kieninger, A. Eichner, J. Steinmann, S. Kampmeier, W. Schneider-Brachert*

E0973 Molecular epidemiology and transmission dynamics of vancomycin-resistant *Enterococcus faecium* in Belgian hospitals (2022-2023). *S. De Koster** (Edegem, Belgium), *S. Van Kleef-Van Koeveringe, H. Jansens, S. Vandamme, T. Demuyser, M. Vanden Driessche, Y. Glupczynski, S. Malhotra-Kumar, V. Matheeußen*

E0974 Increasing Prevalence of Linezolid-resistant Enterococci: Outbreak or Overuse? *R. Traynor** (Cork, Ireland), *G. Brennan, I. O Callaghan, E. Keily, E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. Doherty, C. Hickey*

E0975 Continuous 2-year surveillance for airborne fungi at hospitals in the same city: Impact of season, construction, a construction accident and HEPA-filtered/positive pressure rooms. *M.H. Nguyen** (Pittsburgh, United States), *C. Clancy, Z. Wilkins, Y. Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, A. Ayres, S. Graham*

EW174 13:30 – 15:30 Hall 11

Educational Session

CLN IPC

Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia

Chairs *Fusun Can (Istanbul, Türkiye)*
Jeroen Schouten (Nijmegen, Netherlands)

W0481 13:30 Artificial Intelligence to predict VAP *Miia Jansson*

(Oulu, Finland)

W0482 13:50 Metagenomic approach to VAP diagnosis. *Jacques Schrenzel (Geneva, Switzerland)*

W0483 14:10 Viruses in VAP and HAP: should we worry about them? *Catia Cilloniz (Barcelona, Spain)*

W0484 14:30 Optimising antibiotic therapy in VAP. *Pinyo Rattanaumpawan (Bangkok, Thailand)*

SY170 13:30 – 15:30 Hall 13

2-hour Symposium

TRN

Novel strategies for eliminating the 'worst films ever'

Chairs *Elisa Borghi (Milan, Italy)*
Markus Zeitlinger (Vienna, Austria)

S0465 13:30 What answers can biofilm PK/PD modelling provide? *Coen Van Hasselt (Leiden, Netherlands)*

S0466 14:00 subMIC antibiotic effects to improve biofilm PK/PD parameters – still relevant? *Francoise Van Bambeke (Brussels, Belgium)*

S0467 14:30 PK/PD-based optimisation of antibiotic treatments to suppress resistance in dynamic biofilm models. *Maria Dolores Macia Romero (Palma De Mallorca, Spain)*

S0468 15:00 Giving antibiotics an upper hand in the treatment of biofilm infections – antibiotic augmenting strategies. *Claus Moser (Copenhagen, Denmark)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Scientific Affairs Subcommittee

SY171 13:30 – 15:30 Hall 14

2-hour Symposium

DX

Enhancing efficiency and reducing cost in microbiological diagnostics using pool testing

Chair *Mauricio Farfan (Santiago, Chile)*

S0469 13:30 Congenital cytomegalovirus detection by pool testing in saliva. *Giannina Izquierdo (Santiago, Chile)*

S0470 14:00 Detection of blood-borne pathogens in asymptomatic blood donors by pool testing. *Patricia Alvarez (Rio De Janeiro, Brazil)*

S0471 14:30 Large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosis. *Melissa Sander (Bamenda, Cameroon)*

S0472 15:00 Pool testing for screening of bacterial sexually transmitted infections. *Tba*

OS130 13:30 – 14:30 Hall 16

1-hour Oral Session

CLN DX

Advances in fungal diagnostics

Chair *Sarah Delliere (Paris, France)*

O0935 BAL galactomannan dynamics predict survival in critically ill patients with virus-associated pulmonary aspergillosis. *V. Delanote* (Leuven, Belgium), J. Wauters, S. Feys, J. Heylen, H.M. Lauwers, C. Jacobs, L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans, P. Meersseman, M. Peetermans, E. Van Wijngaerden, A. Wilmer, K. Lagrou*

O0936 Retrospective Assessment of a New Chemiluminescence Immunoassay for Serum (1, 3)- β -D-Glucan Levels in Patient with Invasive Fungal Infections. *Z. Zhou* (Tianjin, China), K. Yuan, L. Ye, S. Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q. Wang, G. Zhang, H. Wang, Y. Zhao, G. Li*

O0937 Evaluation of a multiplex PCR assay using barcoded magnetic bead technology for detection of fungal pathogens in bronchoalveolar lavage fluid: a diagnostic aid for invasive fungal infections. *S. Zhang**

ESCMID Global 2025 - Programme

(Baltimore, United States)

O0938	<p>Combined use of (1,3)-β-D-glucan and PCR in oral wash for <i>Pneumocystis jirovecii</i> pneumonia diagnosis in non-HIV population A. Falcó-Roget* (Barcelona, Spain), A. Albasanz-Puig, A.B. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len, I. Ruiz-Camps, M.T. Martín-Gómez</p>
O0939	<p>Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12-week mortality: a retrospective cohort study H. Lamberink* (Amsterdam, Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk</p>

SY168	<p>13:30 – 15:30</p> <p>2-hour Symposium</p>	Hall 2
-------	---	--------

Staphylococcus aureus: its expansion dynamics and interactions with its pals

Chair Barbara C. Kahl (Münster, Germany)

S0457	13:30	<p><i>S. aureus</i> and its special relationship to <i>S. epidermidis</i> Andreas Peschel (Tübingen, Germany)</p>
S0458	14:00	<p>The role of the <i>S. aureus</i> type VII secretion system in host-bacterial community interactions Tba</p>
S0459	14:30	<p>Clonal population expansion of <i>S. aureus</i> occurs due to escape from a finite number of intraphagocyte niches Simon Foster (Sheffield, United Kingdom)</p>
S0460	15:00	<p>How bacteriophages and pathogenicity islands drive the evolution of <i>S. aureus</i> John Chen (Singapore, Singapore)</p>

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

EW172	<p>13:30 – 15:30</p> <p>Educational Session</p>	Hall 3
-------	--	--------

Beyond the gift of life: viral infection during pregnancy

Chairs Gülsen Özkaya Sahin (Lund, Sweden)
Simona Ruta (Bucharest, Romania)

W0473	13:30	<p>Hepatitis B during pregnancy: diagnosis, management and outcome Tba</p>
W0474	13:50	<p>RSV and Influenza during pregnancy: management and outcome Monika Redlberger-Fritz (Vienna, Austria)</p>
W0475	14:10	<p>Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guideline Marianne Leruez-Ville (Paris, France)</p>
W0476	14:30	<p>Novel methods of vaccine administration to newborns Tba</p>

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)

SY169	<p>13:30 – 15:30</p> <p>2-hour Symposium</p>	Hall 4
-------	---	--------

Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria

Chairs Agnes Maria Sonnevend (Pécs, Hungary)
Kyriaki Xanthopoulou (Cologne, Germany)

S0461	13:30	<p>Globally emerging resistance patterns of Enterobacteriales Sasheela Ponnampalavanar (Kuala Lumpur, Malaysia)</p>
S0462	14:00	<p>Non-fermenters still important globally: a review of spread and resistance Anupa Thampy (Vellore, India)</p>
S0463	14:30	<p>Innovative rapid diagnostic methodologies for Gram-negative pathogens Laurent Dortet (Le Kremlin-</p>

(Bicêtre, France)

S0464	15:00	<p>Tailoring treatment to resistant Gram-negative bacteria: newer therapeutic approaches Juan P. Horcajada (Barcelona, Spain)</p>
-------	-------	--

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW173	<p>13:30 – 15:30</p> <p>Educational Session</p>	Hall 5
-------	--	--------

Tropical dermatology: a case-based approach

Chairs Pedro Legua (Lima, Peru)
Bobbi Pritt (Rochester, United States)

W0477	13:30	<p>Parasitic diseases Tba</p>
W0478	13:50	<p>Madura foot and other implantation mycoses M Ramam (New Delhi, India)</p>
W0479	14:10	<p>Mycobacteria Francisco Bravo (Lima, Peru)</p>
W0480	14:30	<p>Approach to rash in the returning traveller Frank O. D. Pettersen (Oslo, Norway)</p>

OS127	<p>13:30 – 14:30</p> <p>1-hour Oral Session</p>	Hall 6
-------	--	--------

The good, the bad and the itchy: update on STIs

Chair Tatum Mortimer (Athens, United States)

O0920	<p>High frequency of Nichols-like strains of <i>Treponema pallidum</i> subsp. <i>pallidum</i> circulating in Barcelona, Spain P. Nadal-Baron* (Barcelona, Spain), P. Nadal-Barón, J. Trejo-Zahinos, M. Arando, A. Barberan-Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M. Valverde Espinal, A. Canals Quintana, J.J. González-López, A. Antón, M. Alberty, O. Mitjà, N. Larrosa, Y. Hoyos-Mallecot</p>
-------	--

O0921	<p>Doxycycline post-exposure prophylaxis (doxy-PEP) use and outcomes in metropolitan Detroit C. Arena* (Detroit, United States), N. Everson, R. Kenney, I. Brar, S. Gudipati, N. Yared, S. Davis, M. Veve</p>
-------	--

O0922	<p>The Gonococcus Bacterial Load Measured by the Cycle Threshold (Ct) in Urinary Samples Correlates with Symptomatology G. Beraud* (Orleans, France), T. Prazuck, L. Barhoum, H. Meyjonnade, J. Effa, L. Hocqueloux, A. Seve, J. Guinard, K. Kochbati, E. Carbonelle, C. Guillaume</p>
-------	---

O0923	<p>STI pathogen interactions and viability in men who have sex with men (MSM) E. Rayo* (Zurich, Switzerland), D. Onorini, C. Leonard, H. Martí, T. Pesch, B. Hampel, N. Low, N. Borel</p>
-------	--

O0924	<p>Epidemiology of bacterial genitourinary infections among women with recurrent vulvovaginal Candidiasis (RVVC) in Nigeria S. Fayemiwo* (Ibadan, Nigeria), L. Novak-Frazer, I. Adewole, R. Rautema-Richardson</p>
-------	---

OS129	<p>13:30 – 14:30</p> <p>1-hour Oral Session</p>	Hall 7
-------	--	--------

Biofilm biology and control

Chair Laura Escolà-Vergé (Barcelona, Spain)

O0930	<p>Influence of non-coding small RNA00203 in biofilm cells of <i>Acinetobacter baumannii</i>: Transcriptomic and phenotypic D. Gebrelibanos* (Hong Kong, China), P. Leung, A.M. Shenkutie, F. Chow</p>
-------	---

O0931	<p>Sub-MIC antibiotic effects on <i>Pseudomonas aeruginosa</i> biofilm streamer formation A. Di Claudio* (Pieve Emanuele, Italy), R. Rusconi, E. Secchi, G. Savorana</p>
-------	---

O0932	<p>Regulation of Novel Genes and Their Downstream</p>
-------	--

ESCMID Global 2025 - Programme

	<p>Functions in the AI-2-Mediated Quorum Sensing System of <i>Klebsiella pneumoniae</i><i>X. Chu*</i> (Beijing, China), <i>Q. Yang</i></p>		<p>recombination, and co-circulation<i>D. Wang*</i> (Shenzhen, China)</p>
00933	<p>Exploring structural differences in biofilms of smooth and rough <i>Mycobacterium abscessus</i> clinical strains through confocal laser scanning microscopy<i>C. Maria*</i> (Madrid, Spain), <i>M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea</i></p>		
00934	<p>Antibacterial and biofilm eradication of mupirocin-loaded nano-emulsions<i>Z. Najmi*</i> (Novara, Italy), <i>A.C. Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin</i></p>		
OS126	<p>13:30 – 15:30</p> <p>2-hour Oral Session</p> <p>CLN DX PHEI</p> <p>Emerging viruses, diverse threats</p> <p><i>Chair</i> <i>Luisa Barzon (Padua, Italy)</i></p>	Hall 8	
00910	<p>Epidemiological and clinical features of mpxv during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort study<i>I. Brosius*</i> (Antwerp, Belgium), <i>E. Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijk, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-Bokalanga, J.J. Muyembe-Tamfum</i></p>		
00911	<p>Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023<i>G. Romano*</i> (Pavia, Italy), <i>G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti</i></p>		
00912	<p>Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024<i>M. Torres Portillo*</i> (Toronto, Canada), <i>K. Williams, R. Lababidi, A. Thomas, K. Khan</i></p>		
00913	<p>Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023<i>L. Mueller*</i> (Berlin, Germany), <i>M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. John, V.M. Corman</i></p>		
00914	<p>Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 protein<i>A. Hirvonen*</i> (Vantaa, Finland), <i>C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Benschop</i></p>		
00915	<p>Health-economic impacts of chikungunya vaccination in 34 countries<i>J. Zhou*</i> (Oxford, United Kingdom), <i>N. Salant, D. Smith, D. Hollingsworth, K. Pouwels, S. Radoykova, J. Lord, K. French</i></p>		
00916	<p>Clinical importance of a new tick-borne flavivirus, Alongshan Virus: retrospective serologic and molecular study in Switzerland<i>F. Tagini*</i> (Lausanne, Switzerland), <i>O. Opota, A. Eggermann, A. Coste, G. Greub</i></p>		
00917	<p>From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health Approach<i>S. Ahmad*</i> (Tampere, Finland)</p>		
00918	<p>Building a screening protocol for the detection of Orthobunyavirus oropoucheense infection<i>G. Gagliardi*</i> (Milan, Italy), <i>D. Mileto, A. Mancon, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci</i></p>		
00919	<p>Substantial viral diversity in bats and rodents from East Africa: insights into conservation,</p>		
OS128	<p>13:30 – 14:30</p> <p>1-hour Oral Session</p> <p>ANT CLN</p> <p>AI Aiding AMS</p> <p><i>Chairs</i> <i>Marlieke De Kraker (Geneva, Switzerland)</i> <i>Bhanu Sinha (Groningen, Netherlands)</i></p>	Hall 9	
00925	<p>Using natural language processing to understand free-text antibiotic prescriptions<i>A. Martin*</i> (Middlesbrough, United Kingdom), <i>L. Christopher</i></p>		
00926	<p>Enhancing Antimicrobial Stewardship Through Collaboration Between an Intelligent System and Infectious Disease Experts<i>H.M. Wei*</i> (Taichung, Taiwan, China), <i>Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P. Hwang</i></p>		
00927	<p>Augmented Intelligence in Infectious Diseases (AI²D) as an antimicrobial stewardship tool for early antibiotic discontinuation in suspected lower respiratory tract infections<i>J.L. Lim*</i> (Singapore, Singapore), <i>P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan, S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yip, P.Y. Zhou, Y. Wang, S.J. Chung, L.H.A. Kwa</i></p>		
00928	<p>Virtual antimicrobial stewardship ward rounds: predicting antibiotic course stopping decisions in hospitals using machine learning<i>K. Yuan*</i> (Oxford, United Kingdom), <i>J. Wei, C.H. Yoon, Q. Gu, W. Walker, T. Zhu, D. Eyre</i></p>		
00929	<p>Prospective evaluation of a machine learning-based decision support system for intravenous-to-oral antibiotic switching<i>W. Bolton*</i> (London, United Kingdom), <i>R. Wilson, P. Georgiou, A. Holmes, T.M. Rawson, M. Gilchrist</i></p>		